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Follicular dendritic cells (FDCs) reside in primary B-cell follicles and in 
the light zones of germinal centers (GCs) in secondary follicles, where their 
dendrites interdigitate forming extensive networks intimately interacting with B-
cells. In GCs, FDCs can be found at the edges attached to the supporting reticular 
fibers. They trap and arrange immune complexes (ICs) in vivo and in vitro in a 
periodic manner with 200–500Å spacing and provide both antigen-specific and 
 xv
   
non-specific accessory signals to B-cells. FDCs exist in resting and activated 
states, with two characteristically different phenotypes. In their activated state, 
FDCs upregulate the expression of accessory molecules and cytokines important 
in the FDC-B cell interaction in GCs. We sought to determine the mechanisms 
influencing the transition of FDCs from a resting to an activated state in GCs 
and their impact on T-cell dependent (TD) and independent (TI)-GC reactions 
(GCRs). 
 We found that IC-FDC interactions via FDC-FcγRIIB induce the 
upregulation of FDC-FcγRIIB, -ICAM-1, and -VCAM-1, at both the protein and 
mRNA levels. We also reported for the first time the expression of TLR-4 on 
FDCs. Moreover, engagement of FDC-TLR4 with LPS activated NF-κB, up-
regulated expression of important FDC-accessory molecules, including FcγRIIB, 
ICAM-1, and VCAM-1, and enhanced FDC accessory activity in promoting recall 
IgG responses. Moreover, IC-activated FDCs produced IL-6 and FDC-IL-6 
promoted GCRs, somatic hypermutation (SHM) and IgG production. 
Further, we reported that binding of FDCs to collagen coated surfaces 
induced restoration of their dendritic processes and networks in vitro. In addition, 
we designed an FDC-supported in vitro model capable of induction and 
assessment of primary human antibody responses to protein antigens 
characterized by class-switching and affinity maturation. 
Uniquely, we generated TI immune responses to TD protein Ags in the complete 
absence of T cell help in vivo and in vitro. In the presence of FDC-associated second 
 xvi
   
 xvii
signals such as BAFF and C4BP, FDC- FcγRIIB-periodically trapped-ICs induced the 
production of Ag-specific IgM, GC-development and plasmablast-differentiation in anti-
Thy-1-pretreated nude mice. Purified murine and human B cells cultured in vitro with IC-
bearing FDCs also showed the production of antigen–specific IgM within just 48 h. 
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 General Introduction 
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The secondary lymphoid tissues (the Theatre) 
Secondary lymphoid tissues (e.g Lymph nodes and spleen), are the theatre where 
players of the immune system meet to orchestrate the initiation of an immune (adaptive) 
response.  
Under steady-state conditions, peripheral tissues are patrolled by only low 
numbers of lymphocytes that can potentially respond to invading microorganisms (1). 
Secondary lymphoid tissues facilitate the efficient interaction between the immune 
system and microorganisms. They possess a highly organized micro-architecture that 
maximize the probability of antigen encounter with an antigen-specific lymphocyte and 
are necessary for the compartmentalization of numerous cellular interactions, thus 
providing the optimal environment for initiation of immune responses, including the 
determination of cell fate (2). Moreover, they are remarkably well connected to the blood 
and lymphatic systems, allowing them to continually sample and concentrate antigens 
that are circulating throughout the body.  
Secondary lymphoid tissues are characterized by their efficient role in reducing 
pathogen spread throughout the host by capturing pathogens; via the action of the 
strategically localized macrophages (3,4), and by the production of innate immune 
mediators, such as type I interferons (IFNs) (5). These rapidly induced innate immune 
mechanisms reduce the pathogen load in anticipation of an adaptive immune response to 
be mounted. They also help bring antigen presenting cells (APCs) in contact with 
infrequent antigen-specific lymphocytes for the induction of an efficient antigen specific 
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immune response (6,7). In addition, they provide the necessary factors for the survival 
and differentiation of lymphocytes (2,8).  
Beneath the protective outer collagenous capsule of a lymph node (LN), distinct 
regions with unique features have been described. Underneath the subcapsular sinus, the 
LN cortex with the well organized aggregates of B-cells; known as follicles, can be 
observed. The LN follicles are considered to contain the largest population of IgMmed 
IgDhi CD21med CD23hi B cells in the body. They are also sites rich in radiation-resistant 
follicular dendritic cells (FDCs). Adjacent to the follicles, the paracortex; which is the T-
cell zone that is enriched in antigen presenting cells (APCs) and high endothelial venules 
(HEVs), can be detected. The HEVs mediate the recruitment of APCs that have 
encountered the antigen in the periphery. They are also specialized in the continuous 
supply and drainage of lymphocytes to the LNs and the periphery, respectively. The 
paracortex is also characterized by a network of collagenous conduit fibers, which permit 
the passage of low molecular weight molecules of the lymphatic fluid, such as 
lymphokines and small antigens (9). The medulla is the innermost area of the lymph node, 
it contains B and T cells that are organized into medullary cords as well as antibody 
forming cells (AFCs; plasmablasts and plasma cells) and is also rich in DCs and 
macrophages (10).  
Germinal centers (the Stage) 
The germinal center (GC) was first described in 1884 by Walther Flemming, who 
observed a site of large lymphocytes undergoing mitosis in the follicles of lymph nodes 
and other secondary lymphoid organs and proposed this site to be a major source of all 
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lymphocytes in the body (11,12). Although this originally proposed function of the GC 
was disproven, Flemming’s work motivated subsequent intense studies concerning GCs.   
GCs are the sites where efficient antibody affinity maturation occurs through the 
process of clonal proliferation, somatic hypermutation and selection (13-15). GCs are 
known to be associated with T dependent antibody responses, and are identified as the 
main sites where high-affinity antibody-secreting plasma cells and memory B cells are 
generated.  
A T cell dependent immune response is initiated when infrequent antigen-specific 
T and B cells cognately interact at the boundary between B-cell follicles and T cell zones 
(16-18). The activated B-cells can then move to extra-follicular areas where they 
proliferate and differentiate into short-lived plasma cells or move into the B cell follicles 
and proliferate within the FDC network, giving rise to GCs (19,20). As the GC matures, 
two main compartments; termed dark and light zones, become evident. The light zone is 
mainly occupied by FDCs with their complex network of processes intimately interacting 
with B cells, whereas few processes extend into the dark zone, where actively 
proliferating lymphocytes are densely packed (12). 
Follicular Dendritic Cells (FDCs) and the FDC-B-T cell interaction (the players) 
1. FDCs Morphology, Phylogeny and Development  
Owing to their unique morphology and follicular location, the antigen retaining 
cells residing in primary follicles, and light zones of germinal centers in secondary 
follicles, were given the name “Follicular Dendritic Cells” (FDCs). In 1968, Szakal and 
Hanna published the first electron micrographs and description of FDCs (21-23). 
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Follicular dendritic cells constitute a pleomorphic, non-phagocytic group of dendritic 
type cells, which possess either filiform dendrites or “beaded” dendritic processes. 
Filiform dendrites of FDCs, which have an average length and diameter of 15-20 and 0.1-
0.3 μm, respectively, tend to branch and anastomose near the cell body forming a 
radiating “sunburst”-like pattern (24). Studies of FDCs at the ultrastructural level 
revealed that they have single, and sometimes double, lymphocyte-size cell bodies, with 
an irregular, lobated euchromatic nucleus (sometimes there are multiple nuclei), Golgi 
apparatus, numerous small vesicles, and some mitochondria which are not abundant in 
the dendritic processes (24). The microspheres of the “beaded” dendrites range between 
0.3 and 0.6 μm in diameter and are termed ICCOSOMES [immune complex-coated 
bodies (some-s)] (25-28).  
Information available on FDCs is based primarily on studies using humans and 
rodents. However, FDCs are present and functional in birds and if FDCs are defined 
broadly as cells with the ability to trap and retain ICs, they appear to exist in all jawed 
vertebrates, including amphibians, reptiles and fish. The origin of FDCs remains unclear. 
FDCs are radiation resistant making it difficult to study development using adoptive 
transfer models. At present there are some data supporting a haematopoietic origin while 
even more data support a stromal cell origin. 
2. Immunoregulatory mechanisms involving FDCs 
a. Capturing, retention and periodic arrangement of antigen-antibody complexes 
(Immune complexes; ICs) by FDCs. 
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Follicular dendritic cells capture and retain antigens (Ags) in the form of immune 
complexes (ICs), via their surface expressed FcγRIIB (CD32) and complement receptor 
(CR2; CD21) (29-31). Antigens trapped on FDCs remain in their native conformation, a 
phenomenon that was confirmed by their continued recognition by specific antibody (Ab) 
and, on isolation, their co-migration with native Ag when applied to sizing columns (32) 
Moreover, horse radish peroxidase (HRP) retained its activity and was chemically 
detectable on the FDC cytoplasmic membranes indicating that the native structure was 
conserved at the tertiary protein structure level; hence the enzymatic activity was 
preserved. In mice, conventional soluble protein Ag-Ab ICs are retained on FDCs with a 
t1/2 of ~2 months; nevertheless, Ags have been detected a full year after injection (33).  
FDCs trap ICs in a periodic manner, a phenomenon that was discovered using 
scanning EM with Ag trapped in vivo (24), revealing an orderly, spiraling, arrangement 
of ICs made up of alternating light and dark bands. The same periodicity was observed in 
recent in vitro studies (34) where ICs were arranged on FDCs with a 200Å to 500Å 
spacing between epitopes. This spacing correlates with the 95-675 Å spacing originally 
described by Dintzis as optimal for B cell receptor for Ag (BCR) cross-linking and 
activation in thymic independent (TI) responses.  
IC trapping by FDCs in primary (35) and secondary (36-38) immune responses is 
critical for induction of GC reactions, class switching, somatic hypermutation, affinity 
maturation, and regulation of IgG and IgE serum levels (35,38-53). In primary responses 
to thymic dependent (TD) Ags, ICs form as soon as Ab is produced and, by four days 
after Ag challenge, ICs may be found on splenic FDCs. The kinetics of recall responses is 
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dramatic. Ags are almost instantaneously converted into ICs by Ab persisting from prior 
immunization and by 1 min after challenge labelled Ags can be detected on cells in a 
chain transporting ICs to FDCs deeper in the lymph node cortex.  IC retention is localized 
and Ag injection into a single limb of an immune mouse will be restricted to the draining 
lymph nodes and to a lesser extent in the spleen. With time, FDC-Ag becomes more and 
more focused to lymph nodes nearest the site of Ag injection and by 1 year, persisting Ag 
and specific Ab-forming cells are almost exclusively confined to the most proximal 
lymph node (51,54). 
b. Molecular FDC-T-B-cell interactions. 
FDC promote B-cell proliferation and survival by providing both Ag-dependent 
and independent signals. The ability of FDC to prolong B cell viability relates to both 
Ag-specific and non-specific signaling, and the FDC-mediated co-stimulatory signals are 
not species-restricted, as evidenced by the ability of murine FDC to provide co-
stimulation to human B and T cells and vice versa (55,56). The Ag–Ab complexes 
trapped by FDCs provide intact Ag for interaction with BCRs on GC B cells and this Ag–
BCR interaction provides a positive signal for B cell activation and differentiation 
(36,44). FDC-FcγRIIB binds the Fc regions of Igs, thereby inhibiting the SHIP signaling 
pathway and thus minimizes ITIM activation in B cells by reducing co-cross-linking of 
BCR and B cell-FcγRIIB (30,57,58). FDC–CD21L binds complement receptor 2 (CR2 or 
CD21) on the B cell via CD21 in the B cell co-receptor complex consisting of 
CD19/CD21/TAPA-1. Engagement of CD21 in the B cell co-receptor complex by 
complement-derived FDC–CD21L delivers a critical co-signal. Co-ligation of BCR and 
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CD21 facilitates association of the two receptors, and the cytoplasmic tail of CD19 is 
phosphorylated by a tyrosine kinase associated with the B cell receptor complex. This co-
signal dramatically augments stimulation delivered by engagement of BCR by Ag, and 
blockade of FDC–CD21L reduces the immune responses considerably (typically 10- to 
1000-fold (29).  
In addition to the accessory signals delivered by the complement derived CD21L 
interacting with the CD21/CD19/TAPA-1 complex, activated forms of both C3 (C3b) and 
C4 (C4b) can bind C4 binding protein (C4BP), which in humans and likely in rodents, 
co-localizes with ICs on FDCs as well as CD40 in secondary B cell follicles. C4BP is a 
novel CD40 ligand capable of activating B cells through CD40. C4BP in immune 
complexes (ICs) trapped on FDCs has been shown to signal B cells via intact CD40 in 
short-lived antigen-specific TI GCs independent of the T-cell derived CD40L (CD154) 
expression (59). Several other FDC-associated molecules are also involved in and are 
critical for B-cell activation, FDC- B-cell-activating factor of the TNF family (BAFF) 
(60-62), engaging B cell-BAFF-R (60,63), has been reported to be involved in several 
immunological phenomena, such as T independent B cell responses and antibody isotype 
switching, CD21 & CD23 expression, peripheral B-cell and plasma cell survival, MZ B 
cell integrity and GC maintenance (64). FDC-8D6 and CD44 engaging their ligands on B 
cells are also involved as co-stimulatory signal-providing molecules in FDC-B cell 
interactions (65). Further, FDC-CXCL-13, which attracts B cells and helps organize 
follicles (66,67), IL-6 that promotes terminal B cell differentiation (68), and membrane-
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bound molecules necessary for FDC-B cell synapse formation, ICAM-1 and VCAM-1 
(69) are also critical in B cell activation.  
c. FDC-phenotypes and major FDC-molecules (receptors, cytokines, chemokines, 
etc.) with known functions 
FDC-phenotypes in primary and secondary follicles are very different. In 
secondary follicles (i.e. germinal centres), FDCs bear high levels of FcγRIIB, ICAM-1, 
and VCAM-1, which are involved in converting poorly immunogenic ICs into a highly 
immunogenic form as well as facilitating FDC-B cell interactions. In contrast, FDC-
FcγRIIB, -ICAM-1, and -VCAM-1 levels are low and difficult to detect in primary 
follicles.  
Expression of FDC accessory molecules is subject to regulation; and as reported 
here in projects 1-3 (70-72), engagement of ICs, TLR ligands, or collagen type 1 induces 
FDC activation and upregulation of these molecules. Similarly, FDC-FCγRIIB mediated 
trapping of ICs in vitro, induces the secretion of BAFF and IL-6 (projects 4 and 5 in the 
present work [(73) & in press]). FDC-activation by TLR agonists was generally done 
using lipopolysaccharide (LPS). However, FDCs express mRNA for TLR2, 3, 4 & 9 and 
injection of poly I:C increases FDC-FcγRIIB in draining lymph nodes similar to results 
for LPS (project 3 (71)). FDCs also express CD44 and CD29 and FDC binding to 
collagen type I in vitro induces regeneration of FDC processes and networks with 
features in common with networks in vivo (project 2 (72)). A major consequence of 
activation is a marked increase in accessory activity. For example, the number of FDCs 
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needed for IgG responses in vitro could be reduced four-fold and somatic hypermuation 
could be increased if FDCs were activated (project 3 (71) & (35)).  
FDCs express and secrete various molecules with important immunoregulatory 
functions as listed below in table 1 (Reviewed in (74)). 
FDC-molecules Immunoregulatory role 
FcγRIIB 
(CD32) 
1- Conversion of poorly immunogenic ICs into a highly 
immunogenic form: FDCs express high levels of FcγRs relative to 
GC B cells and these receptors bind immunoglobulin-Fc in ICs and 
minimize binding to B cell FcγRIIB. Thus, cross-linking of BCR and 
B cell-FcγRIIB via ICs is minimized, ITIM signalling is reduced, and 
B cells are productively signalled.  
2- FDC activation: Both wild-type (WT) and FcγRIIB–/– mice trap ICs 
but only WT mice respond to ICs by up-regulating FcγRIIB, ICAM-
1, and VCAM-1. Similarly, blockade of FDC-FcγRIIB results in 
inhibition of IC-induced FDC-IL-6 and FDC–BAFF production 
indicating the importance of FDC-FcγRIIB in FDC activation and 
cytokine production.    
3- IC periodicity: In the absence of complement, ICs are trapped by 
FDC-FcRs and are periodically arranged on FDC dendrites. ICs 
trapped via complement receptors do not induce the B cell activation 
characteristic of periodically arranged Ags.  
4- Long term IC retention: Complement-mediated IC trapping in the 
draining lymph nodes of FcγRIIB-/- mice is normal. However, long-
term retention of ICs is reduced in FcγRIIB-/- mice suggesting the 
importance of this receptor in the long-term retention of ICs. 
5- Regulation of serum IgG levels: High IgG levels feedback on Ag 
retained on FDC dendrites and “zip” them together thus hiding the 
ICs within "ball-of-yarn"-like dendritic convolutions. When Ab 
levels decline, Ab dissociates from Ag-epitopes, the dendrites 
unravel and the persisting Ag is exposed to memory B cells. This 
exposure initiates a rebound in Ab and memory B cell production, 
thereby maintaining humoral immunity. 
FcεRII (CD23) 
Immune complex retention and regulation of IgE levels: Serum IgE 
is suppressed in CD23 transgenic (Tg) mice where FDC-CD23 and B 
cell-CD23 are elevated. Adoptive transfer studies indicated that IgE 
production is suppressed when normal lymphocytes are used to 
reconstitute Tg mice with high levels of FDC-CD23. Furthermore, 
isolated Tg-FDCs augment IgG production normally but IgE 
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production is reduced suggesting that a high level of FDC-CD23 
selectively suppresses IgE.  
Fcα/μR 
Immune complex retention: In humans FDCs are the predominant 
cell type expressing Fcα/μR. This Fc receptor can bind Abs of both 
IgM and IgA isotypes and may function in Ag presentation and B cell 
selection in the GC response in systemic and mucosal immunity.  
CR1/2 
(CD21/35) 
Immune complex retention especially in the spleen: Splenic IC 
retention does not occur without Complement  
CD21L (iC3b, 
C3d or C3dg) 
B cell co-stimulation via CD21: Engagement of CD21 in the B cell co-
receptor complex by complement derived FDC-CD21L delivers a 
critical co-signal. Co-ligation of BCR and CD21 facilitates association 
of the two receptors and the phosphorylation of the cytoplasmic tail of 
CD19 by a BCR-complex-associated tyrosine kinase. This co-signal 
augments stimulation delivered by Ag and blockade of FDC-CD21L 
reduces B cell proliferation, activation induced cytidine deaminase, and 
Ab production 10 to 1,000 fold. 
FDC-M1 
(Mfge8) 
Clearance of apoptotic bodies: Fat globule epidermal growth factor 8 
(Mfge8) “licenses” tingible body macrophages to engulf apoptotic 
bodies in GCs and helps minimize autoimmunity   
FDC-M2  
(C4b eptiope) 
Binds C4b localized with FDC-ICs: C4b binding protein (C4BP) binds 
C4b and co-localizes with ICs on FDCs. FDC-C4BP has been shown to 
signal B cells via CD40, independent of T-cell CD40L (CD154). 
Injection of mice with FDC-M2 inhibits C4BP localisation and TI-GC 
development. 
ICAM-1 
(CD54) 
VCAM-1 
(CD106) 
MadCAM-1 
Stability of the FDC-B cell synapse: Abs reactive with murine ICAM-
1 and/or leukocyte functional Ag-I (LFA-I) interfere with FDC-B cell 
clustering resulting in reduced B cell proliferation. In addition, VLA-4 
and VCAM-1 have been observed in GCs and likely also play a role in 
FDC-B cell interactions. These adhesion molecules are thought to 
stabilize the FDC-B cell synapse and promote interaction of FDC-Ag 
and FDC-costimulatory molecules with B cells.  
CXCL13 
B cell homing to lymphoid follicles via CXCR5: CXCL13 is secreted 
by FDCs and acts as a chemoattractant for B cells via the CXCR5 
chemokine receptor. FDC development and expression of this 
chemokine depend on LTα1β2, TNF-α and related molecules. A 
persistent LTa1β2 stimulus is important for both the induction and the 
maintenance of FDC networks. Further studies suggest that the 
maintenance of the primary lymphoid follicle structure is mediated by a 
positive feedback loop: CXCL13 stimulates B cells to express high 
levels of LTα1β2 and in turn LTα1β2 stimulates FDCs to produce 
CXCL13. 
IL-6 GC development and terminal B cell differentiation: FDCs are the source of IL-6 in GCs. Engaging FDC-FcγRIIB by ICs activates FDCs 
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and enhances FDC-IL-6 production. FDC-IL-6 promotes GC 
development, IgG production, and somatic hypermutation.  
IL-15 
Enhancement of GC B cell proliferation: IL-15 is produced by FDCs 
and is captured by IL-15Rα on the surface of FDCs. Surface IL-15 is 
active and promotes GC-B cell proliferation. GC-B cells have the 
signal-transducing components (IL-2/15Rβγ), but not a receptor for 
binding of soluble IL-15 (IL-15Rα) and the IL-15 signal may be 
delivered by trans-presentation from FDCs to GC-B cells via cell-cell 
contact.  
8D6 (CD320) 
B cell anti-apoptosis: The 8D6 molecule inhibits apoptosis and 
influences both proliferation and Ab secretion by GC B cells. Moreover, 
GC B cells that are induced to differentiate into pre-plasma cells are the 
most sensitive to the neutralizing effects of anti-8D6. 
BAFF 
Enhancement of T independent B cell proliferation: FDC-BAFF has 
the ability to support TI B cell activation. The outcome of BAFF 
signalling is multifaceted and different receptors mediate different 
functions. Peripheral B cell survival, plasma cell survival, MZ B cell 
integrity, GC maintenance, CD21 & CD23 expression, T independent B 
cell responses, and Ig class switching may be influenced by BAFF. 
CD40 
Regulation of FDC-CD23: FDCs express CD40 and when incubated 
with either CD40L trimer or agonistic anti-CD40 Ab, the expression of 
FDC-CD23 is increased both at the mRNA and protein levels. As 
explained above, FDC-CD23 helps regulate IgE levels.  
Toll-like 
receptors 
(TLRs) (2, 3, 
and 4) 
Engagement of Pathogen-associated molecular patterns (PAMPs) 
and FDC activation: Dramatic upregulation of FDC-ICAM-1, VCAM-
1, and FcγRIIB is observed after injecting LPS into animals expressing 
wild-type TLR4 but not in animals with mutated TLR4. Incubation of 
FDCs with LPS in vitro upregulates FcγRIIB, ICAM-1, and VCAM-1. 
FDC activation by TLR agonists has been largely studied with LPS. 
However, FDCs express mRNA for TLR2, 3, 4 & 9 as well, and 
injection of poly I:C increases FDC-FcγRIIB to levels comparable with 
LPS.   
CD44 
CD29 
Interaction with ECM proteins, regeneration of FDC dendrites and 
B cell anti-apoptosis: FDCs express CD44 and CD29 and FDC binding 
to collagen type I in vitro induces the regeneration of FDC processes 
and networks. CD44 also enhances B-cell adherence to FDCs allowing 
delivery of the FDC-derived B cell survival signals including 8D6 and 
BAFF.  
TNF-α 
T cell stimulation: FDCs produced soluble tumor necrosis factor alpha 
(TNFα) that increases transcription and production of HIV in GC T 
cells.  
IL-7 Interleukin 7 has been found in isolated tonsilar FDCs using RT-PCR and intracellular staining. IL-7 signalling coupled with crosslinking of 
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surface immunoglobulin receptors results in B cell proliferation. 
LT-R (and 
TNFα)  FDC development and maturation 
 
d. T-dependant and independent-immune responses and FDCs 
By the 1950s, the lymphopoietic function of the thymus had been well established, 
but no one believed that it had any immunological role. It was a common principle that 
thymus was a useless organ that had become unnecessary during evolution; a conclusion 
that was based on a number of observed phenomena (75).  
First, efficient immune responses were documented in mice thymectomized in 
adult life (76). Moreover, thymus lymphocytes were inefficient in initiating immune 
reactions after adoptive transfer to appropriate recipients if compared to lymphocytes 
from the spleen, lymph nodes and blood. Again, thoracic duct lymphocytes homed 
efficiently from blood into lymphoid tissues, with the thymus as ‘the only exception’, 
where only very few lymphocytes lodged (75). In addition, antibody-forming plasma 
cells and germinal centers were absent from thymus tissue, although so prominent in 
spleen and lymph nodes. However, in 1961, Miller published in The Lancet the first data 
supporting an immunological function for the thymus (77) and in 1962 Martinez et al. 
and Miller (78,79) provided data further supporting the direct or indirect involvement of 
the thymus in immunological reactions and its role as a supply of lymphocytes to other 
lymphoid tissues.  
Inspite of the general assumption, by that time, that all the immune responses of 
neonatally thymectomized animals to all types of antigenic stimuli are impaired (80-82), 
Humphrey and Parrott in 1964 (83) showed that mice thymectomized at birth can, in 
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certain circumstances (e.g. in response to pneumococcal polysaccharides), produce as 
much or even more antibody than intact controls.  
The term Thymus-dependent was first assigned to histologically delineated areas 
of lymphocyte depletion in secondary lymphoid tissue of neonatally thymectomized mice 
(immediately surrounding the central arterioles in the spleen, and constitute the mid and 
deep cortical zones of the lymph nodes) (84-87). The remaining areas in the peripheral 
lymphoid organs were all designated 'thymus-independent' (88). In 1966 Micklem et al. 
(89) demonstrated the presence of cells from two distinct origins in the peripheral 
lymphoid tissues and in 1969 Davies and co-workers (90,91) demonstrated the bone 
marrow origin of thymus-independent areas of the secondary lymphoid organs. This 
concept was further supported by proceeding studies, and the term T-cells and B-cells (i.e 
of bone marrow origin) was assigned to cells in thymus-dependant and thymus-
independent areas of the secondary lymphoid organs, respectively (92,93). Subsequent 
studies showed a clear distinction between thymus-dependent and independent 
populations based on functional and phenotypic analysis (94). 
T cell-independent antigens represent two major groups. TI type 2 (TI-2) antigens 
are characterized by their large molecular weight, possession of repeating immunogenic 
epitopes, ability to activate the complement cascade, poor in vivo degradability, and 
inability to stimulate MHC class II-dependent T cell help. TI type 1 (TI-1) antigens, on 
the other hand, are characterized by being mitogenic for B cells. In contrast to TI antigens, 
T cell-dependent antigens (TD), which comprise soluble proteins or peptides are 
characterized by their ability to associate with MHC molecules on an antigen presenting 
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cell (APC), which subsequently interact with and activate T cells, in part, through ligation 
of their T cell antigen receptor complex (TCR), as well as through binding of accessory 
and adhesion molecules (reviewed in (95-104)).  
TI-2 antigens express repetitive epitopes on a stable backbone with an extended 
length of 460 nm. This backbone carries 48 epitopes that can engage 10-50 mIg receptors 
forming a small number of highly cross-linked clusters with 14-fold reduction in the 
diffusion coefficient of the bound mIg receptors. This conformation is critical for 
delivering the BCR-mediated signal in TI-2 responses and is achieved by minimizing the 
extent of modulation and disappearance of Ig from the surface of antigen-specific B cells 
thus allowing for prolonged contact of the antigen with mIg and therefore persistent B-
cell signaling with relatively low antigen concentrations. In addition to the spatial density 
and affinity of antigens, BCR signaling in TI responses is also influenced by important 
regulatory molecules such as complement and Fc-receptors (97-99). In addition, Ig 
secretion is enhanced by additional immunostimulatory signals (second signals) such as 
complement fragments, C4-binding protein (C4BP), B-cell-activating factor of the TNF 
family (BAFF), pathogen-associated molecular patterns (PAMPs), DC-, macrophage-,α-
β, γ-δ, and NK T-cell- derived factors (95-97,105-107). Antibody responses to TI 
antigens are characterized by the absence of a typical immunological memory, failure to 
induce classic GC formation, and the involvement of mIgD, Bruton’s tyrosine kinase 
(Btk), B-1 and MZ B cells.  
Studies showed that virus-specific IgM responses are mounted in athymic nude, 
TCRα- TCRβ- TCRαβ- and TCRαβγδ-knockout mice infected with Coxsackie, 
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influenza, vesicular stomatitis virus and many other viral models. Moreover, all of the 
antiviral TI antibody responses reported so far are directed to viral antigens repetitively 
displayed in the virions (108). Besides, antibodies bound to strictly ordered, but not to 
irregularly arranged, viral antigens dramatically enhanced the induction of anti-antibodies 
after a single immunization and without using adjuvants (109).  
In addition to the well known role of FDCs in GC reactions of the classic TD 
responses, our studies revealed an important role of FDCs in augmenting and enhancing 
B-cell proliferation and Ab responses, respectively, in in vitro B cell cultures stimulated 
with slg-dependent (anti-δ) or -independent (LPS) polyclonal activators (40). 
Subsequently, molecules involved in FDC-mediated enhancement of Ab responses by B 
cells in Ag-driven or LPS-stimulated systems were characterized and revealed an 
important interaction between a complement-derived CD21 ligand on follicular dendritic 
cells and CD21 on B cells in the initiation of IgG responses (29,39,44). The fact that 
blockade of CD21 receptors on B-cells co-cultured with FDCs results in the reduction of 
Ab responses to the TD antigen tetanus toxoid (TT), and to the TI type 1 pokeweed 
mitogen (PWM), further supports the importance of FDC-associated molecules (CD21 
ligand) in the enhancement of Ab responses by B-cells (56). 
FDC-FcγRIIB is another important molecule that influences B-cell Ab responses. 
FDC- FcγRIIB binds the Fc regions of Igs thereby inhibiting the SHIP signaling pathway 
and thus minimizes ITIM activation in B cells by reducing co-cross-linking of BCR and 
B cell-FcγRIIB (57,58). The role of FDC-FcγRIIB in B cell activation has been 
investigated under Ag-specific and anti-BCR ligation conditions. The addition of ICs to 
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cultures of Ag-specific T and B cells elicited pronounced Ab responses only in the 
presence of FDCs. In addition, Ag-specific responses in cultures containing FDCs 
derived from FcγRIIB-/- mice or FcγRIIB-/- mice transplanted with wild-type Ag-specific 
T and B cells and challenged with specific Ag were significantly depressed compared 
with those of controls with wild-type FDC in vitro and in vivo (30). In another study, the 
addition of normal FDCs, but not FDCs lacking FcγRIIB from FcγRIIB-/- mice, reduced 
and reversed the anti-BCR-induced SHIP phosphorylation in A20 cells supporting the 
concept that binding Ig Fc regions by FDC-FcγRIIB could inhibit the SHIP signaling 
pathway and thus minimize ITIM activation in B cells by reducing co-cross-linking of 
BCR and B cell-FcγRIIB (57). Again, the immune response to the immunodominant Ag 
of Actinobacillus actinomyctemocomitans, which is a 150 kD polymer of disaccharide 
repeating units capable of maintaining immune responses for long periods of time in the 
absence of continuous source of the Ag, increased 3-40-fold after the addition of Ag-
specific IC-bearing FDCs in in vitro cultures(110).  
TI polysaccharide antigens activate the alternative complement pathway directly 
and the classical pathway indirectly by making ICs with specific IgM produced early in 
the immune response. In addition to the accessory signals delivered by the complement 
derived CD21L interacting with the CD21/CD19/TAPA-1 complex, activated forms of 
both C3 (C3b) and C4 (C4b) can bind C4 binding protein (C4BP), which in humans and 
likely in rodents, co-localizes with ICs on FDCs as well as CD40 in secondary B cell 
follicles. C4BP is a novel CD40 ligand capable of activating B cells through CD40. 
C4BP in immune complexes (ICs) trapped on FDCs has been shown to signal B cells via 
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intact CD40 in short-lived antigen-specific TI GCs independent of the T-cell derived 
CD40L (CD154) expression. Consistent with the hypothesis that ICs on FDCs can 
provide antigen-specific, complement-derived, and CD40-mediated signals to B cells 
initiating B cell proliferation in TI GCs (59).  
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CHAPTER 1  
Follicular dendritic cell (FDC)-FcγRIIB engagement via immune 
complexes induces the activated FDC phenotype associated with 
secondary follicle development 
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Introduction 
Follicular dendritic cells (FDC) are localized to the light zones of 
germinal centers (GC), where their dendritic processes interdigitate and form 
three-dimensional networks or FDC-reticula that help these non-circulating cells 
to remain localized (37,42). FDC functions include the capture and retention of 
immune complexes (IC) (30), promotion of B cell survival (111-115), and the 
production of high-affinity Ab (39,116). The ability to stimulate B cells depends 
in large measure on the ability of FDC to trap and present Ag to specific B cells. 
FDC capture and retain Ag in the form of IC, and starting in the early 1970s, a 
number of studies elegantly documented that complement and complement 
receptors (CR) were necessary for optimal IC trapping and retention (117-121). 
Although, Fc receptors may not be as important as complement and CR in IC 
trapping, they do appear to enhance long-term retention of IC by FDC (30). 
Both FDC and B cells express FcγRIIB (57,58), but B cell activation 
may be inhibited by immunoreceptor tyrosine-based inhibition motif (ITIM) 
signaling mediated by IC coligating the B cell receptor for Ag (BCR) and B cell-
FcγRIIB (reviewed in (122,123)). Engagement of BCR in the absence of such 
coligation induces rapid activation of tyrosine kinases, generation of inositol 
phosphates, elevation of cytoplasmic Ca2+ concentrations, and activation of 
mitogen-activated protein kinases (reviewed in (122,123)). These events 
promote B cell activation and lead to proliferation, differentiation, and Ab 
secretion (reviewed in (124)). In marked contrast, coligation of BCR and 
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FcγRIIB by IC leads to inhibition of the extracellular Ca2+ influx, reduction of 
cell proliferation, blockage of blastogenesis, and inhibition of Ig synthesis 
(reviewed in (122-124)). Nevertheless, on FDC, IC provide potent activation 
signals for B cells that result in induction of GC dark zones where B cells are 
proliferating and differentiating rapidly (reviewed in (125)). However, FDC 
lacking FcγRIIB or expressing only low levels of FcγRIIB are unable to convert 
poorly immunogenic IC into a highly immunogenic form for B cells, although 
they can trap IC using CR (30). In active GC, FDC express high levels of FcR 
relative to B cells, and it appears that these receptors bind Fc portions of Ab in 
IC and minimize their binding to FcR on B cells (30,44,57). Thus, cross-linking 
of BCR and FcγRIIB via IC is minimized, ITIM signaling is reduced, and B cell 
proliferation and differentiation is promoted. 
In follicles lacking GC, FDC exhibit a resting phenotype with significant 
CR1/2 levels, but with low levels of FcγRIIB, ICAM-1, and VCAM-1, raising 
the issue of mechanisms involved in activating FDC adequately to productively 
present IC to B cells. Remarkably, challenge of actively immunized mice with 
Ag induces a dramatic increase in FDC-FcγRIIB expression. Up-regulation of 
FDC-FcγRIIB is apparent within 24 h, reaches a peak by day 3, and remains 
high for at least 10 days (57,58). The rapidity of this response suggested that 
memory T and B cells were not involved and prompted the hypothesis that 
interaction of IC with FcγRIIB on FDC up-regulated the expression of FcγRIIB 
as well as of other surface molecules that participate in the immune response, 
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including ICAM-1 and VCAM-1 (69,126,127). A recent paper by Victoratos et 
al. (128) provides support for the concept that IC binding of FcR on FDC can 
lead to up-regulation of FDC-ICAM-1 and -VCAM-1. 
To test this hypothesis, mice were passively immunized with anti-OVA 
Ab, and the levels of FcγRIIB, ICAM-1, and VCAM-1 on FDC-reticula and 
purified FDC were determined 3 days after challenging wild-type (WT) and 
FcγRIIB-/- mice with OVA. Both WT and FcγRIIB-/- mice trapped OVA-anti-
OVA Ab IC, but only the WT mice responded with dramatic up-regulation of 
FcγRIIB, ICAM-1 and VCAM-1. Furthermore, addition of IC to purified FDC 
from WT mice, but not FcγRIIB-/- mice, in vitro prompted the production of 
mRNA for FcγRIIB, ICAM-1, and VCAM-1 within 3 h, indicating that this Fc 
receptor promoted activation rather than inhibition as it is known to occur in 
other cells including T cell-associated dendritic cells (122,123,129). In short, the 
data support the concept that direct interaction of IC with FDC-FcγRIIB up-
regulates FcγRIIB, as well as ICAM-1 and VCAM-1, indicating that 
engagement of FcγRIIB is important in initiating pathways leading to FDC 
activation, as indicated by the expression of molecules on FDC needed for 
accessory function. 
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Materials and methods 
Animals 
BALB/c mice 6-8 wk old were purchased from the National Cancer 
Institute, and FcγRIIB KO mice (C57BL/6; 129-Fcγr2tm1) were obtained from 
Taconic Farms (Hudson, NY). Mice were housed in shoebox cages and food and 
water were given ad libitum. Animals were handled in compliance with 
guidelines established by VCU's institutional animal care and use committee. 
Ab and other reagents 
The rat anti-mouse CD16/32 (clone2.4G2), CD106 (mVCAM-1), FDC-
M1, biotin labeled anti-rat kappa Ab and the DAB substrate kit were from BD 
PharMingen (San Diego, CA). Rat anti-mouse CD54 Ab (ICAM-1), HRP-
conjugated goat anti-rat IgG, and HRP-conjugated goat anti-rabbit IgG were 
from Southern Biotech (Birmingham, AL). Rabbit anti-OVA Ab was purchased 
from Biodesign International (Saco, ME) and normal rabbit serum from Gibco 
(Grand Islands, NY). Anti-biotin microbeads and MACS LS columns were 
purchased from Miltenyi Biotec GmbH (Auburn, CA). 
FDC isolation 
FDC were isolated by positive selection from LN (axillary, lateral 
axillary, inguinal, popliteal, and mesenteric) of adult mice as described (130). 
Before isolation, mice were irradiated with 1000 rad to eliminate most 
lymphocytes. On the day of isolation, mice were killed, LN were collected, 
opened and treated with 1.5 mL collagenase D (22 mg/mL, C-1088882; Roche), 
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0.5 mL of DNase I (5000 U/mL, D-4527; Sigma), and 2 mL DMEM with 
20 mM HEPES. After 45 min at 37°C in a CO2 incubator, released cells were 
washed in 5 mL DMEM with 10% FCS. Cells were then sequentially incubated 
with FDC-specific Ab (FDC-M1) for 45 min, 1 µg of biotinylated anti-rat light 
chain for 45 min, and with 20 µL anti-biotin microbeads (Miltenyi Biotec) for 
15-20 min on ice. The cells were layered on a MACS LS column and washed 
with 10 mL ice-cold MACS buffer. The column was removed from the 
VarioMACS and the bound FDC were released with 5 mL MACS buffer. 
Isolation of peritoneal macrophages 
DMEM (20 mL) was injected i.p. and the cells were recovered by 
peritoneal lavage. The cells were washed by centrifugation and resuspended in 
complete DMEM with 10% FCS. 
Isolation of lymphocytes 
Lymphocytes were suspended by grinding LN from non-irradiated mice 
between the frosted ends of two sterile slides in complete DMEM with 10% 
FCS. The suspension, containing 30-45% B cells, was washed and resuspended 
in complete medium. 
IC preparation and cell cultures 
FDC isolated from murine LN were cultured at 1 × 106 cells/mL in 5-mL 
polypropylene tubes containing 1 mL complete medium supplemented with 10% 
FCS. OVA and rabbit anti-OVA Ab IC were made at a final ratio of 1 ng/mL 
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OVA to 6 ng/mL anti-OVA Ab. The cultures were maintained for 12 h at 37°C 
in a CO2 incubator unless otherwise indicated. 
Analysis of FcγRIIB, ICAM-1, and VCAM-1 mRNA levels by qRT-PCR 
Total cellular RNA was extracted by using TRIzol reagent (Invitrogen 
Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. 
Then, the one-step RT-PCR reaction was achieved by using an iCycler (Bio-
Rad, Hercules, CA). The TaqMan one-step RT-PCR master mix reagent kit 
(ABI, Foster City, CA) was used for RT-PCR. The amplification of various 
mRNA and 18S RNA were run in separate wells using the same amount of total 
RNA retrieved from the same sample. The sequences for the various 
oligonucleotides starting with the forward primer, followed by reverse primer, 
then probe and going from 5′ to 3′ are indicated in Table 1. Amplifications were 
performed under the following conditions: 48°C for 30 min (cDNA synthesis), 
initial denaturation at 95°C for 10 min followed by 40 cycles of denaturation at 
95°C for 15 s and a combined annealing/extension step at 60°C for 1 min. 
Finally, fold differences in mRNA expression levels were calculated using the 
ΔΔCT method (131). The PCR efficiency was first ascertained to be close to 
100% by performing multiple standard curves using serial mRNA dilutions. An 
amplification cycle threshold value (CT value), defined as the PCR cycle number 
at which the fluorescence signal crosses an arbitrary threshold, was calculated 
for each reaction. The fold change between mRNA expression levels was 
determined as follows: Fold change = 2-ΔΔCT, where ΔΔCT = (CT-GoI - CT-Hk) 
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Sample - (CT-GoI - CT-Hk) Control, where CT: cycle threshold, GoI: gene of 
interest, Hk: house keeping gene.  
 
Table 1. Primer and probe sequences used in real-time qRT-PCR analysis 
Sense primer TCCTAGTATCCTTGGTCTATCTC 
Anti-sense primer GTGAGTAGGTGATCGTATTCTC FcγRIIB 
Probe 50-FAM- AAGCAGGTTCCAGACAATCCTCCT-30-BHQ-2a)
Sense primer  TTGAGAACTGTGGCACCGTG 
Anti-sense primer CAGCTCCACACTCTCCGGAA mICAM1 
Probe 50-FAM- CGCTTCCGCTACCATCACCGTGTATTCG-30-BHQ-1a) 
Sense primer  GTGACCTGTCTGCAAAGGAC 
Anti-sense primer AAAGGGATACACATTAGGGACTG mVCAM1 
Probe 50-FAM- AAGAGAACCCAGGTGGAGGTCTACTCATTC-30-BHQ-1a) 
Sense primer  AAAATTAGAGTGTTCAAAGCAGGC 
Anti-sense primer CCTCAGTTCCGAAAACCAACAA 18S rRNA 
Probe 50-Cy5- CGAGCCGCCTGGATACCGCAGC-30-BHQ-2a) 
a) Black hole quencher. 
 
Immunizations and immunohistochemistry 
Three mice were subcutaneously injected in the front legs with an initial 
dose of 100 µL rabbit anti-OVA Ab (10 mg/mL) followed 1 h later by 100 µL 
OVA (1 mg/mL) (Sigma, St. Louis, MO). A final dose of 100 µL rabbit anti-
OVA Ab (10 mg/mL) was injected 1 h later. Controls were injected with OVA + 
NSS or with rabbit anti-OVA Ab alone. At 3 days post immunization, axillary 
LN were collected and frozen in CryoForm embedding medium (IEC, Needham 
Heights, MA) and frozen sections of 10 µm thickness were cut on a Leitz (1720 
Digital) cryostat and air-dried. Five representative midsagittal sections were 
collected and processed together for the quantitative analysis. Following acetone 
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fixation, the sections were rehydrated and the endogenous peroxidase activity 
was quenched with PBS containing 0.1% phenylhydrazine-HCl (Sigma). The 
sections were washed and saturated with 10% BSA, then incubated with: mouse 
adsorbed HRP-conjugated goat anti-rabbit IgG, unlabeled rat anti-mouse 
CD16/CD32 (FcγRIIB), CD106 (VCAM-1), or CD54 Ab (ICAM-1). The 
sections with rat Ab were washed and then incubated with mouse adsorbed 
HRP-conjugated goat anti-rat IgG. The sections were developed with a DAB 
substrate kit (BD PharMingen) and images were captured using an optronics 
digital camera and analyzed using Bioquant Nova software. 
The rat mAb 2.4G2 recognizes murine FcγRIIB and FcγRIII. However, 
FDC-reticula in GC of FcγRIIB-/- mice do not label with 2.4G2, indicating that 
activated FDC have little if any FcγRIII (30). Accordingly, we attribute the 
histochemical labeling of FDC-reticula in WT mice with 2.4G2 to FDC-
FcγRIIB. 
Analyses of immunohistochemistry results 
BIOQUANT NOVA Advanced Image Analysis software (R&M 
Biometrics, Nashville, TN) was used to analyze the immunohistochemistry as 
described (58). This system allowed us to determine number, position, area, and 
density of the labeling after setting an arbitrary threshold that was the best for 
the FDC-reticula. This predefined threshold was used throughout to enable 
reliable comparisons. 
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Flow cytometry 
FDC were isolated from WT and FcγRIIB-/- mice 3 days after 
subcutaneous injection of Ag and Ab to form IC. Control mice were injected 
with saline. Except for CD32/CD16-FITC labeling, FDC were first incubated 
with mouse Fc-Block (BD PharMingen) for 15 min on ice, followed by anti-
CD54/ICAM-1-FITC Ab, anti-CD106/VCAM-1-FITC Ab or isotype control for 
60 min in the dark at 4°C. After washing, the cells were analyzed using an 
FC500 flow cytometer and Cytomics RXP analysis software. Histograms were 
gated for FDC based on their forward and side scatter properties established 
with FDC phenotypic markers including FDC-M1, CD21/35, and CD32 (130). 
The figures were plotted using WinMDI software (Scripps Research Institute). 
Statistical analysis 
For analysis of results including qRT-PCR data, a t-test (two-tailed distribution) 
was used. To account for multiple comparisons, a p value of less than 0.01 was 
required to conclude significance. 
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Results 
FDC-mediated IC trapping 
Increases in FDC-FcγRIIB are apparent 1-3 days after challenge of immune 
mice with Ag, prompting the postulate that FDC may be activated by 
encountering IC. If IC directly initiated up-regulation, then memory T and B 
cells would not be important and IC in normal mice should activate FDC. To 
test this, we passively immunized WT and FcγRIIB-/- mice with rabbit anti-OVA 
IgG and challenged with OVA to form IC. Localization of the IC on FDC-
reticula after 3 days was determined with immunohistochemistry and 
morphometrically analyzed (Fig. 1A1-A5). Complement and CR are known to 
facilitate trapping of IC on FDC (117-121); thus, IC strongly labeled FDC-
reticula in both passively immunized WT and FcγRIIB-/- mice. In contrast, 
neither anti-OVA Ab nor OVA in the presence of nonspecific rabbit serum 
(NSS) were retained on the FDC-reticula, confirming the importance of the IC. 
The number of FDC-reticula ranged between five and six in IC-immunized WT 
and FcγRIIB-/- mice compared to a total lack of labeling in Ag- or Ab-alone-
injected animals (Fig. 1A4). The average reticular size was approximately 
250 000 µm2 (Fig. 1A5) whereas the average density per reticulum, which 
reflects the amount of IC staining, ranged between 110 and 120 pixels and did 
not differ between WT and knockout (KO) mice.  
   
 30
IC-mediated up-regulation of FDC-FcγRIIB expression 
We hypothesized that direct interaction between IC and FDC-FcγRIIB 
up-regulates FcγRIIB expression in an auto-regulated or self-induced manner. 
To begin testing, we analyzed FcγRIIB labeling in FDC-reticula of 3 days 
passively immunized animals (Fig. 1B1-B5). Whereas the number of FcγRIIB 
labeling FDC-reticula in passively immunized WT animals ranged between five 
and six, the number in control non-immune mice with Ag in NSS or Ab alone 
averaged <1 per midsagittal draining axillary LN section (p <0.001). No labeling 
was detected on sections from FcγRIIB-/- mice (Fig. 1B3). The reticular size in 
passively immunized WT animals measured 144 200 µm2 compared to 8200, 
6153 and 6131 µm2 in the non-immunized WT, Ag-alone- and Ab-alone-
injected controls, respectively (p <0.001). The average density per reticulum, 
which indicates the intensity of FcγRIIB labeling, was highly variable in the 
control groups which include reticula induced by environmental Ag that were in 
various stages of decline. Moreover, the density of labeling was almost 
homogenous in the 3-day reticula in passively immunized animals, and this 
contrasted with the variability in the controls where the initial time of 
stimulation could not be determined. 
IC increase FcγRIIB mRNA levels in FDC but not in B lymphocytes or 
macrophages 
The immunohistochemical results support the concept that FcγRIIB is 
important in up-regulating FDC-FcγRIIB. However, many other cells, including  
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Figure 1: Analysis of light micrographs illustrating trapping of IgG-OVA IC (A1-A5) 
and labeling with anti-FcγRIIB Ab (B1-B5) in the FDC-reticula of draining axillary 
LN. Mice were passively immunized with rabbit anti-OVA Ab, followed by OVA to 
produce IC. After 3 days, draining axillary LN were harvested, sectioned, and midsagittal 
sections were labeled. IC-retaining reticula were labeled in (A1-A5) using anti-rabbit IgG. 
(A1) Representative passively immunized and OVA-challenged WT mouse ×50; 
(A2) representative no-IC (Ab alone or NSS + Ag) WT mouse ×80; (A3) representative 
passively immunized and challenged FcγRIIB-/- mouse ×50. (A4) Number and (A5) size 
of FDC-reticula per midsagittal axillary LN section. FDC-reticula were labeled for 
FcγRIIB in (B1-B5). (B1) Representative passively immunized and challenged WT 
mouse ×50; (B2) no-IC WT mouse with a GC ×50; (B3) representative passively 
immunized and challenged FcγRIIB-/- mouse ×50. (B4) Number and (B5) size of FDC-
reticula per draining midsagittal axillary LN section. The averages were calculated using 
data from three mice, and results illustrate the means ± SEM. 
[Normal View 59K | Magnified View 95K] 
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mast cells and macrophages, can interact with IC in vivo and could play a role in 
regulating expression of FDC-FcγRIIB. However, if direct interaction between 
IC and FcγRIIB induces FDC-FcγRIIB, then addition of complement-free IC to 
purified FDC should result in increased FcγRIIB mRNA. To examine this, we 
determined the effect of IC on FcγRIIB mRNA levels in purified FDC using 
quantitative reverse transcriptase PCR (qRT-PCR). The fold change in FcγRIIB 
mRNA in IC-treated FDC, as compared to untreated FDC, was calculated. IC 
treatment resulted in an approximately 2000-fold increase in FcγRIIB mRNA in 
12 h, whereas treatment with Ab alone or Ag alone was without effect (Fig. 2A). 
This response appeared to be FDC specific because B cells, which bear 
FcγRIIB, and macrophages treated with the IC for the same period of time did 
not show any change in FcγRIIB expression (Fig. 2B). This result minimizes the 
probability that contaminating B cells or macrophages in the FDC preparations 
contribute to the dramatic increase in FcγRIIB mRNA levels. Furthermore, this 
result is consistent with histochemistry where the increase in FcγRIIB on FDC 
was dramatic, but was not apparent on adjacent B cells (Fig. 1B1).  
Anti-FcγRIIB Ab blocks the IC-mediated increase in FcγRIIB mRNA levels 
WT FDC treated with rat anti-mouse CD16/32 Ab (clone 2.4G2) for 
30 min prior to IC addition showed no change in FcγRIIB mRNA levels (Fig. 
2C). Since 2.4G2 blocks FcγRIIB, this result further supported a crucial role of 
FcγRIIB in mediating the IC-induced FcγRIIB expression on FDC. 
Kinetics of IC-induced increases in FcγRIIB mRNA 
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The IC-induced increase in FDC-FcγRIIB mRNA levels was determined 
at 1, 3, 12 and 24 h. Increased FcγRIIB mRNA levels were apparent within 3 h 
and increased over the entire 24-h period (Fig. 2D). 
IC-mediated up-regulation of FDC-ICAM-1 and -VCAM-1 expression 
Murine ICAM-1 and VCAM-1 are inducible on FDC and high levels 
coincide with GC formation (132,133). Furthermore, these adhesion molecules 
are critical to the ability of FDC to stimulate B cells (69). In the present study, 
we sought to determine the impact of IC on FDC-ICAM-1 and -VCAM-1 
expression. Three days after passive immunization and Ag challenge, FDC-
ICAM-1 and -VCAM-1 were analyzed with immunohistochemistry (Fig. 3). The 
number of ICAM-1- and VCAM-1-labeled FDC-reticula 3 days after IC 
formation in passively immunized WT animals ranged between five and six per 
midsagittal draining axillary LN section and corresponded with IC trapping and 
FcγRIIB expression. In contrast, the number in non-immune WT, Ag-alone-, 
Ab-alone-, and passively immunized FcγRIIB KO mice was approximately one 
per midsagittal draining axillary LN section (p <0.01). The same difference 
between IC vs. Ag or Ab alone existed with cumulative reticular size for FDC-
ICAM-1 and -VCAM-1 in passively immunized WT animals. In contrast, 
neither ICAM-1 nor VCAM-1 labeling in FDC-reticula of passively immunized 
FcγRIIB-/- mice was significantly changed after IC treatment (Fig. 3).  
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Figure 2: RT-PCR quantification of IC-mediated FcγRIIB mRNA induction in FDC. 
(A) FDC (1 × 106) were isolated from LN and cultured for 12 h in the presence of 
50 ng/mL OVA (Ag), 300 ng/mL anti-OVA Ab (Ab) or the combination of OVA + anti-
OVA Ab to form IC. (B) IC-mediated FcγRIIB mRNA induction was not observed in B 
cells or macrophages. FDC, B cells, and peritoneal macrophages (1 × 106) were cultured 
in the presence of 50 ng/mL OVA (Ag), 300 ng/mL anti-OVA Ab (Ab) for 12 h. 
(C) Induction of FcγRIIB mRNA production in FDC by IC was blocked by anti-FcR Ab 
(2.4G2). FDC (1 × 106) were cultured for 12 h in the presence of 50 ng/mL OVA (Ag), 
300 ng/mL anti-OVA Ab (Ab), directly or after being treated with 2.4G2 (2 µg in a final 
volume of 200 µL) for 30 min on ice. (D) Kinetics of IC-induced FcγRIIB mRNA 
production in FDC. FDC were cultured in the presence of 50 ng/mL OVA (Ag), 
300 ng/mL anti-OVA Ab (Ab), and maintained for 1, 3, 12 and 24 h at 37°C in a CO2 
incubator. Data are expressed as fold increase in mRNA. These results are representative 
of three separate experiments of this type, and results are depicted as the means ± SEM 
for replicate cultures. [Normal View 26K | Magnified View 39K] 
   
 36
 
 
   
 37
Figure 3: Analysis of light micrographs of draining axillary LN illustrating 
immunohistochemical labeling of FDC-reticula with anti-VCAM-1 (A1-A5) and anti-
ICAM-1 Ab (B1-B5). LNs were harvested 3 days after passive immunization and 
challenge with OVA to form ICs. VCAM-1 labeling of FDC-reticula is analyzed in (A1-
A5). (A1) Representative, passively immunized and challenged WT mouse ×50; (A2) no-
IC WT mouse with a GC ×50; (A3) a passively immunized and challenged FcγRIIB-/- 
mouse with a labeled GC ×80. (A4) Number and (A5) size of FDC-reticula per draining 
midsagittal axillary LN section. ICAM-1 labeling of FDC-reticula is shown in (B1-B5). 
(B1) Representative passively immunized and challenged WT mouse ×50; (B2) no-IC 
WT mouse with a labeled GC ×50, (B3) passively immunized and challenged FcγRIIB-/- 
mouse with a labeled GC ×80. (B4) Number and (B5) size of FDC-reticula per draining 
midsagittal axillary LN section. The averages were calculated using data from three mice, 
and results illustrate the means ± SEM. [Normal View 61K | Magnified View 96K]
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Up-regulation of surface expression of FcγRIIB, ICAM-1 and VCAM-1 on IC-
stimulated FDC confirmed by flow cytometry 
Flow cytometric analysis of FcγRIIB, ICAM-1 and VCAM-1 on FDC purified 
from WT mice showed significantly increased labeling 3 days after IC 
stimulation (Fig. 4A-C). Whereas 39% of FDC were FcγRIIB positive from 
unstimulated WT mice, 70% were FcγRIIB positive after IC activation (Fig. 
4A). Labeling with anti-ICAM-1 Ab indicated that 30% of unstimulated WT 
FDCs were CD54/ICAM-1 positive, whereas 65% were positive after IC 
stimulation (Fig. 4B). Similarly, CD106/VCAM-1 was expressed on 6% of 
unstimulated WT FDC, rising up to 38% in IC-activated FDC (Fig. 4C). In 
contrast, FcγRIIB-/- FDC showed no change in surface expression of 
CD54/ICAM-1 (Fig. 4D), or CD106/VCAM-1 (Fig. 4E) after binding IC.  
IC-mediated induction of FDC-ICAM-1 and -VCAM-1 mRNA in vitro 
If engagement of FDC-FcγRIIB with IC initiates pathways leading to up-
regulation of surface molecules that participate in interactions with GC B cells, 
then RNA messages for these molecules should be apparent after IC stimulation. 
Using qRT-PCR, mRNA levels for ICAM-1 and VCAM-1 in FDC from WT 
and FcγRIIB-/- mice were determined after culture with IC for 3, 12 and 24 h, 
and the fold change was calculated using mRNA levels in untreated FDC as the 
baseline. In WT FDC, mRNA levels for FcγRIIB, ICAM-1, and VCAM-1 were 
significantly elevated within 3 h and dramatically increased after 24 h (Fig. 5). 
In contrast, FDC from FcγRIIB KO mice did not display any changes in ICAM-
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1 or VCAM-1 mRNA levels (Fig. 5). Controls included IC made in the presence 
of fresh complement to enhance IC binding to FDC from FcγRIIB KO and WT 
mice. The presence of complement fragments in the IC did not up-regulate 
ICAM-1 or VCAM-1 mRNA levels in KO mice or enhanced the IC-mediated 
up-regulation of these molecules in WT mice (data not shown).  
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Figure 4: Effect of IC stimulation on FDC-CD32/CD16, CD54/ICAM-1 and 
CD106/VCAM-1 surface expression. FDC were from WT (A-C) or FcγRIIB-/- (D, E) 
mice. Three days after subcutaneous injection of IC or saline, FDC were isolated and 
labeled for CD32/CD16, CD54/ICAM-1 or CD106/VCAM-1, and analyzed by flow 
cytometry. WT FDC exhibited increased surface expression of CD32/CD16 (A), 
CD54/ICAM-1 (B) and CD106/VCAM-1 (C) when stimulated with IC, whereas FcγRIIB-
/- FDC showed no change in the surface expression of CD54/ICAM-1 (D) or 
CD106/VCAM-1 (E) upon IC treatment. These data are representative of three separate 
experiments of this type. [Normal View 41K | Magnified View 63K]
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Figure 5: Effect of IC stimulation on mRNA for markers indicative of the activated 
FDC phenotype. FDC were cultured in the presence of 50 ng/mL OVA (Ag) and 
300 ng/mL anti-OVA Ab (Ab) for 3, 12 and 24 h. Total RNA was isolated and FcγRIIB, 
VCAM-1, and ICAM-1 mRNA were quantified using qRT-PCR. Data are expressed as 
fold increase in mRNA of IC-activated FDC above the basal level expressed in untreated 
FDC. These results are representative of three separate experiments of this type, and 
results are depicted as the means ± SEM of replicate cultures. 
[Normal View 17K | Magnified View 25K] 
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Discussion 
The phenotype of FDC in primary and secondary follicles is very 
different. In secondary follicles, FDC bear high levels of FcγRIIB, ICAM-1 and 
VCAM-1, and these molecules are involved in converting poorly immunogenic 
IC into a highly immunogenic form for B cells and in facilitating FDC-B cell 
interactions required for optimal FDC accessory activity (30,57,69,132). In 
contrast, in primary follicles, FDC-reticula can be found by labeling with anti-
CR1/2 Ab, but FcγRIIB, ICAM-1, and VCAM-1 levels are low and difficult to 
detect (30,132,134). These relationships prompted questions about how FDC are 
activated and what molecules participate in the activation process. Disruption of 
lymphotoxin (LT)/TNF, or their cognate receptors, disrupts LN organogenesis 
and interferes with FDC development (135-138). Furthermore, these molecules 
are important to maintain FDC with a functional phenotype, as indicated by the 
loss of IC and the activated phenotype when these interactions are blocked 
(136,139). Activated B cells are known to provide LT and TNF, suggesting that 
B cell activation might lead to FDC activation and that could explain why FDC 
associated with resting B cells exhibit a resting phenotype while those in active 
GC express an active phenotype (138-141). However, in recall responses, FDC 
activation is evident before B cell activation is apparent, suggesting that the IC 
itself might play a role in activating FDC (57,58). The data presented here 
support this concept. Encounter of FDC-FcγRIIB with Ag-Ab complexes in the 
absence of complement in vitro leads to increased mRNA for FcγRIIB in 
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purified FDC in 3 h. Increased levels of FDC-FcγRIIB could be detected by 24 h 
in passively immunized mice, and by 3 days not only was the labeling intense, 
but the area occupied by FcγRIIB-positive FDC-reticula on a single midsagittal 
draining axillary LN section had increased between 10- and 15-fold (10 000 µm2 
to nearly 150 000 µm2). Results for ICAM-1 and VCAM-1 were similar, with 
mRNA being clearly elevated in isolated cells within 3 h and 10-15-fold 
increases in the area of FDC-reticula being occupied by labeled FDC. 
The importance of FcγRIIB in initiating the signaling pathway for these 
molecules is supported by results indicating that IC could be trapped on FDC-
reticula by FcγRIIB-/- mice, but there was no increase in mRNA or protein for 
ICAM-1, or VCAM-1. Furthermore, blocking FcγRIIB on WT FDC with anti-
FcR Ab (clone 2.4G2) also blocked the mRNA response. FcγRIIB-/- mice 
exhibited ICAM-1 and VCAM-1 labeling at a frequency of approximately one 
FDC-reticulum per LN section, indicating that FDC in these animals could 
express these molecules. However, the presence of five to six IC-retaining 
reticula per LN section did not correspond with any increase in ICAM-1 or 
VCAM-1. The complement receptors are capable of trapping IC on FDC in 
these KO animals (30), but CR engagement did not mediate the IC-induced up-
regulation of VCAM-1 or ICAM-1. Thus, the signaling pathways involved in 
converting resting FDC in primary follicles into activated FDC that emerge as 
the secondary follicles develop appears to be initiated by FDC-FcγRIIB 
engaging IC. 
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The molecules used to characterize FDC activation are known to be 
important in FDC-B cell interactions. The FcγRIIB binds the Ig-Fc in IC and 
thus minimizes ITIM activation as a consequence of coligation of B cell-
FcγRIIB and BCR (57,58). The adhesion molecules, ICAM-1 and VCAM-1, are 
important in stabilizing FDC-B cell interactions leading to FDC-B cell clusters, 
and FDC accessory activity is most apparent in the clustered cells (69). 
Engaging FDC-FcγRIIB with IC induced a significant rise in ICAM-1 and 
VCAM-1 mRNA within 3 h and showed a dramatic increase after 24 h. In some 
experiments, we also examined mRNA for FDC-CD40 which has no known role 
in interactions between FDC and B cells. In this case, no increase in mRNA was 
found after engaging FDC-FcγRIIB with IC (data not shown). These results 
indicate that stimulation through FDC-FcγRIIB does not induce mRNA 
production generally, but does promote messages for proteins involved in B cell-
FDC interactions. 
In the present study, the initial trapping in FcγRIIB-/- mice was 
indistinguishable from WT after 3 days. These data are consistent with the well-
established role of complement and CR in IC trapping by FDC and suggest that 
CR on resting FDC in primary follicles would trap IC very well. The trapped IC 
could engage the low level of FDC-FcγRIIB and auto-up-regulate this receptor 
as well as up-regulate other molecules important in FDC-B cell interactions. We 
reason that IC formation and binding to FDC-FcγRIIB would occur as soon as 
the first Ab appears in a primary response and within minutes after injecting Ag 
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into an immune animal for a recall response. This rapid up-regulation would 
facilitate GC formation, leading to class switching, somatic hypermutation, and 
the selection of B cells with high-affinity receptors needed to facilitate affinity 
maturation (39). 
Phenotypic changes in FDC-reticula appear to be closely associated with 
the dynamics of the GC reaction. Typical GC have a lifespan of approximately 
3 wk (137) and their termination begins around day 14. This corresponds with 
alterations in FDC morphology including termination of iccosome production, 
and persisting Ag becomes buried within a labyrinth of membrane, thus 
minimizing BCR stimulation (28). While primary FDC-reticula can be labeled 
with CR1/2, FDC with the activated phenotype are associated with active peanut 
agglutinin (PNA)+ GC (30). The lack of activated FDC-reticula in the absence of 
PNA labeling strongly suggests that the activated FDC phenotype is lost as the 
GC reaction is terminated. 
FcγRIIB is generally considered to be an inhibitory receptor and is known to 
reduce the functionality of B cells, mast cells, and conventional dendritic cells (reviewed 
in (122,142)). However, in FDC, this receptor appears to promote a phenotype associated 
with FDC accessory activity. Clearly, engaging the same FcγRIIB receptor on B cells 
with the same IC did not lead to an apparent up-regulation of FcγRIIB on GC B cells or 
an increase in mRNA on isolated B cells. Thus, the FcγRIIB signaling pathway leading to 
the change in FDC phenotype is likely very different in FDC vs. other FcγRIIB-bearing 
cells. A recent report by Victoratos et al. (128) indicates that IκB kinase (IKK)2-
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dependent signals are critical for IC-driven induction of VCAM-1 and ICAM-1 
expression in FDC through the canonical NF-κB pathway, whereas, p55TNFR is 
essential for FDC network formation and maintenance, which is independent of IKK2. 
The data reported here are in complete harmony with these results (128). 
Critical ligand-receptor reactions involved in FDC-B cell interactions include Ag-
BCR, CD21L-CD21 and FcγRIIB-Fc. These receptor-ligand interactions are not MHC 
restricted and murine as well as human FDC work across MHC and even species barriers 
(56). FcγR genes are derived from a common ancestral gene, and the FcγRII genes in 
humans and mice are structurally related with a single FcgRIIB gene coding for a single 
protein chain characterized by an extracellular ligand-binding domain together with an 
intracellular cytoplasmic tail (143,144). The present data support the concept that 
engagement of murine FDC-FcγRIIB with IC induces the activated phenotype, and we 
reason that ICs likely activate human FDC as well. 
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CHAPTER 2  
Toll-like Receptor-4 on Follicular Dendritic Cells:  
An Activation Pathway that Promotes Accessory Activity 
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Introduction 
Accessory cells of the immune system tend to remain quiescent until 
they encounter alarm signals that promote activation. Activation involves 
upregulation of molecules, including co-stimulatory molecules, needed for 
optimal presentation of Ag to specific lymphocytes and the initiation of adaptive 
immune responses.  Infectious agents are a major source of alarm signals that 
are recognized by pattern recognition receptors (PRRs) that engage conserved 
pathogen-associated molecular patterns (PAMPs) (145-147). The range of 
molecular patterns recognized by PRRs includes signals from injured or stressed 
host cells and tissues (148,149).  Prominent PRRs include the evolutionarily 
conserved membrane bound Toll-like receptors (TLRs) that recognize PAMPs 
and initiate responses in organisms as diverse as flies and mammals (150-154). 
TLR4 is an especially clear example of a receptor that is known to engage LPS, 
an amphiphilic molecule in the outer leaflet of the outer membrane of Gram-
negative bacteria, and activate accessory cells (149,155,156).  
Follicular dendritic cells (FDCs) are localized to the light zones of 
germinal centers (GCs), where their dendritic processes interdigitate and form 
three-dimensional FDC-networks or -reticula (44,46,157) that help these non-
circulating cells remain fixed while attracting specific lymphocytes (47,67).  
FDC functions include the capture and retention of ICs (22,30,158), promotion 
of B cell survival (111-115,115) and promotion of high affinity Ab production 
(39,116).  The phenotype of FDCs in primary and secondary follicles is very 
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different. In secondary follicles, FDCs bear high levels of FcγRIIB, ICAM-1, 
and VCAM-1 and these molecules are involved in converting poorly 
immunogenic ICs into a highly immunogenic form for B cells and in facilitating 
FDC-B cell interactions (30,57,69,132). In contrast, FcγRIIB, ICAM-1, and 
VCAM-1 levels are low and difficult to detect in FDC-reticula of primary 
follicles (30,132,134). The presence of these resting and activated FDCs 
prompted the hypothesis that FDCs, like other accessory immune cells, may 
express PRRs capable of recognizing PAMPs leading to the acquisition of an 
activated phenotype required for optimal FDC accessory activity.   
To begin hypothesis testing, we sought to determine if FDCs express 
TLR4 and if LPS can activate FDCs via TLR4. Activation was indicated by 
increased expression of FDC function-associated molecules FcγRIIB, ICAM-1 
and VCAM-1 by flow cytometry. TLR4 expression on FDCs in situ was studied 
with immunohistochemistry followed by flow cytometric and RT-PCR analyses 
on purified FDCs. The role of FDC-TLR4 engagement with LPS was 
investigated by adoptive transfer of wild-type LPS-responsive C3H/HeN 
leukocytes into TLR4-mutated LPS-hyporesponsive C3H/HeJ mice with host 
FDCs. The TLR4 activation pathway involves NF-κB activation and the 
involvement of this pathway was examined by flow cytometric analysis of 
intracellular phospho-IκB-α in FDCs.  Finally, we sought to determine if 
activated FDCs have increased accessory activity as indicated by the enhanced 
ability to promote specific IgG responses in vitro.   
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The results indicated for the first time that FDCs express TLR4 on their 
surfaces and that TLR4 engagement mediates activation as indicated by a 
marked increase of FDC function-associated molecules and that activation 
involves the NF-κB pathway.  Moreover, like other accessory cells, activated 
FDCs have increased accessory activity as indicated by increased anti-OVA 
production in comparison with non-activated FDCs. An important implication of 
these studies is that TLR agonists may promote immune responses not only by 
stimulating dendritic cells (DCs) and enhancing T cell function but also by 
stimulating FDCs and promoting B cell function. An understanding of how TLR 
agonists influence FDC activation may give insight into how adjuvants should 
be formulated to give optimal humoral immune responses when administering 
vaccines. 
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Materials and Methods 
Animals 
Six to eight weeks old BALB/c mice were obtained from the National Cancer 
Institute (Bethesda, MD). The C3H/HeNTac mice were from Taconic Farms 
(Hudson, NY), and the C3H/HeJ mice were from the Jackson Laboratory (Bar 
Harbor, ME). All mice were housed in standard plastic shoebox cages with filter 
tops and maintained under specific pathogen-free conditions in accordance with 
guidelines established by Virginia Commonwealth University Institutional 
Animal Care and Use Committee.  
Antibodies and other reagents 
Sigma (L-7895) cell culture tested, gel-filtration purified, γ-irradiated 
LPS from Salmonella typhosa was used in this study with more than 99% purity. 
FITC conjugated rat anti-mouse CD106 (mVCAM-1, catalog # 553332), CD54 
(mICAM-1, catalog # 553252), CD16/CD32 (FcγRII/III, catalog # 553144), Fc 
blocker (2.4G2, catalog # 553142), rat anti-mouse FDC-M1 (catalog # 551320), 
biotinylated anti-rat κ light chain (catalog # 553871), rat IgG2bκ (catalog # 
553988), Rat IgG2aκ (catalog # 554688), hamster IgG1κ (catalog # 553971) 
isotype controls, streptavidin-HRP (catalog # 550946) and the DAB substrate kit 
(catalog # 550880) were from BD PharMingen (San Diego, CA). FITC 
conjugated rat anti mouse TLR4 was from Imgenex (San Diego, CA, catalog # 
IMG-428C). Anti-biotin microbeads, CD45R (B220) MicroBeads (130-049-
501), and MACS LS columns were purchased from Miltenyi Biotec GmbH 
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(Auburn, CA). Rabbit anti-mouse TLR4 (ab47093) and biotinylated goat anti 
rabbit IgG (ab6720-1) were purchased from Abcam (Cambridge, MA). Biotin 
labeled goat anti-rat IgG was from Southern Biotech (Birmingham, AL, catalog 
# 3050-08) and the Universal Block was from KPL (Gaithersburg, MD, catalog 
# 71-00-61). Antibodies used in flow cytometry were used at a concentration of 
1 μg/106 cells while antibodies used in immunohistochemistry were used at a 
concentration of 5 μg/ml. 
Immunohistochemical labeling of TLR4, FDC-M1, and GL-7 in situ 
Popliteal LNs were collected from normal BALB/c mice and frozen in 
CryoForm embedding medium (IEC, Needham Heights, MA). Frozen sections 
of 10 μm thickness were cut on a Leica (Jung Frigocut 2800E) cryostat and air-
dried. Following absolute acetone fixation, the sections were dehydrated and the 
endogenous peroxidase activity was quenched with the Universal Block. The 
sections were washed and saturated with 10% BSA. Serial sections were 
incubated with unlabeled rabbit anti-mouse TLR4 or rat anti-mouse FDC-M1. 
Sections were washed and then incubated with biotin-conjugated goat anti-rabbit 
or anti-rat IgG followed by streptavidin-HRP. The sections were developed 
using a DAB substrate kit. For germinal center B cell labeling, 10 μm cryostat 
sections of axillary lymph nodes from OVA-immunized BALB/c mice were 
labeled with IgM rat anti-mouse T- and B-cell activation antigen (GL-7, Ly-77) 
(eBioscience 14-5902-85), followed by biotinylated goat anti-rat IgM (Southern 
Biotech 3020-08) and phosphatase-labeled streptavidin (KPL 15-30-00). The 
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sections were developed with SIGMAFAST™ BCIP/NBT alkaline phosphatase 
substrate (Sigma, B5655). Rabbit polyclonal IgG (Abcam ab27478), rat IgG2c 
(BD Biosciences 553982) rat IgM (eBioscience 14-4341) isotype controls were 
similarly treated. Images were captured with Optronics digital camera and 
analyzed with Bioquant Nova software.  
DC, FDC, and B cell isolation  
DCs were isolated from splenic leukocytes using the CD11c micro-bead 
kit from Miltenyi Biotec GmbH (Auburn, CA). FDCs were isolated by positive 
selection from LNs (axillary, lateral axillary, inguinal, popliteal, and mesenteric) 
of irradiated adult mice as previously described (130). One day before isolation 
mice were irradiated with 1000 rad to eliminate most lymphocytes, then mice 
were killed, LNs were collected, opened and treated with 1.5 ml collagenase D 
(22 mg/mL, C-1088882; Roche), 0.5 mL of DNase I (5000 U/mL, D-4527; 
Sigma), and 2 mL DMEM with 20 mM HEPES. After 45 min at 37°C in a CO2 
incubator, released cells were washed in 5 mL DMEM with 10% FCS. Cells 
were then sequentially incubated with FDC-specific Ab (FDC-M1) for 45 min, 
1 µg of biotinylated anti-rat κ light chain for 45 min, and with 20 µl anti-biotin 
microbeads (Miltenyi Biotec GmbH (Auburn, CA) for 15-20 min on ice. The 
cells were layered on a MACS LS column and washed with 10 ml ice-cold 
MACS buffer. The column was removed from the VarioMACS and the bound 
FDCs were released with 5 ml MACS buffer. B220+ B cells were isolated from 
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BALB/c lymph nodes using CD45R (B220) MicroBeads from Miltenyi Biotec 
GmbH (Auburn, CA).  
Labeling of purified FDCs and B220+ B cells with anti-TLR4  
FDCs and B220+ B cells isolated from BALB/c mice were incubated 
with mouse Fc-Block (BD PharMingen) for 15 min on ice, followed by FITC 
conjugated rat anti mouse TLR4 or isotype control for 60 min in the dark at 4°C. 
After washing, the cells were analyzed using an FC500 flow cytometer and 
Cytomics RXP analysis software. Histograms were gated for FDCs based on 
their forward and side scatter properties established with FDC phenotypic 
markers including FDC-M1, CD21/35, and CD32 (130). The figures were 
plotted using WinMDI software (Scripps Research Institute).  
Detection of TLR4 mRNA in purified FDCs by RT-PCR 
Total cellular RNA was extracted from 2x106 FDCs purified from lymph 
nodes or spleens as well as control splenic dendritic cells of BALB/c mice using 
TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA) according to the 
manufacturer's instructions, and a 100 ng was reverse transcribed into cDNA 
using GeneAmp Gold RNA PCR Core Kit. One tenth of cDNA was primed with 
TLR4 specific primers 5'-GCTTTCACCTCTGCCTTCAC-3' and 3'-
CGAGGCTTTTCCATCCAATA-5' and amplified by PCR.  PCR products were 
electrophoresed in 1.5 % agarose, stained with ethidium bromide, and visualized 
by UV trans-illuminator. 
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Analysis of FcγRIIB, VCAM-1, and ICAM-1 on LPS-treated FDCs in vivo 
and in vitro 
FDCs were positively selected with FDC-M1 from the draining lymph 
nodes of irradiated BALB/c mice three days after injecting 25 μg of LPS in the 
four limbs. Control FDCs were isolated from saline injected mice. In addition, 1 
x 106 purified FDCs were treated in vitro with 10 μg LPS in 1 ml media for 
three days and the surface expression of FcγRIIB, VCAM-1, and ICAM-1 was 
compared with 1 x 106 control FDCs cultured in media without LPS. Analysis 
was done by incubating FDCs with mouse Fc-Block (BD PharMingen) for 
15 min on ice, followed by FITC conjugated rat antibodies against FcγRIIB, 
ICAM-1, and VCAM-1 or isotype control for 60 min in the dark at 4°C. After 
washing, the cells were analyzed by flow cytometry.  
Adoptive transfer 
C3H/HeJ and C3H/HeN recipients were exposed to 600 rad of irradiation 
and one day later they were reconstituted with 2 x 107 LPS-responsive C3H/HeN 
total splenic leukocytes injected behind the neck. The mice were challenged 
with LPS in the legs and the FDCs were isolated after 3 days. 
 Analysis of FcγRIIB, VCAM-1, and ICAM-1 on LPS-treated C3H/HeN and 
C3H/HeJ FDCs 
FDCs were positively selected from the lymph nodes of C3H/HeN or 
C3H/HeJ mice three days after injecting 25 μg of LPS in each limb and control 
FDCs were isolated from saline injected mice. FDCs were first incubated with 
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mouse Fc-Block for 15 min on ice, followed by FITC conjugated rat antibodies 
against FcγRIIB, ICAM-1, and VCAM-1 or isotype control for 60 min in the 
dark at 4°C. After washing, the cells were analyzed by flow cytometry.  
Intracellular labeling of phospho-IκB−α in Purified FDCs treated with LPS 
in vitro  
Purified FDCs were serum-starved for 24 hours then treated with 10 
μg/ml LPS overnight in DMEM with 10% FCS. Control groups of unstimulated 
FDCs as well as macrophage cell line J774 were similarly treated. Cells were 
washed then fixed and permeabilized using Fix & Perm cell permeabilization kit 
(Caltag, Burlingame, CA). Intracellular phospho-IκB-α was labeled with rabbit 
anti-phospho-IκB-α (Cell Signaling Technology, Danvers, MA) followed by PE 
conjugated goat anti-rabbit IgG and cells were analyzed with flow cytometry. 
Cell culture and ELISA assessment of OVA specific IgG 
Lymph nodes cells from OVA-immunized BALB/c mice were cultured, 
in the presence of 100 ng/ml OVA-anti-OVA ICs, with FDCs isolated from 
LPS-treated mice and compared with control FDCs at ratios of 64, 128 and 256 
lymphocytes per FDC. The media was changed after one week and OVA 
specific IgG was assessed by ELISA 7 days later as previously described (29). 
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Results 
Immunohistochemical labeling of TLR4 on FDCs but not on GC B cells in 
situ 
As shown in panel A of Fig. 1, adjacent sections of lymph nodes were 
labeled with FDC specific marker FDC-M1 (Fig. 1A-a) and anti-TLR4 (Fig. 1A-
c). TLR4 co-localized with the FDC-M1 as indicated by the labeling in the area 
between the arrows. The characteristic labeled FDC-network or reticulum made 
up by interactive dendrites of FDCs can be seen. Germinal center B cells 
intermingle with FDCs and we sought to determine if they label with anti-TLR4 
and contribute to the labeling in Fig. 1A-c. Germinal center B cells are activated 
and labeled with anti-mouse T- and B-cell activation antigen GL-7 (Fig. 1B-a), 
but in contrast with FDCs, they did not label with TLR4 in adjacent lymph node 
sections (Fig. 1B-c).  Thus TLR4 labeling in GCs appeared to be attributable to 
FDCs and not B cells.  Isotype controls (Fig. 1A-b, A-d, B-b, B-d) were included 
and shown to the right of the corresponding labeled sections.   
TLR4 labeling of purified FDCs  
To confirm expression of TLR4, FDCs were purified by positive 
selection using the monoclonal Ab FDC-M1, and labeled with anti-TLR4-FITC. 
As illustrated in panel C of Fig. 1, flow cytometric analysis revealed that 
virtually the entire FDC population shifted to the right when labeled with anti-
TLR4 with more than a two fold increase in mean fluorescent intensity (MFI) 
over the background control. Analysis was restricted to viable cells indicating 
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that TLR4 is expressed on the surface of FDC membranes. B cells positively 
selected with B220, an antigen expressed on B lineage cells throughout their 
development but not on plasma cells, also appeared to shift to the right as a 
consequence of anti-TLR4 labeling (Fig. 1D). However, in contrast with FDCs 
where the MFI more than doubled upon labeling with anti-TLR4, the increased 
MFI for the B cells was only 0.2 above the isotype control. In short, murine B 
cells may express some TLR4 but it is unlikely that they are making a 
significant contribution to the strong TLR4 labeling in GC areas where the FDC-
reticulum identified by FDC-M1 is present.  
TLR4 mRNA in purified FDCs  
RNA extracted from purified FDCs from murine lymph nodes (Fig. 2A) 
and spleen (Fig. 2B) was reverse transcribed into cDNA. TLR4 specific primers 
were used to amplify the relevant DNA and the results were compared with 
similarly treated purified splenic dendritic cells (DCs) as a positive control (Fig. 
2C). Gel electrophoresis of amplified PCR products revealed a single 361 bp 
band shared between dendritic and follicular dendritic cells indicating TLR4 
expression by FDCs. 
LPS-mediated upregulation of FDC-FcγRIIB, -ICAM-1, and -VCAM-1 
Injecting LPS increased the levels of FcγRIIB, ICAM-1, and VCAM-1 
on FDCs from the draining lymph nodes (Fig. 3A-a, b, c) where virtually the 
entire FDC population shifted to the right when labeled with antibodies reactive 
with these markers and the MFI approximately doubled in each case. Similarly,  
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Figure 1: Labeling of FDCs with anti-TLR4. A, Illustrates TLR4 labeling on FDCs in 
situ using immunohistochemistry. Adjacent sections from popliteal LNs were labeled for 
TLR4 and the FDC-specific marker FDC-M1. As indicated by arrowheads, FDC-M1 
labeling (Aa) colocalized with TLR4 expression (Ac), and the characteristic labeling of 
FDC network or reticulum made up by interactive FDC dendrites can be seen. B, Lack of 
TLR4 labeling on GC B cells. Adjacent sections from axillary LNs of OVA-immune 
animals were labeled with GL-7, anti-mouse T and B cell activation Ag (Ba), and anti-
TLR4 (Bc). As shown between arrowheads, GL-7+ B cells did not label with anti-TLR4. 
Isotype controls (Ab, Ad, Bb, and Bd) are shown to the right of the appropriate adjacent 
section. C, Flow cytometry was used to assess TLR4 labeling of purified FDCs in vitro. 
Purified FDC preparations were labeled with anti-TLR4-FITC and compared with an 
isotype control. The MFI of TLR4-FITC-labeled FDCs was double the isotype control. D, 
TLR4 labeling of purified B220+ B cells. Purified B220+ B cell preparations were labeled 
with anti-TLR4-FITC and compared with an isotype control. B220+ B cells were hardly 
labeled with TLR4-FITC, and the MFI of TLR4-FITC-labeled B cells was 0.2 above the 
MFI of the isotype control. These data are representative of three separate experiments of 
this type. 
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Figure 2: RT-PCR analysis of TLR4 mRNA in purified FDCs. Total RNA extracted 
from purified FDCs of mouse LNs (A) and spleen (B) were primed with TLR4-specific 
primers and compared with purified DCs isolated from mouse spleen (C). A single 361-
bp band shared between DCs and FDCs is seen, providing evidence for TLR4 expression 
in FDCs. 
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Figure 3: Up-regulation of FcγRIIB, ICAM-1, and VCAM-1 on LPS-treated FDCs in 
vivo (A) and in vitro (B). FDCs were purified from the LNs of LPS-treated BALB/c mice 
and compared with control FDCs isolated from saline-injected mice (A). Likewise, 
purified FDC preparations treated in vitro with LPS for 3 days were compared with 
control FDCs cultured in medium without LPS (B). FDCs were labeled with FITC-
conjugated rat Abs against FcγRIIB (a), ICAM-1 (b), and VCAM-1 (c) or isotype control. 
The MFI of FITC-labeled FDCs were almost double the corresponding isotype controls 
in vivo and in vitro, although the intensity of VCAM-1 up-regulation on FDCs stimulated 
in vitro was comparatively less. These data are representative of three separate 
experiments of this type. 
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treating purified FDCs in vitro (Fig. 3B-a, b, c) with LPS for three days increased the 
levels of FcγRIIB, ICAM-1, and VCAM-1 expression on FDCs although the intensity of 
VCAM-1 upregulation was comparatively less. 
 FDCs purified from TLR4-mutated C3H/HeJ mice did not respond to LPS 
even when reconstituted with leukocytes from TLR4 wild-type mice 
FDCs from wild-type LPS-responsive C3H/HeN mice upregulated FDC-
FcγRIIB, ICAM-1, and VCAM-1 when injected with LPS (Fig. 4A) much like 
the BALB/c mice shown in Fig. 3. Moreover this response persisted after 
irradiation and reconstitution with LPS-responsive C3H/HeN total splenic 
leukocytes (Fig. 4B). In marked contrast, FDCs from TLR4-mutated C3H/HeJ 
mice failed to upregulate FDC-FcγRIIB, -ICAM-1, and -VCAM-1 after LPS 
injection (Fig. 4C) even after reconstitution with wild-type TLR4 LPS-
responsive C3H/HeN leukocytes (Fig. 4D). This suggests that LPS engagement 
of TLR4 on the FDC is important, and that FDC activation is not simply a 
response to cytokines being produced by other TLR4 responsive leukocytes. 
LPS mediated upregulation of intracellular phospho-IκB-α in FDCs 
indicative of NF-κB activation  
Signaling through TLR4 typically involves the NF-κB pathway 
prompting the hypothesis that stimulation of FDCs with LPS would upregulate 
intracellular phospho-IκB-α in FDCs.  Purified FDCs were incubated with 10 
μg/ml LPS overnight. Control groups included unstimulated FDCs and murine 
macrophage cell line J774 that were similarly treated. Flow cytometric analysis 
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revealed that the MFI of intracellular phospho-IκB-α in the control macrophage 
cell line about doubled after exposure to LPS (Fig. 5A). The FDC response to 
LPS was very similar and the increase in MFI was even higher (Fig. 5B).  
Similar results were obtained with 0.1 and 1μg of LPS but the results were most 
apparent with the 10 μg dose illustrated in Fig. 5. 
LPS activated FDCs exhibited enhanced accessory activity in promoting recall 
responses in vitro.  
FDCs from normal mice are known to enhance recall responses 
optimally at ratios between 1 FDC to 4 - 16 lymphocytes although detectable 
accessory activity may be apparent with more lymphocytes (159). We reasoned 
that LPS activated FDCs would have enhanced accessory activity and that might 
be most apparent in IgG recall responses at low FDC to lymphocyte ratios. 
When cultured at a ratio of 1 FDC to 64 lymphocytes, the IgG anti-OVA 
produced in cultures containing activated FDCs was about 4 times higher than 
the production with FDCs from normal mice which in turn produced anti-OVA 
IgG comparable to 1 activated FDC to 256 lymphocytes (Fig. 6). In marked 
contrast, FDCs from normal mice were without detectable activity at 1 FDC to 
256 or even 128 lymphocytes (Fig. 6).   
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Figure 4: Lack of up-regulation of FcγRIIB, ICAM-1, and VCAM-1 on FDCs purified 
from TLR4-mutated C3H/HeJ mice even when reconstituted with leukocytes from 
TLR4 wild-type mice. The levels of expression of FcγRIIB, ICAM-1, and VCAM-1 in 
TLR4-intact LPS-responsive C3H/HeN were assessed using flow cytometry 3 days after 
LPS injection (A) or after irradiation, reconstitution with C3H/HeN leukocytes, and LPS 
injection (B). Similarly, FcγRIIB, ICAM-1, and VCAM-1 in TLR4-mutated C3H/HeJ 
mice were analyzed 3 days after LPS injection (C) or after irradiation, reconstitution with 
C3H/HeN leukocytes, and LPS injection (D). FDCs from TLR4-intact LPS-responsive 
C3H/HeN mice demonstrated up-regulation of FcγRIIB, ICAM-1, and VCAM-1 when 
injected with LPS, and that persisted after irradiation and reconstitution. On the contrary, 
FDCs purified from TLR4-mutated C3H/HeJ mice failed to up-regulate their FcγRIIB, 
ICAM-1, and VCAM-1 upon encountering LPS, and that persisted even after 
reconstitution with TLR4-intact LPS-responsive C3H/HeN leukocytes. These data are 
representative of three separate experiments of this type. 
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Figure 5: Up-regulation of intracellular phospho-IκB-α in purified FDCs treated with 
LPS in vitro. Purified FDC preparations were treated with 10 µg/ml LPS overnight, and 
control groups of unstimulated FDCs as well as macrophage cell line J774 were included. 
FDC intracellular phospho-IκB-α rose after LPS treatment to levels comparable to those 
seen in the control macrophage cell line. These data are representative of three separate 
experiments of this type. 
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Figure 6: Activated FDCs have enhanced accessory cell activity in OVA-specific recall 
responses. OVA-specific lymphocytes were cultured, in the presence of OVA-anti-OVA 
ICs, with FDCs isolated from LPS-treated mice and compared with control FDCs at 
ratios of 64, 128, and 256 lymphocytes to 1 FDC. Two weeks later, OVA-specific IgG 
was assessed by ELISA. At all tested ratios, cultures containing activated FDCs promoted 
significantly higher anti-OVA IgG levels than cultures with control FDCs, (p < 0.01; 
Student’s t test). Averages were calculated using data from three cultures, and results 
illustrate the means ± SEM. 
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Discussion 
 Engagement of TLRs on DCs leads to physiological and phenotypic 
changes that dramatically alters their ability to present Ag to T cells 
(145,160,161).  DC alterations include changes in: survival, chemokine receptor 
expression, chemokine secretion, migration, cell shape and endocytic activity 
(162).  LPS and other TLR agonists promote DCs maturation and accessory 
activity in priming naïve T cells, promoting clonal expansion, and stimulating 
differentiation of T cells into effectors (163). We reasoned that for the immune 
system to respond to microbial invasion as an integrated unit, microbial patterns 
encountered early in immune responses should activate not only the DC-T cell 
axis but also the FDC-B cell axis. The data reported here indicated that FDCs 
express surface TLR4 and that engagement of this receptor in vivo and in vitro 
altered their physiology and phenotype leading to FDC activation.  Moreover, 
activated FDCs were far more effective in enhancing the production of specific 
IgG than FDCs from normal mice. Immune complex bearing FDCs reside in 
germinal centers where B cells: proliferate, isotype switch, somatically 
hypermutate, become memory cells, and transition from B cells into antibody 
forming cells (reviewed in (46,125)). Considerable data indicate that FDCs 
influence these B cell functions (reviewed in (44,46)). An understanding of FDC 
activation could facilitate our ability to manipulate the immune system such that 
the appropriate adjuvants could be selected to activate FDCs and optimize 
humoral immune responses when vaccines are administered.  
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Analysis of mRNA by RT-PCR in the present study suggested that TLR4 
expression in DCs and FDCs is comparable. The fact that FDCs are barely 
endocytic and retain Ag in immune complexes on their surfaces (164) allows the 
surface expressed FDC-TLR4, as shown by flow cytometry, to engage LPS in an 
environment spatially associated with other FDCs accessory functions, including 
IC trapping and receptor mediated B cell-FDC clustering and interactions. The 
presence of TLR4 molecules inside the FDCs has not been excluded, but clearly 
anti-TLR4 labels FDC membranes intensely. Cytokines help activate many cell 
types and we reasoned that cytokines induced by LPS may play an important 
role in FDC activation.  However, no support for this idea was found in the 
present study. When normal splenic leukocytes, that are fully capable of 
secreting cytokines upon TLR4 engagement, were injected into irradiated TLR4 
mutated C3H/HeJ mice and challenged with LPS, the FDCs with mutated TLR4 
still failed to activate (Fig. 4D). These results argue that functional TLR4 on 
FDCs is important. Moreover, when purified wild-type FDCs were treated with 
LPS in vitro, they responded well suggesting that FDC-TLR4 is sufficient (Fig. 
3B). 
FDC-associated germinal center B cells failed to label 
immunohistochemically in situ with anti-TLR4, and purified B cell preparations 
positively selected with the pan-B cell marker CD45R (B220) were barely 
labeled with anti-TLR4 by flow cytometry. These data are consistent with 
similar results reported by Akashi et al where cell surface TLR4-MD-2 was 
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hardly detectable on CD19-positive B cells and intracellular staining by the 
saponin detergent did not make a difference (165).  
FcγRIIB plays an important role in FDC-B cell interactions. Both FDC 
and B cells express FcγRIIB (57,58), but B cell activation may be inhibited by 
immunoreceptor tyrosine-based inhibition motif (ITIM) signaling mediated by 
IC coligating the B cell receptor for Ag (BCR) and B cell-FcγRIIB (122,123). 
Engagement of BCR in the absence of such coligation induces rapid activation 
of tyrosine kinases, generation of inositol phosphates, elevation of cytoplasmic 
Ca2+ concentrations, and activation of mitogen-activated protein kinases 
(reviewed in (122,123)). These events promote B cell activation and lead to 
proliferation, differentiation, and Ab secretion (124). In marked contrast, 
coligation of BCR and FcγRIIB by ICs leads to inhibition of the extracellular 
Ca2+ influx, reduction of cell proliferation, blockage of blastogenesis, and 
inhibition of Ig synthesis (122-124). Nevertheless, ICs on FDCs provide potent 
activation signals for B cells that result in induction of germinal center dark 
zones where B cells rapidly proliferate and differentiate (reviewed in (125)). 
However, FDCs lacking FcγRIIB or expressing only low levels of FcγRIIB are 
unable to convert poorly immunogenic IC into a highly immunogenic form for B 
cells, although they can trap IC using CRs (complement receptors) (30). In 
active GC, FDCs express high levels of FcR relative to B cells, and these FDC-
Fc receptors bind Fc portions of Ab in ICs and appear to minimize their binding 
to FcR on B cells (30,44,57). Accordingly, cross-linking of BCR and FcγRIIB 
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via IC is minimized, ITIM signaling is reduced, and B cell proliferation and 
differentiation is promoted. Thus, activating FDCs and increasing FDC-FcγRIIB 
levels would be expected to enhance accessory activity. 
FDCs and B cells form large clusters in culture and B cells proliferate 
adjacent to FDCs much like they do in the dark zone of GCs in vivo (69). FDC-
ICAM-1 and -VCAM-1 are important adhesion molecules and blocking these 
molecules inhibits clustering of FDCs and B cells and the ability of B cells to 
proliferate in GC reactions in vitro (69). Upregulating these adhesion molecules 
should promote FDC-B cell interactions, facilitate clustering and presentation of 
FDC-Ag to B cells, and enhance the GC reaction. The signaling pathway known 
to up-regulate FDC-ICAM-1 and -VCAM-1 is mediated via the NF-κB (128) 
and up-regulation of FDC-ICAM-1 and -VCAM-1 may be initiated by ICs 
engaging FDC-FcγRIIB (70). Similarly, the NF-κB pathway appeared to be 
activated when FDC-ICAM-1 and -VCAM-1 were upregulated by LPS 
engaging FDC-TLR4 in the present study. 
The initial exposure to appropriate immunogen primes T cells and 
stimulates specific B cells to begin making Abs. Specific Abs bind the 
immunogen and form ICs, ICs are trapped by FDCs, B cells are stimulated by 
the Ag in FDC-ICs, and GC reactions are initiated. The data presented here 
suggest that FDCs can be activated by TLR4 agonists and such agonists can be 
delivered by the pathogen or with the immunogen. Thus, FDCs could be 
activated and ready to trap ICs and optimally stimulate B cells as soon as the 
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first ICs are made. The ICs themselves can activate FDCs but that requires 24 to 
48 hours after encountering adequate amounts of ICs (70). The present study 
indicated that FDCs were activated via TLR4 engagement in 3 days, and that 
would precede Ab production and IC formation.  Thus, ICs could be trapped by 
activated FDCs and that would speed up and enhance GC events including B 
cell proliferation, isotype switching, somatic hypermutation, memory cell 
formation, transition from B cells to antibody forming cells, selection, and 
affinity maturation. In addition to TLR4, preliminary studies using RT-PCR 
indicated that FDCs express TLR-2, TLR-3 and TLR-9. By use of flow 
cytometry with purified FDCs we were able to confirm expression of TLR-2 and 
TLR-3. Stimulation of FDCs with the TLR-3 ligand poly (I:C) resulted in 
upregulation of CR1/2, FcγRIIB and VCAM-1. However, the data suggest that 
TLRs may differ in their impact on FDC phenotype & function and further 
studies in this area are in progress. Nevertheless, an understanding of how FDCs 
can be optimally activated via TLR engagment could provide information 
needed to control and enhance the development of protective humoral immune 
responses. 
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CHAPTER 3 
FOLLICULAR DENDRITIC CELLS STIMULATED BY 
COLLAGEN TYPE I DEVELOP DENDRITES AND 
NETWORKS IN VITRO 
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Introduction 
Follicular dendritic cells (FDCs) are located in the light zone of germinal 
centers (GCs), where their dendritic processes interdigitate and form three-
dimensional networks or FDC-reticula (42,46,157,166). Functions of FDCs 
include the production of chemokines that help organize lymphoid follicles (67), 
capture and retention of immune complexes (ICs) (30), presentation of ICs to B 
cells under conditions that minimize activation of the immuno tyrosine 
inhibitory motif in B cells (44), promotion of B cell survival (111-114,114), 
promotion of Ig class switching, production of high affinity Abs, B cell selection 
associated with affinity maturation and production of B memory cells with high 
affinity receptors (39,116,167). 
Although description of antigen localization in lymphoid follicles dates 
back to 1950 (168), the nature of the antigen retaining cells remained obscure 
until described at the ultrastructural level in rodent spleen or lymph node 
sections by Szakal and Hanna (21) and Nossal et al (166) in 1968. These authors 
reported radiolabeled antigen associated with highly convoluted infoldings of 
the plasma membrane of FDCs, and antigen was associated with electron dense 
material found in the extracellular spaces adjacent to FDC processes (21,22). 
Subsequent studies indicated that these antigen retaining cells are not free to 
circulate and Ag remained localized to FDCs in the draining lymphatics for 
months to years (51). Consequently, antibody induced by the retained Ag is 
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restricted to draining lymph nodes and this pattern was followed for as long as 
one year (51). 
Several cells in lymphoid tissues have dendritic processes that 
distinguish them from lymphocytes and typical macrophages; however, the 
ability of FDCs to trap and retain ICs for long periods makes them unique. 
Different names have been used for FDCs, e.g. antigen retaining reticular cells, 
follicular immune complex retaining cells, follicular antigen-binding dendritic 
cells, follicular reticular cells, follicular dendritic reticulum cells, and dendritic 
macrophages until 1982 when the name: follicular dendritic cell was accepted 
(23).  
Morphologically, FDC are characterized by their irregularly shaped 
euchromatic nuclei surrounded by a narrow rim of cytoplasm from which long 
slender highly convoluted dendrites emanate (42). Although FDCs represent 
only 1–2% of GC cells, their numerous long slender dendrites intertwine and 
create an extensive network or reticulum that makes them a prominent GC 
component (42). The extensive network enables FDCs to be in intimate contact 
with neighboring B cells (90% of GC cells) and T cells (5–10% of GC cells) 
(11,42,169). FDCs use complement (119,120) and FcγRs (30,170) to capture 
and retain ICs and they deliver the Ag in the form of IC-coated bodies 
(iccosomes) to neighboring B cells for subsequent presentation to GC T cells to 
obtain T cell help (38).  
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Our understanding of FDC biology has been promoted by use of 
enriched FDCs in vitro. Twenty-one years ago we isolated and characterized 
FDCs from murine lymph nodes. These FDCs were identified by the ICs they 
retained, and descriptions were based on light microscopy using Nomarski 
optics, scanning electron microscopy, and transmission electron microscopy. 
These freshly isolated FDCs had numerous long filliform or beaded dendrites 
and lacked the ability to adhere to glass or plastic (42). Subsequent enrichment 
procedures included whole body irradiation to remove the irradiation sensitive 
lymphocytes, Percoll replaced BSA in the gradients, and more recently positive 
selection with FDC-M1 antibodies on magnetic columns (69,130). Increased 
handling resulted in individual FDCs that appeared almost spherical under light 
microscopy and short to medium length dendritic processes were only readily 
apparent under electron microscopy (130). Clearly, the FDC-reticulum, so 
characteristic of cells in vivo, had been destroyed and the longer FDCs were 
cultured the less dendritic they appeared.  
Structure typically promotes function and numerous attempts were made 
to increase dendrite formation and reestablish FDC-reticula in vitro without 
success. Given that FDC purification requires use of collagenase and that FDCs 
may be found at the edges of the GCs attached to the supporting reticular fibers 
(171), we reasoned that isolated FDCs might reattach to collagen and form 
processes and reticula. To test this, positively selected FDCs were incubated on 
dried collagen and collagen related molecules. The results presented here 
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indicate that FDCs bind these molecules and that interaction with collagen type I 
promotes dendrite formation and the production of FDC-reticula in vitro. In 
short, FDCs placed on collagen-coated plates, attached to the matrix, 
regenerated processes, and formed immobile networks with numerous features 
in common with networks in vivo.  
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Materials and Methods 
Animals 
Normal 6- to 8-wk-old BALB/c mice were purchased from the National 
Cancer Institute. The mice were housed in standard plastic shoebox cages with 
filter tops and maintained under specific pathogen-free conditions in accordance 
with guidelines established by Virginia Commonwealth University Institutional 
Animal Care and Use Committee.  
Antibodies and other reagents 
Rat-tail collagen type I was purchased from Roche Diagnostic GmbH 
(Indianapolis, IN). Hyaluronic acid, Biglycan and Laminin were from Sigma (St 
Louis, MO). Rabbit anti-collagen Type I and biotin-conjugated goat anti-rabbit 
IgG were from Abcam (Cambridge, MA). FDC-M1, biotin-labeled anti-rat 
kappa, Streptavidin-HRP and DAB substrate kit were from BD PharMingen 
(San Diego, CA). Anti-Biotin MicroBeads, and MACS LS columns were 
purchased from Miltenyi Biotec GmbH (Auburn, CA).  
FDC Isolation 
FDCs were isolated by positive selection from axillary, lateral axillary, 
inguinal, popliteal, and mesenteric lymph nodes of adult mice as recently 
described (130). In brief, one day before isolation four mice were irradiated with 
1000 rads to eliminate most lymphocytes. On the day of isolation, mice were 
killed, lymph nodes were pooled, and the capsules were opened using two 26-
gauge needles. The nodes were incubated with 1.5ml of collagenase D 
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(22mg/ml, C-1088882, Roche), 0.5ml of DNase I (5000 units/ml, D-4527, 
Sigma), and 2 ml DMEM with 20 mM HEPES. After 45 min at 37oC in a CO2 
incubator, the released cells were washed in 5ml DMEM with 10 % FCS. Cells 
were then sequentially incubated with FDC specific Ab (FDC-M1) for 45 min, 
1μg of biotinylated anti-rat-κ light chain for 45 min, and with 20μl anti-biotin 
MicroBeads (Miltenyi Biotec) for 15-20 min on ice. The cells were layered on 
MACS LS column and washed with 10ml of ice-cold MACS buffer. The 
column was removed from the VarioMACS and the bound cells were released 
with 5ml of MACS buffer. Approximately 85 to 95% of these cells were FDC-
M1+, CD40+, CR1/2+, and FcγRIIB+. 
FDCs adhesion assessment 
One million freshly purified FDCs were layered on collagen type I, 
laminin, biglycan or hyaluronic acid layers. Twelve hours later, cells were 
washed off the matrices and the released cells were counted. The percentage of 
attached cells was calculated. Control lymphocytes and FDCs on plastic were 
compared.  
Collagen coating of plates 
Ten mg sterile lyophilized rat tail collagen type I was dissolved in 5 ml 
sterile 0.2% acetic acid (v/v) to give a final concentration of 2 mg/ml, pH was 
adjusted to 7.4 ± 0.2 by 0.1 M NaOH and 0.1M HCl. Twenty-four-well culture 
plates were coated with collagen type I at a concentration of 5 μg/cm2. Collagen 
was air dried on the plates for 2 hours at 250C in a laminar flow hood.  
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Light microscopy and FDC labeling  
FDCs, 1x106, were cultured in DMEM supplemented with 10% FCS on 
collagen type I for up to 30 days. Cultures were directly examined using a Nikon 
Bio-inverted microscope equipped with Nomarski optics and digital images 
were acquired. Thirty days old FDC cultures were labeled for FDC-M1 and ICs. 
Cultures were washed with PBS and incubated with FDC specific marker M-1 
or OVA-rabbit-anti-OVA ICs for 2 hours. Cells were fixed in 0.9% 
glutraldehyde + 1% paraformaldehyde for 10 min and washed. Cells were then 
incubated for 45 mins with biotinylated mouse anti-rat-kappa light chain (MRK-
1) followed by streptavidin-HRP, for FDC-M1 labeling, or HRP-conjugated 
goat anti-rabbit IgG, for IC labeling. Rat IgG isotype control for FDC-M1 and 
non-specific rabbit serum control for IC labeling were similarly treated. HRP 
was developed with DAB substrate and images were captured.  
Scanning Electron Microscopy  
Thirty days old FDC cultures on collagen type I were washed with PBS 
and fixed in 0.9% glutraldehyde + 1% paraformaldehyde (24). Small culture 
chips were prepared and examined with JSM-820 JEOL scanning electron 
microscope.  
Immunohistochemical labeling of collagen type I and FDC-M1 in vivo 
Popliteal LNs were collected 5 and 48 hours after footpad injection of 10 
μg OVA in BALB/c mice passively immunized with rabbit anti-OVA IgG and 
frozen in CryoForm embedding medium (IEC, Needham Heights, MA). Frozen 
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sections of 10-μm thickness were cut on a Leica (Jung Frigocut 2800E) cryostat 
and air-dried. Following absolute acetone fixation, the sections were dehydrated 
and the endogenous peroxidase activity was quenched with PBS containing 
0.1% phenylhydrazine-HCl (Sigma, St Louis, MO). The sections were washed 
and saturated with 10% BSA. Serial sections were incubated with unlabeled 
rabbit-anti-type I collagen or FDC specific marker M-1. Sections were washed 
and then incubated with biotin-conjugated goat anti-rabbit or biotinylated mouse 
anti-rat-kappa light chain (MRK-1) followed by streptavidin-HRP. The sections 
were developed with a DAB substrate kit (BD Pharmingen, CA) and images 
were captured using Optronics digital camera and Bioquant Nova software.  
Flow Cytometry  
Positively selected FDCs were incubated with purified mouse Fc-block 
(2.4G2) for 15 mins on ice followed by 30 mins incubation with FITC-
conjugated mAb against CD29 (β1), CD49b (α2), CD49a (α1), CD44 and isotype 
matched controls. Cells were washed thoroughly and analyzed by Beckman 
Coulter FC500 flow cytometer and Cytomics software.  
   
 90
Results 
Assessment of FDC adhesion to extracellular matrices (ECM) components 
After overnight incubation, 80 to 90% of FDCs on plastic and lymphocytes on 
collagen type I, laminin, biglycan or hyaluronic acid could be removed by 
washing indicating a lack of adherence (Data not shown) In marked contrast, 
80% of cells in FDC preparations bound these extracellular matrices and 
remained fixed (Fig. 1). 
 Light microscopy of FDCs cultured on collagen type I 
Many FDCs cultured on collagen type I started to spread out and 
acquired small processes within a week. Cell processes were visible within 14 
days (Fig. 2a) forming occasional chains or interconnections between cells (Fig. 
2b). By day 30, the cell bodies were spread out and most cells had very fine 
filiform processes that appeared to form networks through interdigitation of cell 
processes with neighboring cells (Fig. 2c).  
Scanning electron microscopy of FDCs on collagen type I 
To determine the nature of the FDC processes, scanning electron 
microscopy (SEM), was used to study thirty-day-old FDC cultures on collagen 
type I where numerous convolutions and branching of fine filiform dendrites 
were apparent (Fig. 3a, 3b, 3c). The dendrites often emanated from one pole of 
the cell body that was approximately 10-12 μm in diameter. Smaller dendrites 
appeared to help anchor the cell body to the collagen extended from the 
opposing parts of the cell body (Fig. 3c). Higher magnification showed dendrites  
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Figure 1: Adhesion of FDCs to extracellular substrates. Positively selected FDCs that 
expressed FDC-M1+, CD40+, CR1/2+, and FcγRIIB+ were incubated on plastic, collagen 
type I, laminin, biglycan, or hyaluronic acid. After 12 h, approximately 85% of FDCs on 
plastic could be removed by washing, whereas 85% of the FDCs bound to substrates 
remained attached  
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Figure 2:  Light microscopy of FDCs cultured on collagen type I. Purified FDC 
preparations were incubated on collagen type I for 30 days. Within the first 14 days, 
although many cells remained rounded, FDCs cultured on collagen type I started to 
spread out and acquire small processes (a) with occasional chains or interconnections (b). 
By day 30, most cells had extended long thin processes that formed networks by 
interdigitation with the processes from neighboring cells; the cell bodies had spread out 
(c)  
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Figure 3:  Scanning electron microscopy (SEM) of FDCs on collagen type I showing 
dendritic regeneration. FDCs in 30-day-old cultures on collagen type I showed 
numerous convolutions and branchings of fine filliform dendrites (a–c). Cell processes 
emanated primarily from one pole of cell body (diameter of 10–12 μm) with some 
smaller dendrites helping to anchor the cell body to the collagen (c)  
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emanating from one pole of an FDC and crossing over another cell body (Fig. 
4a, 4b). Groups of 4-6 FDCs were seen forming networks much like those seen 
in situ (Fig. 5a, 5b, 5c).  
Immunohistochemical labeling of FDC reticula for FDC-M1 and ICs 
Functionally, active FDCs are characterized by the presence of FDC-M1 
and the ability to trap ICs (130). Cultures of 30 day FDCs, with well developed 
dendrites and networks, labeled with the FDC-specific monoclonal Ab FDC-M1 
(Fig. 6a) and were able to trap and retain OVA-anti-OVA ICs (Fig. 6c). Isotype 
controls for FDC-M1 (Fig. 6b) and ICs (Fig. 6d) lacked labeling.  
Immunohistochemical labeling of collagen type I and FDC-M1 in vivo 
The presence of reticular fibers interspersed between FDC dendrites was 
reported at the ultrastructural level at the periphery of the light zone (37). This 
prompted an examination of the localization of collagen type I in lymphoid 
follicles as related to germinal center FDCs. Five hours after footpad challenge 
with OVA in BALB/c mice passively immunized with rabbit anti OVA IgG, 
collagen type I abundantly co-localized with the specific FDC monoclonal 
antibody FDC-M1. However, two days later, collagen type I exhibited 
characteristic marginal distribution around the FDC-M1+ area (Fig. 7). 
Expression of CD29 and CD44 on FDCs 
The rapid binding of FDCs to collagen prompted us to look for collagen 
binding receptors on FDCs. Flow cytometric analysis showed that 
approximately 85% of FDCs expressed CD29; the β1 integrin subunit shared by 
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collagen (α1, 2, 3, 9, 10, 11β1), laminin (α6β1) and fibronectin (α4β1) receptors as 
well as the hyaluronic acid receptor CD44 (Fig. 8). CD29 and CD44 may, in 
part, mediate the interaction between FDCs and collagen type I and its 
associated molecules. However, FDCs treated with mAbs against these 
molecules still bound collagen type I without difficulty (Data not shown). 
Expression of α1/CD49a and α2/CD49b integrins were not detectable in 
significant amounts on freshly isolated FDCs (Fig. 8).  
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Figure 4:  Origin of dendrites at higher magnification; SEM. The developed dendrites 
clearly emanate from one pole of the FDC (b). Some dendrites cross over other cell 
bodies (a) 
   
 100
 
   
 101
Figure 5:  Groups of 4–6 FDCs on collagen type I showing the formation of networks 
(or reticula); SEM (a–c)  
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Figure 6:  Immunohistochemical labeling of FDC reticula with FDC-M1 and ICs. The 
FDCs in cultures maintained for 30 days on collagen type I were heavily labeled with the 
FDC-specific mAb FDC-M1 (a) and retained rabbit OVA-anti-OVA ICs as indicated by 
labeling with goat-anti-rabbit IgG (c); HRP/development with DAB. No labeling was 
observed in isotype controls for FDC-M1 (b) and ICs (d); Nomarski optics 
   
 104
 
   
 105
Figure 7:  Immunohistochemical labeling for collagen type I and FDC-M1. Adjacent 
frozen sections from popliteal lymph nodes were labeled for collagen type I (a, c) and 
FDC-M1 (b, d) 5 h (a, b) and 2 days (c, d) after challenge with OVA in OVA immune 
BALB/c. Sections were incubated with unlabeled rabbit anti type I collagen or FDC-M1. 
Biotinylated goat anti-rabbit or biotin-mouse anti-rat-κ was applied followed by 
streptavidin-HRP. The sections were developed with DAB substrate. Fibers labeled with 
anti-collagen type I were seen co-localizing with FDC-M1 at 5 h (arrows). After 2 days, 
the distribution of collagen type I was restricted to the periphery of the follicle labeled for 
FDC-M1 (arrows)  
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Figure 8:  Expression of CD29 and CD44 on FDCs. Purified FDCs preparations were 
incubated with FITC-conjugated mAb against CD29 (β1; a), CD44 (b), CD49a (α1; c), 
CD49b (α2; d), and isotype-matched controls (gray lines unlabeled FDCs, dotted lines 
isotype controls). Flow cytometric analysis showed that approximately 85% of FDCs 
expressed CD29 (the β1 integrin subunit) and the hyaluronic acid receptor, CD44 
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Discussion 
The move from in vivo to in vitro assessment of FDC biology is 
important given that cells in vitro are more readily amenable to manipulation. 
However, dendrites represent a cardinal morphological feature of FDCs and this 
morphology and the associated networks are largely lost when FDCs are isolated 
(42). Moreover, the more in vitro manipulations are introduced, the less the 
dendritic morphology is apparent (130). Nevertheless, isolated FDCs did have 
accessory activity in vitro and dendritic morphology is identifiable at the 
electron microscopy level but it has been impossible to regenerate the extensive 
processes and networks to study the importance of these structures in vitro. The 
fact that FDCs are fixed in GCs supported by reticular fibers and that enzymatic 
digestion with collagenase was required to release them from their in vivo 
environment prompted the hypothesis that modeling a supporting substrate in 
vitro might stimulate reattachment of isolated FDCs and promote regeneration 
of dendritic processes and networks. We report here that FDCs have a 
remarkable ability to bind to collagen type I and reestablish extensive dendrites 
and networks. Structure typically promotes function and the ability to regenerate 
extensive dendrites and FDC-networks on collagen type I offers a new 
opportunity to study how FDC structures relate to function.  
We reasoned that if FDCs were influenced by collagen or collagen-
associated molecules, then an attachment step would be necessary. To test this, 
positively selected FDCs were incubated on purified collagen type I, laminin, 
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biglycan or hyaluronic acid and left for twelve hours. The vast majority of viable 
FDCs adhered to these matrices. The ability to firmly bind all these matrices 
may help explain why these cells are fixed and do not migrate in vivo. 
Comparison of FDCs incubated on different substrates indicated that collagen 
type I exerted the most influence on FDC morphology. Accordingly, we 
incubated FDCs on type I collagen for 30 days and cultures were examined to 
verify formation of dendrites and reticula. FDCs survived throughout the culture 
period without signs of apoptosis or proliferation which is consistent with the 
reports of long term culture of murine FDCs up to 8 weeks (115) and human 
FDCs up to 150 days (172). In the first week cells started to spread out and 
begin to acquire processes with occasional interconnections. However, by day 
30, most cells had fine processes that formed networks through interdigitation of 
cell processes with neighboring cells. In vivo FDCs trap ICs and form 
interconnecting networks or reticula. Studies with labeled Ag indicate that Ag-
bearing ICs remain localized to FDC-networks in lymph nodes draining the site 
of Ag injection. For example, Donaldson et al (173) reported that antigen 
retaining networks remained localized to lymph nodes draining the injection site 
one year after Ag challenge. Similarly, FDCs in vitro resisted washing off the 
supporting matrices and on collagen type 1 they formed networks that could 
only be mobilized by collagenase treatment.               
FDC-M1 is a marker for FDCs and IC trapping and retention is 
characteristic of FDCs (69,130). To confirm the identity of the cells, 30-day 
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cultures were labeled with FDC-M1 or ICs. Both, FDC-M1 and ICs, intensely 
labeled FDC processes and IC binding and surface retention established this 
FDC function. 
We reasoned that a receptor-mediated mechanism was likely involved in 
attaching FDCs to collagen and in signaling formation of dendrites and reticula. 
Flow cytometric analysis indicated that FDCs express CD29; the β1 integrin 
subunit shared by collagen (α1, 2, 3, 9, 10, 11β1), laminin (α6β1) and fibronectin 
(α4β1) receptors as well as the hyaluronic acid receptor CD44. However, 
blocking these molecules did not prevent FDCs from binding collagen type I 
suggesting there are additional receptors involved. 
Scanning Electron Microscopy was used to study the ultrasturcture of 
dendrites and to make sure the processes emanated from cells and were not 
fibers formed in the collagen. SEM revealed FDCs organized in groups, ranging 
between 4 to 6, forming reticular structures with interconnecting dendrites. 
Dendrites emanated from the cell bodies and some were seen extending from 
one pole of an FDC over the cell body of another FDC. Characteristically, FDC 
dendrites exhibit numerous branches and convolutions, often there is polarity 
regarding the cell body, and processes in vivo may be found attached to collagen 
fibers (37,42). All of these features were apparent with FDCs on collagen type I. 
Besides their structural role, collagens, especially type I collagen which 
is the most abundant collagen type, help define functional properties of tissues 
(174). Hyaluronic acid binds cells via CD44 and is widely distributed in the 
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body. FDC-CD44 may play a role in mechanisms leading to dendrite 
regeneration and network formation seen here since proteoglycan-associated 
hyaluronic acid is seen in rat tail collagen (175). The receptor CD44 has been 
implicated in a number of cellular functions such as adhesion, growth, 
differentiation, and apoptosis (176). Recently, it has been demonstrated that both 
8D6 and CD44 expressed on FDCs mediate their antiapoptotic activity that 
helps maintain lymphomas in vivo (65).  
Collagen type I has been found to enhance activation and dendrite 
formation in other cells. The ability of collagen type I to provoke phenotypic 
changes associated with activation has been described in DCs including GM-
CSF-propagated liver DCs (177) and monocyte-derived DCs (178). In addition, 
network formation and angiogenic stimulation has been described in endothelial 
cells when cultured on type I collagen (179). Moreover, neurons seeded on 
collagen gels regenerated neurites that appear to correspond to axons and 
dendrites (180).  
The characteristic dislocation of collagen type I fibers to the periphery of 
active follicles two days after antigenic challenge agrees with a similar 
observation in reactive human tonsils (181). However, neither the paucity of 
collagen type I associated with FDCs two days after antigenic challenge in vivo, 
nor the ultrastructure of FDC dendrites and networks on the collagenous matrix 
in vitro, support the concept that FDCs produce type I collagen in their 
processes favoring a fibroblastic origin (182). In short, the data presented here 
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indicate that purified FDCs express CD29 and CD44 and are able to regenerate 
their dendritic networks in vitro when cultured on collagen type I. We are 
looking forward to functional studies comparing the activity of free-floating 
FDCs with FDCs in networks with interest.  
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CHAPTER 4 
IL-6 produced by immune complex-activated follicular dendritic 
cells promotes germinal center reactions, IgG responses, and 
somatic hypermutation 
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Introduction 
Follicular dendritic cells (FDCs) are prominent in GCs because their 
numerous long slender dendrites intertwine and create extensive FDC-networks 
or -reticula. These FDC-networks are fixed in the follicles while T and B cells 
are free to circulate. Nevertheless, FDCs release chemokines that attract 
recirculating lymphocytes that help organize the follicle and participate in the 
GC reaction (66,183). FDCs, bearing specific Ag in the form of ICs, are 
requisite for full development of GCs (38,46,69) and interaction of FDCs with 
ICs leads to activation and the expression of high levels of FDC-FcγRIIB, -
ICAM-1 and -VCAM-1 (70). FDC-ICs also deliver a late antigenic signal that 
promotes SHM (35). Important events include: 1) induction of specific Ab that 
binds immunogen and forms ICs, 2) IC trapping by FDCs, 3) GC B cell 
stimulation by Ag in these FDC-ICs, and 4) promotion of SHM by this late 
second Ag signal delivered by IC-bearing FDCs (35). However, FDCs provide 
signals, beyond specific Ag, that promote B cell maturation and we sought to 
determine if FDC-IL-6 promotes SHM. 
Interleukin-6, known in the early literature as B-cell stimulatory factor 
(BSF-2), is recognized for its role in regulating terminal B cell differentiation 
(Reviewed in (184)). Somatic hypermutation (SHM) is a major events in 
terminal B cell differentiation that occurs in germinal centers (GCs) in the 
second wk after primary immunization (Reviewed in (185-188)). It has also 
been reported that murine FDCs are the source of IL-6 in GCs (68) and that ICs 
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activate FDCs (70). This prompted the hypothesis that IC-activated FDCs 
produce elevated levels of IL-6 and that FDC-derived IL-6 is important not only 
for optimal Ab responses but also for GC reactions and SHM. We postulated 
that elevated production of IL-6 by IC activated FDCs, one to two wks after 
primary immunization, would correlate with enhanced GC reactions, IgG 
responses, and SHM. 
While there are numerous reports supporting the hypothesis that FDCs 
produce IL-6 (189-192), there are also studies reporting the inability to detect 
IL-6 in FDCs (193-195). To further test the hypothesis that FDCs produce IL-6 
and that IC-activated FDCs produce elevated levels of IL-6, ICs were added to 
purified FDCs and 2 to 6 days later IL-6 production had clearly increased. 
Specific Ab is induced 4-7 days after primary immunization and IC formation 
would follow soon thereafter. Thus, 6 to 13 days after immunization a burst in 
FDC-IL-6 production would be expected in developing GCs. To test the 
postulate that IL-6 promotes GC reactions, specific IgG responses, and SHM; 
these responses were studied in IL-6 KO mice and in GC reactions in vitro 
where IL-6 was specifically inhibited by anti-IL-6. The present study, including 
both in vivo and in vitro experiments, confirms earlier results indicating, that 
optimal GC reactions and IgG anti-NIP responses require IL-6 and that FDCs 
are the only cells in GC reactions making IL-6 (68). In addition, we found that 
IL-6 was not detectable in in vitro GC reactions with IL-6 KO FDCs with T & B 
cells from WT mice. In contrast, IL-6 production was normal in GC reactions 
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with WT FDCs with T and B cells from IL-6 KO mice. The absence of IL-6 in 
cultures lacking WT FDCs resulted in marked reduction in the rate of SHM that 
coincided with the reduction in specific anti-NIP. Moreover, GCs were abundant 
in irradiated WT mice reconstituted with spleen cells from IL-6 KO mice while 
GCs were virtually undetectable in irradiated IL-6 KO mice reconstituted with 
normal spleen cells. These data provide strong support for the physiological 
relevance of FDC-IL-6 in GC reactions in vitro and in vivo and report for the 
first time that FDC-IL-6 is inducible by ICs and is involved not only in 
influencing the amount but also the mutations that are known to enhance the 
affinity of specific IgG produced. 
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Material and Methods  
Mice, Ag and immunization 
Six to 8 wk old C57BL/6 mice were purchased from the National Cancer 
Institute and female IL-6 KO mice (B6.129S2-116tm1Kopf/J) of the same age 
were obtained from the Jackson Laboratory. The mice were housed in standard 
shoebox cages and given food and water ad libitum. Animals were handled in 
compliance with Virginia Commonwealth University Institutional Animal Care 
and Use Committee guidelines. Mice were immunized by injecting 0.25 or 25 
μg of alum precipitated (NP)36-CGG with ~1.5 x 107 heat killed Bordetella 
pertussis s.c. in each front leg and hind foot in a 50 μl volume to give a total of 1 
μg or 100 μg of (NP)36-CGG /animal. Fourteen days later these mice were bled, 
serum collected, and draining lymph nodes from each group were pooled to 
isolate λ+ B cells for extracting RNA. The serum was used to determine NIP-
specific Ab levels and the RNA was used to determine mutations per 1000 bases 
in the VH186.2 gene segment. In vitro GC reactions were set up using memory 
T cells specific for CGG [T(CGG) cells] isolated from mice one month after 
immunization with 100 μg CGG as described above. To get NP specific λ B 
cells, WT or IL-6 KO mice were immunized with 100 μg (NP)36-CGG plus heat 
killed Bordetella Pertusis as explained above and the λ B cells were isolated 6 
days later.  
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Establishment of IL-6 KO / WT chimeras, immunization, and 
immunohistochemistry  
Two days after irradiation with 600 rads, IL-6 KO (B6.129S2-
116tm1Kopf/J) mice were reconstituted with 108 WT or IL-6 KO splenocytes 
injected SC behind the neck. Similarly, WT C57B/6 mice were reconstituted 
with 108 IL-6 KO or WT splenocytes and 48 hrs later, mice were immunized 
with 1 μg (NP)36-CGG /animal. Fourteen days later these mice were bled, 
sacrificed, and the spleens were frozen in OCT medium. Sera were used for 
determination of the anti-NIP levels, and 10 μm cryostat spleen sections were 
prepared and fixed in absolute acetone. The midsaggital spleen sections were 
labeled for GC B cells with FITC-conjugated anti-B cell activation marker GL-
7, and for the FDC-ICs with Rhodamine-Red-X anti-mouse IgG. Resting B cells 
were labeled with PerCP-Cy5.5 anti mouse B220 and the number of GL-7+ GCs 
were counted in the midsaggital spleen sections.  
Antibodies and Reagents 
Functional grade, Azide free, sterile-filtered, purified anti-mouse 
Interleukin-6 (Cat# 16-7061, Clone MP5-20F3) and rat IgG isotype control Ab 
were obtained from eBioscience.  Rat anti-mouse FDC (FDC-M1), biotin mouse 
anti-rat kappa (MRK-1), anti-mouse CD21/CD35 (Clone 7G6) and anti mouse 
CD32/CD16 (Clone 2.4G2) were purchased from Pharmingen (San Diego, CA). 
Mouse CD45R (B220) MicroBeads, mouse CD90 (Thy1.2) MicroBeads, anti-
Biotin MicroBeads, and MACS LS columns were purchased from Miltenyi 
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Biotec GmbH (Auburn, CA). Biotin labeled rat anti-mouse kappa was purchased 
from Zymed (San Francisco, CA).  Alkaline phosphatase labeled goat anti-
mouse IgG (H+L) and P-Nitrophenylphosphate substrate were obtained from 
Kirkegaard & Perry Laboratories (Gaithersburg, MD). NIP-OVA (4-hydroxy-3-
ioda-5-nitrophenylacetyl conjugated to ovalbumin) and (NP)36-CGG were 
obtained from Biosearch Technologies (Novata, CA). Anti-CGG was obtained 
from hyperimmunized mice with serum anti-CGG IgG levels in excess of 1 
mg/ml.  
FDCs isolation, activation with ICs in vitro, and assessment of IL-6 
production  
FDCs were isolated as described previously (130). Briefly, lymph nodes 
from lethally irradiated mice were gently digested and the cell suspension 
incubated with rat anti-mouse FDC-M1, biotin-mouse anti-rat kappa (Clone 
MRK-1) and anti-biotin magnetic microbeads sequentially. Finally the FDCs 
were positively selected using a magnetic column (MACS). Approximately 85 
to 95% of these cells expressed the FDC phenotype, FDC-M1
+
, CD32
+
, 
CD21/35
+, CD40
+
 and ICAM
+
 (130). Purified FDCs were activated by 
incubating 1x106 cells with 100 ng/ml OVA-ICs made of OVA/rabbit-anti-OVA 
at a ratio of 1:6. Four independent experiments with triplicates of IC-stimulated 
FDCs were set up and culture supernatant fluids were sampled after 2, 4, and 6 
days. In some experiments, culture supernatant fluids were collected after 3, 6, 
and 10 days. Controls of B220 purified B cells, Thy1.2 purified T cells, IL-6 KO 
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FDCs, WT B and T cells, WT B and T cells with IL-6 KO FDCs with or without 
ICs, WT FDCs incubated with IL-6 KO B and T cells with or without ICs, WT 
FDCs incubated with soluble 100 ng/ml OVA, WT FDCs pretreated with 10 
μg/ml azide-free FcγR or CR blockers (mAb 2.4G2, and 7G6 respectively) or 
their isotype controls prior to IC loading and low Tox complement were 
included. IL-6 levels in the fluids were assessed using a Bio-Plex Mouse IL-6 
assay (Bio-Rad, Hercules, CA, 171-G10738), data were collected on a Bio-Plex 
array reader (# LX10004042104), and analyzed using Bio-Plex Manager 
Software 4.1.   
Isolation of lambda light chain positive B cells (λ+ B cells) and memory T(CGG) 
cells 
Single cell suspensions were prepared from draining lymph nodes after priming 
with (NP)36-CGG or CGG as explained above. After depleting kappa light chain 
positive B cells with biotin-anti-κ and anti-biotin microbeads with a MACS 
column, the persisting λ+ B cells were isolated with anti-B220 microbeads using 
a MACS column. The isolated λ+ B cells were more than 98% pure. Memory 
T(CGG) cells from CGG primed mice were incubated with 40μl of anti-CD90.2 
microbeads and the T cells were positively selected using a MACS column.   
In vitro GC reactions and the anti-NIP Ab Response 
GC reactions were initiated in vitro by culturing 1 x 106 unmutated but 6 
day primed λ B cells, 0.5 x 106 T cells, and 0.5 x 106 FDCs in the presence of 
100ng of (NP)36-CGG as free Ag or in ICs. The ICs were made by incubating 
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NP-CGG with anti-CGG at a ratio of 6 ngs/ml anti-CGG to 1 ng of NP-CGG for 
two h and then adding IC containing 100 ng NP-CGG to appropriate wells in 24-
well culture plates. Supernatant fluids were harvested 7 days later and were 
assayed for NIP-specific IgG Ab by ELISA using NIP-OVA to coat the plate.  
Analysis of mutations in the V region 
Anti-NP Igs predominantly use the VH186.2 gene (14,196) and it was 
analyzed in this study. Cells were collected on Day 7 of culture and RNA was 
isolated using Trizol (Invitrogen, Carlsbad, CA). The RNA was then reverse 
transcribed to cDNA with GeneAmp gold RNA PCR Core kit (PE Biosystems, 
Foster city, CA) using oligo dt. The VH186.2 gene followed by D and J regions 
and a proximal segment of the C gamma gene segment was amplified by two 
rounds of nested PCR with high fidelity Pfu-Ultra DNA polymerase (Stratagene, 
La Jolla, CA). The forward and reverse primers for the first round PCR, were 5’-
catgctcttcttggcagcaacagc-3’ and 5’-gtgcacaccgctggacagggatcc-3’, for second 
round PCR, 5’- caggtccaactgcagccag-3’ and 5’-agtttgggcagcaga-3.  The PCR 
reaction was carried out as follows: 95°C 1 min, 56°C 1 min, 72°C 1 min for 30 
cycles followed by 72°C for 10 min. The expected 400bp PCR product was then 
electrophoresed on 1.2% agarose gel, purified by gel extraction using QIAQuick 
kit (Qiagen, Valencia, CA) and cloned using Zero Blunt® TOPO PCR Cloning 
Kit  (Invitrogen, Carlsbad, CA). The plasmids were transformed into one shot 
TOP10 chemically competent cells (Invitrogen, Carlsbad, CA) and plated onto 
LB media containing 50μg/ml ampicillin. Multiple discrete colonies were 
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picked the following day and grown for 24 hours in LB broth containing 
50μg/ml ampicilin in a 37°C shaker. The plasmids were isolated using a 
QIAprep Spin miniprep kit (Qiagen, Valencia, CA) and the insert was 
sequenced using an ABI sequencer. The sequences were analyzed using GCG 
Wisconsin Package (Accelrys, San Diego, CA), clustalW (197,198) and 
BioEDIT (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) software packages. 
Redundant sequences were excluded from our calculation of mutations per 1000 
bases to avoid multiplying the effect of a single mutation. To avoid including N 
terminal additions, changes within 5 bases of the V-D junction were also 
excluded from our calculations of mutations per 1000 bases.  
Immunofluorescence and confocal microscopy 
Draining lymph nodes (popliteal brachial and axillary) were harvested 
from WT or IL-6 KO mice 14 days after immunizing with 1 ug of (NP)36-CGG 
and frozen on dry ice in Optimum Temperature Compound (Tissue-Tec, 
Torrance, CA). Serial 10μ thin sections were cut from the frozen blocks using a 
Jung Frigocut 2800E Cryostat, fixed in absolute acetone, and air-dried. The 
sections were blocked with 10% BSA in PBS and then washed and incubated for 
1 h with 2 μg/ml FITC-conjugated anti-GL7 and Cy5.5-conjugated anti-B220 
(BD Pharmingen, San Diego, CA). Sections were washed, mounted with anti-
fade mounting medium, Vectashield, cover-slipped, and examined with a Leica 
TCS-SP2 AOBS confocal laser scanning microscope fitted with an oil plan-
Apochromat 40X objective. Two lasers were used, Argon (488 nm) for FITC, 
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and HeNe (633nm) for Cy5.5 (shown as pseudo-color magenta). Parameters 
were adjusted to scan at 512 X 512 pixel density and 8-bit pixel depth. 
Emissions were recorded in 2 separate channels. Digital images were captured, 
overlaid and processed with Leica Confocal and LCS Lite softwares. 
BIOQUANT NOVA Advanced Image Analysis software (R&M Biometrics, 
Nashville, TN) was used to analyze the immunohistochemistry as described 
previously (58). After setting an arbitrary threshold, the system allowed us to 
determine number, position, area, and density of labeling that best defined FDC-
reticula. This predefined threshold was used throughout to enable reliable 
comparisons. 
Statistical Analysis 
The number of mutations per sequence was compared using a Poisson 
regression analysis (SAS Proc Genmod version 9.1, SAS Institute Inc.) An 
offset of log(306) was used to normalize the fitted group means to the number of 
nucleotides. Significant chi-square values for SHM data were determined at p 
<0.05. Analysis of IL-6 production, GC numbers, area, and IgG production were 
done using a two tailed Student’s T test and significance was accepted at p 
<0.05. 
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Results  
FDC derived IL-6 and activation via IC-FcR interaction enhanced FDC-IL-6 
To begin testing the hypothesis that FDCs produce IL-6 and that IC-activated 
FDCs produce elevated levels of IL-6, ICs were added to purified FDCs or to purified 
FDCs with T and B cells. As shown in figure 1, all cultures containing WT FDCs 
produced IL-6 at all time points, 3, 6, and 10 days. Moreover, IL-6 production was 
enhanced by IC-mediated FDC activation. In marked contrast, cultures of WT B cells and 
T cells, separately or in combination with IL-6 KO FDCs, did not produce detectable 
levels of IL-6 even when ICs were added.  FDCs isolated from normal mice with FDC-
M1 have detectable levels of ICs on their surfaces but are capable of trapping more IC 
(130) and of being further activated in vitro via engagement of FcγRIIB (71). To further 
examine the need for ICs and FcγRs, FDCs were isolated from normal animals, ICs were 
added as an in vitro activation signal, and supernatant fluids were collected on days 2, 4, 
and 6 (Figure 2). IL-6 was apparent in the control lacking added ICs and it continued to 
accumulate over the 6-day period. FDCs may constitutively express IL-6 or this 
background IL-6 response may occur as a consequence of FDCs encountering ICs in vivo. 
In any case, addition of ICs enhanced FDC-IL-6 production within 48 hrs (p<0.0001) and 
IL-6 production continued to increase over the 6 day period. Inhibition of IC trapping via 
FcγR with the FcR blocker (mAb clone 2.4G2) significantly inhibited FDC-IL-6 
production whereas the isotype control had no inhibitory effect. Moreover, addition of 
soluble Ag (OVA) to the FDCs, rather than OVA in ICs did not stimulate IL-6 production 
above background. We did not see enhancement of FDC-IL-6 production by the  
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Figure 1: FDCs but not B or T cells produce IL-6 and its production is enhanced by 
ICs. WT FDCs incubated with IL-6 KO B and T cells with or without ICs together with 
controls of WT B cells, T cells, IL-6 KO FDCs, WT B and T cells, WT B and T cells 
with IL-6 KO FDCs with or without ICs were set up and culture supernatant fluids were 
sampled after 3, 6, and 10 days. IL-6 levels were assessed with Bioplex. All cultures 
containing WT FDCs produced IL-6 at all time points, 3, 6, and 10 days, and IL-6 
production was enhanced by activating FDCs with ICs. In marked contrast, cultures of 
WT B cells and T cells, separately or in addition to IL-6 KO FDCs, in the presence or 
absence of ICs did not produce detectable levels of IL-6 at any time point. Data are 
representative of the mean of one of four independent experiments with triplicates + SD.  
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Figure 2: ICs induce FDC-IL-6 production by engaging FDC-FcγRs. Purified WT 
FDCs were activated by incubating 1x106 FDCs with 100 ng/ml OVA-ICs made of 
OVA/rabbit-anti- OVA at a ratio of 1:6. Controls of WT FDCs incubated with soluble 
100 ng/ml OVA, and WT FDCs pretreated with 10 μg/ml azide-free FcγR (mAb 2.4G2) 
or its isotype control prior to IC loading were included. IL-6 levels in the fluids were 
assessed using a Bio-Plex Mouse IL-6 assay after 2, 4, and 6 days. As shown, ICs 
enhanced FDC-IL-6 production within 48 hrs (p<0.0001). The IL-6 surge apparent at day 
6 after IC loading, precedes the late phases of the GC reaction (starting day 9-10 after 
primary challenge) when the presence of IL-6 appears to promote somatic hypermutation. 
Inhibiting IC trapping via FcγRs with the FcR blocker (mAb clone 2.4G2) significantly 
inhibited FDC-IL-6 production whereas the isotype control had no inhibitory effect. 
Moreover, addition of soluble Ag (OVA) to the FDCs did not stimulate IL-6 production 
above background. We did not see enhanced FDC-IL-6 production by the addition of low 
Tox complement and complement receptors do not activate FDCs whereas engagement 
of FcγRIIB does (6). Data represent the mean of triplicate cultures + SD and the results 
are representative of four independent experiments of this type  
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including low Tox complement and complement receptors do not activate FDCs whereas 
engagement of FDC-FcγRIIB does (70).  
Anti-IL-6 inhibited specific Ab production in vitro 
Germinal center reactions were set up using purified FDCs, CGG-primed memory 
T cells, and lambda light chain positive B cells (λ+ B cells) isolated from WT mice. The 
λ+ B cells were obtained 6 days after immunization with 100 ug of NP-CGG per mouse. 
The 6 days allowed NP specific λ+ B cells to begin clonal expansion and begin producing 
IgG anti-NIP in vivo. However, as previously shown (196,199,200) and confirmed in our 
studies (35), λ+ B cells taken 6 days after primary immunization have begun class 
switching, IgG production is increasing rapidly, but SHM has not occurred. The amount 
of NIP specific Ab in the supernatant fluids after 7 days of culture was consistent with 
previous results with cells from WT mice (Fig. 3) (35). Without FDCs the anti-NIP IgG 
levels were low (Fig. 3 columns 1 & 2). B cells do not survive well in the absence of 
FDCs and without FDCs only about 20% of our B cells survive for a wk compared with 
80 - 90% in the presence of FDCs (115). Low Ab levels in cultures lacking FDCs are, at 
least in part, a reflection of a loss in B cells. Addition of FDCs to the B & T cells resulted 
in a dramatic increase in anti-NIP production (Fig. 3 column 3). To test the importance of 
IL-6 in promoting this IgG response, neutralizing anti–IL-6 (10 ug/ml) or isotype control 
were added to the B cell, T cells and FDC cultures where optimal anti-NIP responses are 
obtained (35).  Column 4 of Fig. 3 illustrates that anti-IL-6 reduced the anti-NIP response 
by nearly 80%. To determine if the IL-6 served as a survival signal, trypan blue exclusion 
data indicated that 91.7+3 % of the cells at the start of the culture were recovered from 
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cultures containing FDCs and isotype control after 7 days (1.8+0.06 x 106 viable cells 
recovered). Flow cytometry after double labeling with B220-FITC and propidium iodide 
(PI), revealed that 45.7+1.6 % of these cells were B220+/PI-. In cultures containing FDCs 
and anti-IL-6 there were 1.7+0.06 x 106 total viable cells persisting or 88.3+3 % of the 
cells at the start of the culture. Flow cytometry of these cultures revealed that 45.0+1 % 
of these cells were B220+/PI- (p >0.05). These results suggest that IL-6 is promoting B 
cell maturation rather than survival. 
Specific Ab responses and GC development impaired in IL-6 KO mice 
To establish the impact of IL-6 on specific Ab and GC development, WT 
and IL-6 KO mice were immunized with NP-CGG.  At 100 ug of NP-CGG 
/mouse, the IgG anti-NIP levels were not significantly depressed in IL-6 KO 
mice 14 days after immunization (Data not shown). However, when immunogen 
was limited to 1 ug NP-CGG/mouse, the IgG anti-NIP response 14 days after 
primary immunization was clearly suppressed in IL-6 KO mice (Fig. 4A).  We 
reasoned that ICs would not form as rapidly in IL-6 KO animals with reduced 
specific Ab levels and that FDC trapping and activation be delayed and reduced. 
Consequently, B cells would not respond as vigorously resulting in fewer and 
less robust GCs in IL-6 KO mice. To test this, the number and sizes of GCs were 
determined 14 days after primary immunization with 1 ug of NP-CGG. As 
illustrated in Fig.  4B & C, GCs were apparent in both WT and IL-6 KO mice. 
However, GCs in IL-6 KO mice appeared to be scattered and smaller and this 
was confirmed using morphometric analysis which indicated that the number 
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and size of GCs in IL-6 KO mice were about half the WT level (Fig. 4D & E). 
Thus, the reduced anti-NP response correlated with a reduced GC response in 
IL-6 KO mice (Fig. 4A). In addition, the total splenic leukocytes in the IL-6 KO 
mice were about half the number of spleen leukocytes in the WT (94.6 x106 + 
11.5 Vs 61.7 x 106 + 12.6 p<0.01), and the GL-7+ cells represented 3 + 0.2 % 
and 0.6 + 0.3 % of the splenic leukocytes in the WT and the IL-6 KO groups 
respectively (p <0.003).  
Irradiated wild type mice reconstituted with IL-6 KO splenocytes but not IL-6 
KO mice reconstituted with WT splenocytes developed GCs and anti-NIP IgG 
in response to 1 ug NP-CGG. 
FDCs are irradiation resistant and to determine if FDC derived IL-6 is 
important under physiological conditions in vivo, we set up irradiation chimeras 
reasoning that WT FDCs would provide IL-6 and induce GCs and IgG responses 
with IL-6 KO splenocytes. As illustrated in figure 5A, anti-NIP levels were 
significantly lower in the IL-6 KO mice (p < 0.02) as compared to the WT mice 
regardless of the source of donor splenocytes. GCs in the WT mice reconstituted 
with IL-6 KO splenocytes were readily apparent and labeled intensely with GL-
7 (Fig. 5B) and, as expected, these GCs developed in association with the IC-
retaining FDC-network (Fig 5.B2). In marked contrast, GC in IL-6 KO mice 
were poorly developed and very difficult to find even with WT splenocytes 
which could serve as a source of IL-6 (Data Not shown). Moreover, the number 
of GCs per midsaggital splenic section from IL-6 KO mice reconstituted with  
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Figure 3. Anti-IL-6 mediated inhibition of anti-NIP IgG production in GC reactions in 
vitro. GC reactions were set up using cells isolated from WT mice. Culture contents are 
indicated beneath each column (BTAg: B cells, T cells, & Ag; BTIC: B cells, T cells, & 
ICs; BTFDCIC ISO: B cells, T cells, FDCs, & isotype control Ab; BTFDCIC α-IL-6: B 
cells, T cells, FDCs, & anti-IL-6). After 7 days of culture, supernatant fluids were 
collected and assayed for NIP-specific IgG by ELISA. The values represent the mean ± 
SEM from triplicate independent experiments. Either isotype control or anti-IL-6 Ab (at 
10 ug /ml) were added to B, T and FDC cultures and the difference between isotype 
control and anti-IL-6 was statistically significant (p<0.05).  
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Figure 4: Reduced NIP specific serum IgG and a similar reduction in GCs in draining 
axillary lymph nodes from IL-6 KO mice 14 days after primary immunization. Panel A, 
Wild type (WT) or IL-6 KO mice were injected s.c. with 1 ug of alum precipitated 
(NP)36–CGG using heat–inactivated Bordetella pertussis as adjuvant. Two wk after 
primary immunization, serum was collected and assayed for IgG anti NIP. The data are 
representative of two independent experiments with 6 mice in each group. Panel B, 
Illustrates labeling with FITCconjugated anti-GL7 (B1) that labels GC B cells and 
defines a GC within the cortex of a lymph node from a WT mouse. B2 illustrates labeling 
of the same follicle with Cy5.5-conjugated anti- B220 that labels all B cells. B3 is an 
overlay of panels B1 and B2 indicating the extent of GC B cells relative to B cells 
generally. Panels C1, C2, & C3 are the same reagents with an IL-6 KO mouse. Panel D, 
illustrate the number and panel E, size of GL7+ GCs per midsagittal axillary lymph node 
section.  
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Figure 5: WT mice reconstituted with IL-6 KO splenocytes, but not IL-6 KO mice 
reconstituted with WT splenocytes, developed GCs and anti-NIP IgG. Chimeras were 
generated by reconstituting irradiated WT C57B/6 mice with 108 IL-6 KO splenocytes 
and vice versa. One day later, these mice with irradiation resistant FDCs and splenocytes 
were challenged with 1 μg NP-CGG and the NIP-specific IgG was assessed after 14 days 
when the mice were sacrificed. Cryosections were prepared from each spleden, and GCs 
in the midsaggital sections were labeled with GL-7 and counted. As shown in figure 5, 
the anti-NIP levels were significantly lower in the IL-6 KO mice (p < 0.02) as compared 
to the WT mice. Germinal center development in the irradiated IL-6 KO mice was 
markedly impaired (averaged less than 2 as compared with 16 GL-7+ GCs counted in the 
reconstituted WT mice) and GC development was not rescued by reconstitution with WT 
splenocytes capable of producing IL-6.  
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WT splenocytes averaged less than 2 as compared with 16 GL-7+ GCs/section in 
WT mice reconstituted with IL-6 KO splenocytes (p<0.0005).  
SHM impaired in IL-6 KO mice 
IL-6 helps regulate late events in B cell differentiation and we reasoned that IL-
6 may influence SHM, which occurs after the initial induction of IgG anti-NIP 
late in the first wk after primary immunization (35). The antibody response to 
the hapten 4-hydroxy-3-nitrophenylacetyl (NP) coupled to the T cell-dependent 
carrier CGG is dominated in C57BL/6 mice by lambda light chain bearing 
antibodies (201-204) expressing the VH186.2 gene (205).  This response has 
been well characterized and consequently was adopted in the current study. To 
examine SHM, the draining lymph nodes from the mice immunized with 1 ug of 
NP-CGG and studied in Fig. 4 were collected at day 14, the λ+ B cells were 
harvested and SHM was determined. Consistent with the IgG response and GC 
reaction data in Fig. 4, mutations were also apparent but reduced in the IL-6 KO 
mice. The rate of mutation in the VH186.2 gene segment switched to Ig-gamma 
decreased from 18 to 8.9 mutations/1000bp (P <0.001) in WT vs IL-6 KO mice. 
The mutations are illustrated in Table 1 which shows the DNA sequence 
alignment of the VH186.2 gene. The corresponding amino acid sequence 
alignments were done and as expected, most mutations were in the CDR1& 2 
regions (Table 2).  
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Anti-IL-6 inhibited SHM in GC reactions in vitro 
Provided that FDCs bearing the appropriate ICs are present (35), SHM 
can be studied in GC reactions in vitro. This prompted experiments to determine 
if anti-IL-6 will inhibit SHM under controlled conditions in culture to confirm 
the results in vivo. Germinal center reactions were set up in vitro using purified 
FDCs, CGG-primed memory T cells, and λ+ B cells isolated from WT mice. The 
λ+ B cells were obtained 6 days after immunization with 100 ug of NP-CGG per 
mouse. The 6 days allowed NP specific λ+ B cells to clonally expand and begin 
producing IgG anti-NIP in vivo. However, as previously shown (196,199,200) 
and confirmed in our studies (35), λ+ B cells taken 6 days after primary 
immunization are not mutated. However, SHM would be one of the next events 
in a GC reaction. These 6 day B cells were cultured for 7 additional days in vitro 
and the production of specific anti-NIP Ab and mutations in the VH186.2 gene 
segment were determined. The anti-NIP response of these mice is illustrated in 
Fig. 3 where anti-IL-6 reduced the IgG response by nearly 80%.  Similarly, the 
mutation rate in these anti-IL-6 treated cultures was reduced (3.50 vs 0.65 
mutations per 1000 bases in control vs anti-IL-6 treated cultures; P< 0.02). The 
data in Table 3 illustrate the DNA sequence alignment of VH186.2 gene 
obtained in cultures with the isotype control and cultures treated with anti-IL-6. 
Note that most sequences from cultures treated with the isotype control 
contained mutations whereas only two sequences from the anti-IL-6 treated 
cultures contained mutations. Of the 12 sequences analyzed from isotype control 
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cultures there were a total of 13 mutations. Eight of these were replacement 
mutations and five were silent. Six of the eight replacement mutations were in 
the CDR2 region. These data from cultures with the isotype control are 
compatible with the much larger published data sets (35) where mutations in 
vitro with IC loaded FDCs ranged from 3 to 12 mutations/1000 bases with over 
60% of these mutations in CDR1 or CDR2. Results from the anti-IL-6 treated 
cultures were similar in that two of the three mutations were replacement 
mutations. 
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Table 1:   Vh186.2 sequence alignments from 1μg (NP)36-CGG immunized 
WT vs  IL6 KO
Footnote: The sequences shown in table 1 are for lambda B cells obtained from 
WT or IL-6 KO mice whose anti-NIP levels are shown in figure 4 part A.  The 
anti-NIP levels as well as sequence analysis were performed 14 days after 
challenge of these mice with 1 μg of NP-CGG.  
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Table 1:   Vh186.2 sequence alignments from 1μg (NP)36-CGG immunized 
WT vs  IL6 KO
Footnote: The sequences shown in table 1 are for lambda B cells obtained from 
WT or IL-6 KO mice whose anti-NIP levels are shown in figure 4 part A.  The 
anti-NIP levels as well as sequence analysis were performed 14 days after 
challenge of these mice with 1 μg of NP-CGG.  
 Table 2:   Vh186.2 Amino acid sequence alignment from 1 μg (NP)36-CGG 
immunized WT vs IL-6 KO mice 
 Footnote: Data represent Amino acid translation of DNA sequences shown in table 
1, for lambda B cells obtain d from WT or IL-6 KO mice whose anti-NIP levels 
are shown in figure 4 part A. 
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Anti-IL-6 
Table 3: Comparison of Vh186.2 sequence alignments from isotype and anti-IL-
6 treated cultures 
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Discussion 
The contribution of IL-6 to terminal B cell differentiation has long been 
recognized (184). However, the physiological relevance of FDC-IL-6 to GC B 
cell differentiation is unclear given that IL-6 can be produced by many cells and 
IL-6 production by FDCs has not been consistently found (193-195). In the 
present study, we confirmed that murine FDCs produce IL-6 and provide strong 
support for the physiological relevance of FDC-IL-6 in GC reactions. IL-6 was 
not detectable in in vitro GC reactions with IL-6 KO FDCs even with T & B 
cells from WT mice that could serve as a source of IL-6. In contrast, IL-6 
production was normal in GC reactions with WT FDCs with T and B cells from 
IL-6 KO mice. Moreover, FDCs are irradiation resistant and GC reactions were 
abundant in irradiated WT mice reconstituted with spleen cells from IL-6 KO 
mice while GCs were virtually undetectable in irradiated IL-6 KO mice 
reconstituted with normal spleen cells. Moreover, like ICAM-1, VCAM-1 and 
FcγRIIB (70), activating FDCs with ICs upregulated FDC-IL-6 production. 
Immune complexes would be generated in vivo ~3-7 days after primary 
immunization suggesting that a burst in FDC-IL-6 production would occur in 
the follicles ~5 days after immunization and continue for a week or more. 
Although, class switching and low affinity Ab production may occur before a 
GC reaction (19,206), the IgG response is amplified as GCs develop over the 
next week. Moreover, SHM is a late event apparent in GCs after the first wk 
(35,196,199,200). Thus, SHM would coincide with optimal production of IL-6 
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by IC-activated FDCs. Both in vivo and in vitro data indicated that anti-NIP 
responses and SHM can take place in the absence of IL-6, but IL-6 clearly 
promoted both responses. The novel findings reported here are that FDC-IL-6 
levels are upregulated by ICs and that FDC-IL-6 is high in the second week after 
immunization concurrent with SHM, and that IL-6 is required for optimal SHM. 
Thus, FDC-IL-6 appears to influence not only GC development and the level of 
IgG produced, but also the mutations that promote enhanced IgG affinity. 
Results presented here confirm and extend the report of Kopf, et al. (68) 
who first demonstrated that IL-6 mRNA is produced by cells within murine GC 
clusters and determined it was the FDC-enriched populations (> 80 % pure) 
rather than the lymphocytes that produced the IL-6 mRNA. 
Immunohistochemistry performed by these authors on cryosections from 
immune WT mice further supported their results revealing that cells with 
dendritic morphology within FDC-network produced the IL-6. This production 
was limited to active GCs and not detected in primary follicles, which may help 
explain why some studies have failed to detect IL-6 in FDCs. By use of an IL-6 
bioassay, Kopf et al found that IL-6 was present only in cultures containing 
either FDC-lymphocyte clusters or the FDC irradiated population but not in the 
sorted T or B lymphocytes. However, IL-6 was not quantified and our data 
extend this report by quantification of IL-6 production in highly purified FDCs 
in vitro and demonstrated IC mediated induction.  
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The extent of in vivo suppression of the immune response in the IL-6 KO 
mice in the present study appears to be less than that observed by Kopf and 
colleagues (68).  Our use of Bordetella pertussis as adjuvant may have helped 
compensate for the lack of IL-6 in vivo. Alternatively, CGG may be more 
stimulatory in the absence of IL-6 than the OVA they used.  
A previous study of GC reactions in vitro indicated that FDCs promote 
IgG production by B cells taken 6 days after primary immunization. However, in 
the absence of a second late exposure to Ag, SHM was not detected (35). This 
model was used in the present study which suggests that optimal SHM also 
requires IL-6. Typically SHM occurs in the second wk after primary 
immunization, however, if memory T cells are given along with immunogen in 
the form of IgG-ICs, extensive GC development and high levels of SHM can be 
obtained in the first wk in vivo (35). The importance of ICs is indicated by the 
observation that replacing ICs with Ag, which will not load on FDCs, does not 
induce SHM in the first wk even though memory T cells are present (35). 
Moreover, it is important for the ICs be made with IgG to promote SHM (207) 
and IgG-ICs are arranged on FDCs with a periodicity known to optimally 
engage BCRs and stimulate B cells (34,35).  In short, the combined data provide 
support for the concept that the unique ability of FDCs to trap and retain IgG-
ICs for months provides them with the Ag necessary to deliver late specific and 
non-specific signals like IL-6 needed to promote SHM. Moreover, FDCs bearing 
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the appropriate ICs promote activation-induced cytidine deaminase production, 
and affinity maturation by NP specific B cells (39). 
In the present study, the in vivo reductions in specific Ab and SHM in IL-6 KO mice 
were most apparent at low Ag dose.  At our usual immunization dose of 100 ug of NP-
CGG /mouse, neither the reductions in IgG anti-NIP levels nor SHM were statistically 
significant 14 days after immunization (Data not shown). However, defects in Ab 
production and SHM were readily apparent when the dose was reduced to 1 ug of NP-
CGG/mouse. A similar Ag dose-effect relationship has been reported in lymphotoxin 
alpha KO mice.  Mature FDC-reticula and GCs do not develop in these mice, 
nevertheless, if the Ag dose is high enough, SHM is apparent in these FDC-reticula 
defective animals (208). Most infections start with only a few organisms, and if specific 
Ab is significant in immunity, it is important that immunity develops before the infection 
gets widespread.  The results reported here indicate that under low immunogen dose 
conditions FDC-IL-6 is likely to be important in generating rapid production of high 
affinity specific IgG. We look forward to studies testing the relationship between FDC-
IL-6, selection of high affinity clones with SHM, and affinity maturation both in vivo and 
in vitro. 
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CHAPTER 5 
T-Independent Antibody Responses to T-dependent Antigens: A 
Novel Follicular Dendritic Cell-Dependent Activity 
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Introduction 
Antigens are classified as T cell dependent (TD)4 or T cell independent 
(TI) depending on whether T cell help is needed to induce an Ab response. TI 
Ags are further classified into TI type 1 and 2. The TI-1 Ags, such as LPS, are B 
cell mitogens, which function by non-specifically or polyclonally activating 
most B cells (209). The TI-2 Ags, such as polysaccharides, are large molecules 
with repeating epitopes that are typically able to activate complement, but lack 
the ability to induce MHC-dependent T cell help (95). In ideal form, TI-2 Ags 
are flexible, non-degradable, and hydrophilic molecules capable of 
simultaneously engaging multiple B cell receptors (BCRs) (98). The molecular 
structure of classical TI-2 Ags consists of a non-immunogenic backbone 
exhibiting recurring immunogenic epitopes 95-675 Å apart. This periodicity 
appears to be optimal for simultaneously engaging and cross-linking multiple 
BCRs and rapidly inducing IgM responses (within 48 hrs) (98,210).  
Follicular dendritic cells (FDCs) reside in the light zones of germinal 
centers (GC) and retain Ags in the form of immune complexes (ICs). FDC-ICs 
resist degradation and persist for months to years on numerous intertwining 
dendrites. The non-mobile FDCs remain in the GCs where their intertwining 
dendrites create extensive Ag retaining reticula (ARR) intimately in contact with 
numerous mobile B cells (37,42). In GCs, which are typically involved in 
refining humoral immunity to TD Ags, FDCs promote: B cell survival, Ig class 
switching, somatic hypermutation, selection of somatically mutated B cells with 
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high affinity receptors, affinity maturation, B memory production, and induction 
of secondary IgG and IgE responses (29,35,38,46,69,112,114,185,186,211,212).  
FDCs trap Ag in the form of ICs via Fc and C receptors although FcRs 
are adequate to periodically arrange the ICs (34,44,70). In addition to Ag, FDCs 
provide costimulatory signals to B cells. Both C3 (C3b) and C4 (C4b) engage 
C4 binding protein (C4BP) which co-localizes with ICs on FDCs (59). C4BP in 
ICs trapped on FDCs has been shown to signal B cells via CD40 independent of 
T-cell derived CD40L (CD154) (59). Notably, injection of mice with FDC-M2, 
which recognizes an epitope on C4 bound within ICs, inhibits TI GC 
development (59). Moreover, C3- and C4-deficient mice showed impaired TI 
Ab responses consistent with the concept that ICs on FDCs provide Ag-specific, 
complement-derived, and CD40-mediated signals to B cells in TI GCs (59). In 
addition, FDCs produce BAFF (B-cell activation factor of the TNF family) (60-
62) that also promotes TI B cell activation (213,214). The functional outcome of 
BAFF signaling is multifaceted and different receptors mediate different 
functions. Peripheral B cell survival, plasma cell survival, MZ B cell integrity, 
GC maintenance, CD21 & CD23 expression, TI B cell responses and Ig class 
switching all appear to be influenced by BAFF (64).  
The Ags trapped in ICs on FDCs are typically TD and these Ags are 
arranged periodically with characteristic 200-500 Å spacing on the cell surface 
(24,34). The periodicity of ICs on FDCs was reported initially with ICs trapped 
in vivo (24) followed by similar results in vitro (34). This periodicity of TD Ags 
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in ICs on the surfaces of flexible FDC dendrites with 200-500 Å spacing 
corresponds with recurring immunogenic epitopes 95-675 Å apart on a flexible 
backbone of ideal TI-2 Ags (98,210). We reasoned that the periodically arranged 
FDC-ICs would promote extensive BCR cross-linking and would induce rapid 
TI IgM production when delivered in conjunction with cosignals mediated by 
FDC-C4BP and/or FDC-BAFF. 
To test the above hypothesis, ICs were used to load FDCs and B cells 
were stimulated in vivo and in vitro in the absence of T cells or T cell factors. 
Our data indicated that OVA-IC challenged nude mice produced OVA-specific 
IgM within 48 hrs after IC challenge and the response was maintained for 
weeks. In marked contrast, OVA in adjuvant induced no OVA specific IgM at 
any time. The draining lymph nodes of these IC challenged mice exhibited well 
developed GL-7+ GCs associated with FDC- 
ARR and B lymphocyte-induced maturation protein-1+ (Blimp-1+) plasmablasts 
within 48 hrs of IC administration and the GCs persisted for at least 7 days. 
Moreover, purified FDCs loaded with OVA-IC induced purified human and 
murine B cells to produce OVA-specific IgM in vitro in 48 hrs. We also tested 
the postulate that anti-IgD mAb, which can not signal alone, will signal the vast 
majority of B cells as a consequence of engaging multiple BCRs when loaded 
on FDCs in the form of ICs. Evidences of in vitro B cell activation included 
increased levels and redistribution of intracellular phosphotyrosine, expression 
of the B cell activation marker GL-7, Blimp-1+ plasmablast differentiation, B 
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cell proliferation and polyclonal IgM production within 48 hrs. This TI but 
FDC-dependent IgM response was inhibited when FDC-FcγRIIB was blocked to 
interfere with the ability to periodically arrange ICs. Similarly, neutralizing 
FDC-C4BP or BAFF also inhibited this TI response.  In short, this study is the 
first to report the ability of FDCs to convert TD Ags into TI Ags capable of 
inducing B cell activation and Ig production in the absence of T cells or T cell 
factors.  
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Materials and Methods 
Mice 
Homozygous athymic NCr-nu/nu and heterozygous NCr-nu/+ mice were 
purchased from The National Cancer Institute at Frederick, MD (NCI-
Frederick). FDC networks develop in the presence of B cells but much faster in 
normal mice with both T and B cells (215). Accordingly, the nu/nu mice used 
were 9 months of age to be sure the time was adequate for FDC-networks to 
fully develop. Mice were housed in standard plastic shoebox cages with filter 
tops and maintained under specific pathogen-free conditions in accordance with 
guidelines established by Virginia Commonwealth University Institutional 
Animal Care and Use Committee. 
Immunization 
Homozygous nude (nu/nu) and heterozygous (nu/+) mice were injected 
with 20 μg OVA, in each limb, in the form of (1) alum precipitated OVA 
(Sigma-Aldrich, St. Louis, MO, A5503) with Bordetella pertussis, or (2) OVA 
immune complexes (ICs) made of NIP (4-Hydroxy-3-iodo-5- 
nitrophenylacetyl)-OVA (Biosearch Technologies, Novato, CA, N-5041-10) 
+ goat polyclonal anti-tri-nitro-phenol Abs (Anti-TNP, Biomeda corp., Foster 
City, CA, J05) or (3) OVA ICs made of alum precipitated NIP-OVA with 
Bordetella pertussis + anti-TNP. Anti-TNP Abs effectively binds NIP forming 
ICs with the NIP-OVA. Fifty μg azide-free functional grade purified anti-mouse 
CD90 (Thy-1, eBioscience, 16-0901) were given IP per nude mouse 12 hrs 
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before Ag challenge to inhibit residual T cell activity, especially γδ T cells, that 
may be present in these animals. Animals were bled 48 hrs, 1 week and 2 weeks 
after Ag challenge. Homozygous nu/nu mice were also bled after 7 weeks. 
OVA-specific IgM and IgG were assessed in the collected sera and levels were 
recorded after subtracting the pre-immunization background levels. 
Confocal microscopy for GCs, FDC-reticula, and plasmablasts 
Confocal microscopy was used to assess GC development and 
plasmablast differentiation in association with FDC-ARR at 48 hrs and 7 days 
after IC administration. To this end, groups of nu/nu mice were challenged with: 
a) OVA-specific rabbit serum (Meridian Life Science Inc, Cincinnati, OH, 
W59413R) + alum-precipitated OVA and B. pertussis or b) normal (non-
specific) rabbit serum (Gibco, Grand Islands, NY) + alum-precipitated OVA and 
B. pertussis. Two and 7 days later, axillary lymph nodes (LNs) were collected 
and frozen in CryoForm embedding medium (IEC). Frozen sections of 10-μm 
thickness were cut on a Leica (Jung Frigocut 2800E) cryostat then air dried. 
Following fixation in absolute acetone, the sections were blocked with 10% 
horse serum and washed in phosphate buffered saline. Mid-saggital sections 
were triple labeled with GL-7-FITC (BD Pharmingen, San Jose, CA, 553666) 
(for GC B cells), B220-Cy5.5 (Pharmingen, San Jose, CA, 552771) (general B 
cell marker), and Rhodamine Red-X-affinipure goat anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories, West Grove, PA, 111-295-144) multiple 
adsorbed to minimize any cross reactivity with mouse, rat and human serum 
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proteins (to label the OVA ICs retained in the FDC reticulum). To label GC-
associated plasmablasts, the Rhodamine Red-X-affinipure goat anti-rabbit IgG 
was replaced with Blimp-1-PE (Santa Cruz Biotechnology Inc, Santa Cruz, CA. 
sc-13203 PE). Sections were mounted with anti-fade mounting medium, 
Vectashield (Vectashield, Vector Laboratories, Burlingame, Calif.), cover-
slipped, and examined with a Leica TCS-SP2 AOBS confocal laser scanning 
microscope fitted with an oil plan-apochromat 40X objective. Three lasers were 
used, Argon (488 nm) for FITC, HeNe (543 nm) for Rhodamine-Red X or PE, 
and HeNe (633nm) for Cy5.5 (shown as pseudo-color magenta). Parameters 
were adjusted to scan at 512X512 pixel density and 8-bit pixel depth. Emissions 
were recorded in 3 separate channels and digital images were captured and 
processed with Leica Confocal and LCS Lite softwares. 
In vitro stimulation of purified B cells with purified IC-bearing FDCs 
Naïve “untouched” human B cells were purified by negative selection on 
LS MACS separation columns using The Naive B Cell Isolation Kit II (Miltenyi 
Biotec, Auburn, CA, 130-091-150). Murine B cells were purified by positive 
selection using CD45R (B220) on LS MACS separation columns MicroBeads 
(Miltenyi Biotec, Auburn, CA, 130-049-501). 
FDCs were isolated by positive selection from LNs (axillary, lateral 
axillary, inguinal, popliteal, and mesenteric) of irradiated adult mice, as 
previously described (130). In brief, one day before isolation, mice were 
irradiated with 1000 rad to eliminate most lymphocytes, then sacrificed, and 
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LNs were collected, opened, and treated with 1.5 ml of collagenase D (22 
mg/ml, C-1088882; Roche), 0.5 ml of DNase I (5000 U/ml, D-4527; Sigma-
Aldrich), and 2 ml of DMEM with 20 mM HEPES. After 45 min at 37°C in a 
CO2 incubator, released cells were washed in 5 ml of DMEM with 10% FCS. 
Cells were then sequentially incubated with FDC-specific Ab (FDC-M1) (BD 
Pharmingen, San Jose, CA, 551320) for 45 min, 1 μg of biotinylated anti-rat κL 
chain (BD Pharmingen, San Jose, CA, 553871), for 45 min, and 20 μl of anti-
biotin microbeads (Miltenyi Biotec, Auburn, CA, 130-090-485) for 15–20 min 
on ice. The cells were layered on a MACS LS column and washed with 10 ml of 
ice-cold MACS buffer. The column was removed from the VarioMACS, and the 
bound FDCs were released with 5 ml of MACS buffer. 
Purified FDCs were loaded with 100 ng/ml OVA ICs made of 
OVA/rabbit anti-OVA at a ratio of 1:6. IC-loaded FDCs were used to stimulate 
20x106 purified B cells at a ratio of 1FDC:2B cells. Cells were cultures in 10 ml 
culture medium and OVA-specific Abs were assessed after 48 hrs. 
The rat anti-mouse IgD mAb clone 11-26 (SouthernBiotech, 
Birmingham, Alabama, 1120-14) was selected because this mAb per se does not 
induce proliferation of mature B cells in vitro, nor does it activate B cells in vivo 
(216). Consequently, any ability of this mAb to activate B cells would be 
attributable to the influence of FDCs. To load this mAb on FDCs it was 
complexed with Fc-specific rabbit anti-rat IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA, 312-005-046) at a ratio of 1:4 and the ICs were 
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incubated with purified FDCs. Anti-IgD ICs at doses of 0.1, 1.0, and 10 μg/ml 
were used to load FDCs and used to stimulate 104, 105, and 106 purified murine 
B cells in 1 ml cDMEM. Controls included B cells in the absence of FDCs with 
free and complexed anti-IgD in the presence or absence of 10% Low Tox 
Complement (Cedarlane Laboratories Ltd. Ontario, Canada) to provide 
complement-mediated co-stimulation as well as conditions where the B cell 
FcγRIIB was blocked with azide-free anti-CD16/CD32 (mAb clone 2.4G2, 
553140, BD Pharmingen, San Jose, CA) to minimize ITIM signaling. To assess 
the role of FDC-FcγRIIB in IgM production by FDC-IC-stimulated B cells, 
0.5x105 FDCs were treated with 1 μg/ml azide-free anti-CD16/CD32, prior to 
loading with anti-IgD ICs. ICs were trapped with the complement receptors and 
105 B cells were cultured with the IC-bearing FDCs. Culture supernatant fluids 
were assessed after 48 hrs for polyclonal mouse IgM production by ELISA.  
ELISA 
Total and OVA-specific IgM were assessed in sera and culture 
supernatant fluids 48 hrs after stimulation of B cells with OVA or anti-IgD-IC-
bearing FDCs in vivo and in vitro. Samples were loaded on ninety-six well 
plates coated with 100 μg/ml OVA (for OVA-specific Abs) or goat anti-mouse 
IgM (for total IgM). Samples were left overnight, washed, and captured mouse 
IgM was detected with biotinylated goat anti-mouse IgM followed by 
streptavidin-alkaline phosphatase. Alkaline phosphatase was developed with 
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pNPP alkaline phosphatase substrate system (KPL, Gaithersburg, Maryland, 50-
80-00) and read on ELISA reader at 405 nm. 
Assessment of FDC-BAFF production and the effect of neutralizing BAFF 
and C4BP on IgM production by IC-stimulated B cells 
One million purified FDCs were cultured in vitro for 48 hrs alone or with 100 
ng/ml soluble OVA, OVA-ICs, or OVA-ICs, in the presence of 10 μg/ml FcR 
blocker (2.4G2), or rat IgG2b isotype control. Culture supernatant fluids were 
collected and BAFF production was assessed by ELISA using Quantikine 
Mouse BAFF/BLyS/TNFSF13B Immunoassay (R&D Systems, Inc., 
Minneapolis, MN, MBLYS0). To assess the effect of FDC-BAFF blockade on 
IgM production by IC-stimulated B cells, B220 purified B cells were cultured 
with anti-IgD IC-bearing FDCs at a ratio of 1 FDC:2 B cells in the presence of 1 
μg/ml decoy recombinant mouse BAFF R/TNFRSF13C/Fc chimera, (R&D 
Systems, Inc., Minneapolis, MN, 1357-BR). Control conditions included B cells 
alone, B cells + anti-IgD mAb, B cells + anti-IgD ICs, and B cells + anti-IgD 
mAb + FDCs. FDC-M2 is a rat anti-mouse mAb that detects an epitope of C4 
localized to the ICs trapped on FDCs (59,217). This anti-C4 appears to block 
C4-bBP which is capable of interacting with CD40 on B cells (59). In mice 
immunized with TNP-Ficoll, a TI-2 Ag, injection of FDC-M2 blocks the FDC-
IC-mediated CD40-dependent activation of follicular B cells and reduces TI GC 
development by 90% (59). To test the effect of FDC-M2 on IgM production by 
FDC-IC-stimulated B cells, 0.5x106 B220 purified B cells were stimulated with 
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0.25x106 anti-IgD IC-bearing FDCs in the presence or absence of 1 μg/ml 
C4BP-blocking FDC-M2 (from hybridoma cell line generously provided by Dr. 
M. Kosco-Vilbois, NovImmune SA, Switzerland). Forty-eight hrs later culture 
supernatants were collected and assessed for mouse IgM with ELISA. 
Visualization and quantification of intracellular phosphotyrosine in 
stimulated B cells using confocal microscopy and flow cytometry 
Purified B cells were stimulated with anti-IgD-IC-bearing FDCs for 45 
minutes. Cells were washed, fixed, and permibilized using Fix & Perm cell 
permeabilization kit (Caltag Laboratories). Intracellular phosphotyrosine was 
detected with FITC-conjugated anti-phosphotyrosine, clone 4G10, (Upstate 
Biotechnology, Lake Placid, NY, 16045). Cells were washed and analyzed with 
flow cytometry or deposited onto polylysine-coated glass slides for visualization 
with confocal microscopy using argon beam emitting 488 nm laser.  
Flow cytometric analysis of GL-7, Blimp-1, and CFSE labeling of B cells 
stimulated with anti-IgD IC-bearing FDCs in vitro 
Purified B cells were stimulated with anti-IgD IC-bearing FDCs for 48 
hrs then assessed for GL-7 and Blimp-1 expression as well as B cell 
proliferation using carboxyfluorescein diacetate, succinimidyl ester (CFSE) 
dilution assay. To assess GL-7 expression, cells were washed, blocked with Fc-
blocker to reduce non-specific binding of GL-7 to the Fcγ receptors, labeled 
with FITC-conjugated anti-B-cell activation antigen (GL-7), or isotype control 
rat IgM-FITC (BD Pharmingen, San Jose, CA, 553942). An unstimulated B cell 
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control was similarly treated and GL-7 expression was assessed by flow 
cytometry. For intracellular Blimp-1 assessment, purified B cells stimulated 
with anti-IgD-IC-bearing FDCs for 48 hrs, were washed, fixed, and permibilized 
using Fix & Perm cell permeabilization kit (Caltag Laboratories). Intracellular 
Blimp-1 was labeled with PE-conjugated anti-Blimp-1(Santa Cruz 
Biotechnology Inc, Santa Cruz, CA. sc-13203 PE) then cells were washed and 
analyzed with flow cytometry. B cell proliferation was assessed by The 
CellTrace™ CFSE Cell Proliferation Kit (C34554, Invitrogen) following the 
protocol of the manufacturer. The working range of CFSE is 0.5-25 μM/ml, 
however, 1 μM CFSE/106 cells/ml was satisfactory and avoided toxicity that 
occasionally occurs with high concentrations of DMSO that was used as a CFSE 
solvent. After labeling, data were collected using FC500 Flow Cytometer 
Beckman Coulter, analyzed using Cytomics RXP analysis software, and plotted 
using WinMDI software (Scripps Research Institute).  
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Results 
Nude mice challenged with OVA-ICs but not OVA mounted OVA-specific IgM 
responses 
If periodically arranged FDC-ICs can induce specific IgM in the absence 
of T cells, then nude mice should rapidly produce specific IgM when challenged 
with a TD Ag in the form of ICs but not with free Ag. This hypothesis was 
tested in nu/nu mice given 50 μg of α-Thy-1, to block any residual T cell 
activity, and challenged with OVA in adjuvant or OVA in ICs with or without 
adjuvant. As expected, anti-OVA was not detectible in animals immunized with 
OVA over a 7 week period even with adjuvant (Fig. 1-A). In marked contrast, 
OVA-specific IgM was present in the sera of all ICs injected animals with or 
without adjuvant in just 48 hrs. The highest OVA-IgM levels were induced 
using OVA-ICs in adjuvant and these IgM levels were maintained over a 7 week 
assessment period. The adjuvant effect was expected, given that LPS activates 
FDCs and promote their accessory activity (71). Phenotypically normal 
heterozygous nu/+ mice also responded to ICs by producing OVA-specific IgM 
within 48 hrs (Fig. 1-B), although, these IgM levels declined as the isotype 
switched from OVA specific IgM to IgG, in the presence of T cell help (Fig. 1-
C). 
GCs in nude mice are associated with well-developed ARR and plasmablasts 
Rapid induction of OVA-specific IgM responses in nu/nu mice 
challenged with OVA-ICs prompted study of GC development and plasmablast 
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differentiation in their draining lymph nodes. As expected for a TD protein Ag, 
GCs were not detected at day 2 or at day 7 in nu/nu mice challenged with OVA 
+ adjuvant in the presence of non-specific rabbit serum where ICs would not 
form (Fig. 2-A). The B cell follicles labeled with B220 (magenta) but not with 
the GC B cell marker GL-7 (green). In marked contrast, the follicles in nu/nu 
mice challenged with OVA-ICs developed large GCs within 48 hrs and these 
persisted for at least one week (Fig. 2-B). The overlay of B220 and GL-7 
illustrated a GL-7 bright GC B cell zone surrounded by a zone of resting B220 
bright B cells. Note the activation marker GL-7 corresponds with an area of dim 
B220 labeling since activated B cells tend to down regulate B220 upon 
acquisition of the GL-7+ phenotype (218). In Fig. 2-C, labeling with anti-rabbit 
IgG (binds rabbit IgG in OVA + rabbit-anti-OVA IgG ICs) revealed well-
developed crescent-shaped FDC-ARR at day 2 and day 7. A funnel-shaped Ag 
transport site extending from the sub-capsular sinus into the lymph node cortex 
was seen in association with the ARR illustrated at day 7 (37). As shown in the 
overlay, the green GC is capped with the ARR in red and this overlapping 
orange-yellow interface represents the GC light zone.  
The vigorous OVA specific IgM responses in nu/nu mice suggested that 
challenge with OVA ICs would induce plasmablasts and plasma cells, which 
label with Blimp-1. As shown in Fig. 2-D, Blimp-1 positive cells were found at 
the paracortical borders of multiple GCs (red) with a group migrated toward the 
medullary cords deeper in the node. These cells were also GL-7+ and the overlay 
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of Blimp-1 (red) and GL-7 (green) resulted in orange-colored cells suggesting 
that these cells are plamablasts. We reason that these cells are migrating toward 
the medullary cords and bone marrow where they would be expected to mature 
into plasma cells that would no longer label with GL-7. 
Purified OVA IC-bearing FDCs induced OVA-specific IgM production by 
purified B cells within 48 hrs in the absence of T cells and T cell factors 
If periodically arranged FDC-ICs can induce specific IgM in the absence of T 
cells or T cell factors; then purified FDCs should rapidly stimulate specific IgM 
by purified naïve B cells in vitro if they bear Ag in ICs but not with free TD Ag. 
FDC-B cell interactions are not MHC or species restricted and murine FDCs can 
stimulate human B cells effectively (56). Purified murine (Fig. 3-A) or human 
(Fig. 3-B) B cells in cultures lacking T cells and T cell factors produced OVA-
specific IgM in 48 hrs when stimulated with FDCs bearing OVA ICs. Both the 
kinetics of the response and the IgM production are consistent with a T-
independent response. Control conditions, that failed to produce a detectable 
response, included FDCs with B cells stimulated with free OVA that would have 
unfettered access to BCR.  
Purified B cells were signaled by FDCs bearing anti-IgD-ICs as indicated by 
intracellular phosphotyrosine distribution, expression of activation marker 
GL-7, plasmablast differentiation, and B cell proliferation  
If Ags in FDC-ICs promote simultaneous binding and cross-linking of 
multiple BCRs, as we hypothesize, then anti-IgD loaded on FDCs in the form of  
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Figure 1: Nude mice challenged with OVA ICs, but not with OVA, mounted OVA-
specific immune responses in 48 h. A, Groups of nu/nu mice, pretreated with 50 µg of 
anti-Thy-1 to block residual T cell activity, were challenged with alum-precipitated OVA 
with B. pertussis, OVA-ICs, or OVA-ICs with B. pertussis. Serum anti-OVA IgM levels 
were determined 48 h, 1 wk, and 2 wk later, and results were recorded after subtracting 
background levels using preimmunization sera. As expected, anti-OVA was not 
detectible in animals immunized with OVA in adjuvant (baseline tracking). In marked 
contrast, OVA-specific IgM was present in the sera of all IC-injected animals with or 
without adjuvant in just 48 h and was maintained over a 7-wk assessment period. B, 
Phenotypically normal heterozygous nu/+ mice with competent T cell compartment also 
responded to ICs by producing OVA-specific IgM within 48 h, although these IgM levels 
declined over time. C, The phenotypically normal nu/+ also produced IgG, and the 
increase in this isotype correlated with a decrease in IgM. Note that neither class 
switching nor OVA-specific IgG was detectable in nu/nu mice lacking T cell help 
(baseline tracking). Data are represented as mean ± SD. 
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Figure 2: Robust GC and plasmablast responses were induced in nude mice by OVA-
ICs in 48 h and sustained for at least 1 wk in association with IC-retaining FDC-
reticula. Groups of nu/nu mice were challenged with OVA-specific rabbit serum or 
normal (nonspecific) rabbit serum plus alum-precipitated OVA and B. pertussis. Two and 
7 days later, mid-saggittal sections from axillary LNs were triple labeled with GL-7-FITC 
(green, GC-B cells), B220-Cy5.5 (magenta, pan-B cell marker), and Rhodamine Red X-
goat anti-rabbit IgG (red, OVA-ICs in FDC-reticulum). GC-associated plasmablasts were 
labeled with anti-Blimp-1-PE (red). A, GCs were not detected in athymic nu/nu mice 
challenged with OVA and adjuvant at days 2 or 7. The B cell follicles labeled well with 
B220 (magenta) but not with the GC B cell marker GL-7 (green); thus, the overlay 
(B220/GL-7) was magenta. B, As early as 48 h, nu/nu mice challenged with OVA-ICs 
exhibited large GCs that were maintained at least for 1 wk. The GL-7bright B cells (green) 
correspond with an area of B220dim labeling (magenta). The overlay (B220/GL-7) 
illustrates GL-7bright GC B cells surrounded by a zone of resting B220bright B cells. C, 
Labeling with anti-rabbit IgG revealed well-developed, crescent-shaped, ARR (red) both 
at days 2 and 7. Funnel-shaped Ag transport site extending from the subcapsular sinus 
(indicated in this illustration by a red left bracket in the 7 day data) was seen in 
continuation with the ARR. In the overlay of the ARR and the GL-7, the GL-7+ GC B 
cells (green) were seen capped with the ARR (red) and the light zone of the GC where 
the FDC-ARR (red) overlapped with the GC B cells (green) appeared orange-yellow 
(areas between orange arrows). D, Blimp-1+ plasmablasts were found at the paracortical 
borders of multiple GCs (red arrowheads) both at days 2 and 7, and some migrated 
toward the medullary cords deeper in the node (green arrowheads). These cells were also 
GL-7+ (green) giving an orange overlay (yellow arrows). 
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Figure 3: Purified OVA-IC-bearing FDCs induced OVA-specific IgM production by 
purified B cells within 48 h in the absence of T cells. Purified murine or human B cells 
were incubated with purified OVA-IC-loaded FDCs at a ratio of 1FDC:2B cells, and 
OVA-specific Abs were assessed after 48 h. Murine (A) and human (B) B cells stimulated 
with FDCs bearing OVA ICs produced OVA-specific IgM in 48 h. Control conditions 
that failed to produce a detectable response included FDCs with B cells stimulated with 
free OVA that would have had free access to BCRs. Data are represented as mean ± SD 
and are representative of two experiments of this type. 
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ICs should engage multiple BCRs and induce signaling in the vast majority of B 
cells. B cell signaling may be indicated by increases in and redistribution of 
intracellular phosphotyrosine in the form of patches (patching) and owing to cell 
motility and cell surface fluidity such patches can aggregate to one pole of the 
cell in the form of caps (capping) (219,220). The anti-IgD mAb (rat anti-mouse 
IgD clone 11-26) was selected for study because, among a number of rat anti-
mouse IgD mAbs tested, clone 11-26 does not induce B cell activation (216). 
This mAb was complexed with Fc-specific rabbit anti-rat IgG (leaving the Fabs 
free to engage BCRs) and loaded on the surface of FDCs. As shown in Fig. 4-A, 
phosphotyrosine labeling in unstimulated B cells was low and evenly 
distributed. In marked contrast, B cells stimulated with FDCs bearing anti-IgD 
ICs (Fig. 4-B) labeled more intensely and the phosphotyrosine was capped 
(fluorescence localized at one pole of the cell surface), or patched on the 
membrane indicating a marked redistribution. Most B cells exhibited the 
patched or capped intracellular phosphotyrosine pattern consistent with being 
signaled (Fig. 4-C). Moreover, flow cytometric analysis (Fig. 4-D) confirmed 
that the B cells exhibited higher levels of intracellular phosphotyrosine 
(increased MFI) and the entire B cell population had clearly shifted to the right 
suggesting that virtually the entire B cell population had been signaled by anti-
IgD bearing FDCs. High magnification imaging revealed that the 
phosphotyrosine labeling (green) was intense at areas of contact between the B 
cell membrane and the AMCA-labeled IC-bearing FDCs (blue) (Fig. 4-E). In 
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addition, the activation marker GL-7 was induced when B cells were stimulated 
with anti-IgD IC-bearing FDCs in vitro (Fig. 4-F). Note the shift to the right, 
indicating increased GL-7 expression, when B cells were stimulated with anti-
IgD IC-bearing FDCs. The MFI on the highest 33% of FDC-IC-stimulated B 
cells was almost 4 times that of the unstimulated B cell control. Blimp-1 
expression was also induced by IC-bearing FDCs in vitro within 48 hrs. About 
0.6% of B cells expressed Blimp-1 in control cultures lacking anti-IgD IC-
bearing FDCs (Fig. 4-G), however, the addition of anti-IgD IC-bearing FDCs, 
(Fig. 4-H), induced a 4-fold increase (2.4%) and many cells showed high Blimp-
1 levels. Moreover, B cell proliferation was induced by IC-bearing FDCs in 
vitro within 48 hrs. The response was IC-dependent since purified B cells 
cultured with FDCs alone (Fig. 4-I) or FDCs in addition to the mAb rat anti-m-
IgD (Fig. 4-J) did not divide. In contrast, 30% of B cells stimulated with anti-
IgD IC-bearing FDCs showed up to two rounds of division within 48 hrs in the 
absence of T cell and T cell factors (Fig. 4-K).  
Purified B cells stimulated with anti-IgD-IC-bearing FDCs produced IgM 
within 48 hrs 
Given that B cells are signaled by anti-IgD ICs on FDCs, we reasoned 
that the simultaneous engagement of multiple B cell receptors should signal, at 
least some B cells adequately, to rapidly produce IgM. Moreover, this should be 
possible in the absence of T cells or T cell factors as was seen in Fig. 3 with 
OVA ICs. As illustrated in Fig. 5-A, free anti-IgD, or anti-IgD-ICs alone, or in 
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the presence of complement-mediated accessory signals did not stimulate IgM 
production. Blockade of B cell-FcγRIIB to minimize ITIM signaling did not 
alter the lack of responsiveness. In marked contrast, anti-IgD-ICs loaded on 
FDCs stimulated polyclonal B cell IgM production within 48 hrs. This response 
was B cell number dependent (1x104 - 1x106) as shown in Fig. 5-B but 
increasing doses of anti-IgD-ICs (0.1-10 μg/ml) did not improve IgM responses, 
indicating that 100 ng anti-IgD-ICs was an adequate agonist level.  
Blockade of FDC-FcγRIIB, -C4BP, and –BAFF significantly inhibited IgM 
production by FDC-IC-stimulated B cells 
We reasoned that the mechanism underpinning the TI FDC-dependent 
Ab response would require that FDCs deliver both primary and secondary 
signals to B cells.  Periodically arranged Ag is thought to provide the first signal 
and FDC-FcγRIIB appears to be important in periodically arranging ICs such 
that extensive cross-linking of multiple BCRs can occur (34).  As shown in Fig. 
6, blockade of FDC-FcγRIIB with 2.4G2 and loading anti-IgD ICs on FDCs via 
complement receptors resulted in a significant inhibition of IgM production by 
FDC-IC-stimulated B cells (Fig. 6-A). Secondary signals in the form of FDC-
C4BP and -BAFF are believed to promote B cell activation, proliferation and 
IgM secretion. Blockade of FDC-C4BP with FDC-M2 (Fig. 6-B) resulted in 
~75% reduction in the IgM response suggesting that engagement of B cell CD40 
is a critical part of the induction mechanism.  Furthermore, FDCs produce BAFF 
and the level of FDC-BAFF produced was enhanced by the addition of OVA 
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ICs (Fig. 6-C), and this enhancement was abrogated by the FcR blocker 2.4G2 
as previously reported for FDC-ICAM and VCAM (70). Addition of the decoy-
BAFF-R-Fc (Fig 6-D) resulted in 20% inhibition of IgM production [from 633 + 
17 to 503 + 58 with p value <0.02] by the FDC-IC-stimulated B cells indicating 
that FDC-BAFF, together with FDC-FcγRIIB and –C4BP, play important roles 
in the mechanism involved in the FDC-dependent induction of TI Ab responses 
to T-dependent Ags. 
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Figure 4: B cell signaling induced by FDC-anti-IgD-ICs in vitro was indicated by 
intracellular phosphotyrosine distribution, expression of activation marker GL-7, 
plasmablast differentiation, and B cell proliferation. Purified B cells were stimulated 
with anti-IgD-IC-bearing FDCs for 45 min, and the distribution of phosphotyrosine was 
analyzed. A, Phosphotyrosine labeling in unstimulated B cells was low and evenly 
distributed when visualization with confocal microscopy. B, FDC-ICs led to B cell 
signaling, as indicated by increases in and redistribution of intracellular phosphotyrosine 
in the form of patches (magenta arrowhead) and caps (yellow arrowhead). C, Most B 
cells exhibited the patched or capped intracellular phosphotyrosine pattern, consistent 
with being signaled. D, Flow cytometric analysis indicated that the entire B cell 
population had shifted to the right, suggesting that virtually all B cells had been signaled 
by anti-IgD-bearing FDCs, resulting in increased intracellular levels of phosphotyrosine. 
E, High magnification imaging revealed that the phosphotyrosine labeling (green) was 
intense at areas of contact (white arrowheads) between the B cell membrane and the 7-
amino-4-methylcoumarin-3-acetic acid-labeled ICs on FDCs (blue). F, Purified B cells 
were stimulated with anti-IgD IC-bearing FDCs for 48 h and labeled with anti-GL-7 or 
isotype control, and GL-7 expression was assessed by flow cytometry. Compared with 
the isotype control (red, MFI = 2) and the unstimulated B cell control (black, MFI = 2.5), 
B cells stimulated with anti-IgD IC-bearing FDCs (green) shifted to the right indicating 
increased GL-7 expression and an MFI of 9.0 on the highest 33% of activated B cells. G 
and H, Purified B cells were incubated for 48 h alone or with anti-IgD IC-bearing FDCs 
and labeled with PE-conjugated anti-Blimp-1. Approximately 0.6% of the isolated B cells 
expressed Blimp-1 (G). However, the addition of anti-IgD IC-bearing FDCs (H) induced 
a 4-fold increase (2.4%), and many cells in H were in the second and third decades of the 
Blimp-1-PE (y)-axis, indicating high Blimp-1 expression. I–K, Purified B cells cultured 
with FDCs alone (I) or FDCs in addition to the mAb rat anti-m-IgD (J) did not divide, 
whereas 30% of B cells stimulated with anti-IgD IC-bearing FDCs showed up to two 
rounds of division within 48 h in the absence of T cell and T cell factors (K). All results 
are representative of at least three separate experiments. 
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Figure 5: Purified FDCs bearing anti-IgD-ICs on their surfaces induced IgM 
production by purified B cells within 48 h in a B cell number-dependent manner. The 
rat anti-mouse IgD mAb clone 11–26, which does not per se induce proliferation of 
mature B cells in vitro nor activate B cells in vivo, was complexed with Fc-specific rabbit 
anti-rat IgG. A, Purified B cells (105) were cultured under different conditions, and IgM 
production was assessed by ELISA 48 h later. As expected, free anti-IgD mAb (1 µg), or 
anti-IgD-ICs alone, or in the presence of complement-mediated accessory signals did not 
stimulate IgM production, and blockade of B cell-FcγRIIB to minimize ITIM signaling 
did not alter the lack of responsiveness. However, anti-IgD-ICs loaded on FDCs 
stimulated polyclonal B cell IgM production within 48 h. B shows that the IgM response 
was B cell number dependent and that 100 ng of anti-IgD loaded as ICs on FDCs was an 
adequate stimulus. Data are represented as mean ± SD and are representative of three 
experiments of this type. 
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Figure 6: Blockade of FDC-FcγRIIB, -C4BP, and -BAFF significantly inhibited IgM 
production by FDC-IC-stimulated B cells. A, FDC-FcγRIIB was blocked with 2.4G2, 
and anti-IgD ICs, incubated in 10% Low Tox Complement, were trapped using 
complement receptors. Anti-IgD ICs did not stimulate B cells in the absence of FDCs, 
and IgM production by FDC-IC-stimulated B cells was significantly inhibited by 
blockade of FDC-FcγRIIB, which is involved in the periodicity of ICs. B, Half million 
B220-purified B cells were stimulated with 0.25 x 106 anti-IgD IC-bearing FDCs in the 
presence or absence of 1 µg/ml C4BP-blocking FDC-M2 for 48 h, then IgM production 
was assessed by ELISA. The addition of FDC-M2 resulted in ~75% reduction in IgM 
production. Control conditions of B cells alone, and B cells plus anti-IgD ICs, did not 
stimulate IgM production by purified B cells. C, One million FDCs were cultured for 48 
h, and BAFF production was assessed. Addition of 100 ng/ml soluble OVA (OVA Ag) 
did not significantly increase BAFF production over levels produced by FDCs alone. 
Addition of OVA in the form of ICs significantly increased BAFF production by FDCs (p 
< 0.001). This enhancement was minimized by the addition 10 µg/ml FcR blocker 2.4G2 
(p < 0.005 for FDCs + OVA-ICs vs FDCs + 2.4G2 + OVA-ICs). Replacement of 2.4G2 
with its isotype control rat IgG2b restored the enhancement (p = 0.2 for FDCs + OVA-
ICs vs FDCs + isotype Ctrl + OVA-ICs, and p < 0.01 for FDCs + 2.4G2 + OVA-ICs vs 
FDCs + isotype Ctrl + OVA-ICs). D, One million B220-purified B cells were stimulated 
with 0.5 x 106 anti-IgD IC-bearing FDCs in the presence or absence of 1 µg/ml decoy 
BAFF-R-Fc for 48 h; then, IgM production was assessed by ELISA. Addition of the 
decoy-BAFF-R-Fc resulted in 20% inhibition of IgM production (from 633 ± 17 to 503 ± 
58 with p < 0.02). Control conditions of B cells alone, B cells plus anti-IgD mAb, B cells 
plus anti-IgD ICs, and B cells plus anti-IgD mAb plus FDCs did not result in B cell 
stimulation and IgM production, indicating the importance of FDC-ICs in the IgM 
response. Data are represented as mean ± SD and are representative of three experiments 
of this type. 
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Discussion 
The data presented here support the novel concept that FDCs can convert 
TD Ags into TI Ags capable of inducing specific IgM responses in 48 hrs or 
less. We were prompted to test this concept after: 1) observing TD-Ags in ICs 
on FDCs periodically spaced 200-500 Å apart (24,34), which is consistent with 
recurring epitopes 95-675 Å apart on the flexible backbone of an ideal TI-2 Ag 
(98,210); 2) noting the ability of FDCs to provide BAFF and C4BP which are 
known to support TI B cell activation (59-62,213,214). These relationships are 
illustrated in the model shown in Fig. 7, and more details are provided in the 
figure legend. We report here that nude mice, pre-treated with anti-Thy-1 to 
minimize any residual T cell activity, responded to ICs by producing specific 
IgM in 48 hrs while free Ag in adjuvant did not induce IgM in nude mice even 
after many weeks. In contrast, normal mice challenged with Ag in adjuvant 
induced detectible IgM in 4 days followed by IgG (Data not shown), and 
phenotypically normal nu/+ mice injected with ICs exhibited the rapid IgM 
response followed by a switch to IgG, which we attribute to T cell help that is 
lacking in the nu/nu mice (Fig. 1). Moreover, the draining lymph nodes of IC-
challenged nude mice exhibited well developed GL-7+ GCs associated with 
ARR and Blimp-1+ plasmablasts within 48 hrs that persisted for at least one 
week, further supporting the concept that B cells in the follicles are stimulated 
by the ICs on FDCs. In contrast, GCs and plasmablasts were lacking in Ag 
immunized nude controls where the B cells remained in the resting state 
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consistent with the lack of T cell help. TI-2 Ags have been used to load FDCs 
and induce GCs in animals lacking cognate T & B cell interactions. When mice 
with mutations that inactivate the TCR Cβ and Cδ genes were immunized with 
4-hydroxy-3-nitrophenylacetyl (NP)-Ficoll, GCs with peanut agglutinin-binding 
B cells were observed in the splenic follicles. These GCs contained mature IC-
bearing FDCs and although they were rapidly induced, their duration was short 
(104). We reason that engagement of FDC-FcγRIIB by IgG-TD Ag ICs induces 
FDC activation and production of FDC-BAFF and other trophic factors that 
maintain GCs. These in vivo studies were supported by in vitro experiments 
where highly purified IC-bearing FDCs and naïve B cells from humans or mice 
were co-cultured in the absence of T cells or T cell factors. B cells stimulated 
with IC-bearing FDCs in these cultures produced specific IgM in 48 hrs while 
no response was observed when ICs were replaced with free Ag. Both the 
kinetics of the response and the IgM production are consistent with TI 
responses. Furthermore, rat anti-mouse IgD mAb clone 11-26, which by itself 
does not activate B cells (216), became a potent B cell activator when loaded on 
FDCs in the form of ICs capable of simultaneously binding and cross-linking 
multiple BCRs. Within 48 hrs, activation was indicated by increased tyrosine 
phosphorylation in virtually all B cells along with patching and capping together 
with expression of the B cell activation marker GL-7, Blimp-1+ plasmablast 
differentiation, and B cell proliferation assessed by the CFSE dilution assay. 
Moreover, this signaling appeared to be productive in that FDCs bearing those  
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Figure 7: Model illustrating FDC-dependent, T-independent B cell activation and Ig 
production. A, Monomeric proteins generally express only a single copy of each 
antigenic determinant, making them unable to cross-link multiple BCRs and activate B 
cells in the absence of T cell help. B, TI-2 Ags contain numerous periodically arranged 
epitopes (green protrusions) attached to a flexible backbone (red curve). This 
arrangement allows extensive simultaneous cross-linking of BCRs (Y-shaped green). The 
multiple BCR cross-linking delivers a signal leading to B cell activation and Ig 
production. C, FDCs express high levels of FcγRIIB (red) and CRs (blue), which trap ICs 
containing TD Ags (multicolor clusters). ICs loaded via FcγRIIB alone exhibited 
periodicity of 200–500 Å apart (18 ), and we reasoned that this spatial arrangement 
would allow cross-linking of multiple BCRs specific for a single epitope, leading to B 
cell activation and Ig production as in B. D, Transmission electron micrograph showing 
HRP (a TD Ag) retained on the FDC surface in IC clusters 200–500 Å apart. This 
facilitates BCR cross-linking and B cell activation as explained in B and C. E, FDCs 
accessory activity includes secondary signals or cosignals that promote B cell activation 
and Ig production. Specifically, FDC-derived BAFF (22 44 ) ligates BAFF receptors on 
B cells, and FDC-derived C4BP (21 ) ligates B cell-CD40, which is a classical cosignal 
in B cell activation. F, B cells stimulated with IC-bearing FDCs, FDC-BAFF, and FDC-
C4BP rapidly differentiate into plasma cells and secrete Ag-specific IgM. 
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ICs induced polyclonal IgM in 48 hrs consistent with a TI response. Thus, we 
conclude that TD Ags in the form of ICs can induce specific IgM responses in 
an FDC-dependent but T cell independent fashion. 
The concept that TD proteins can trigger B cells when appropriately 
arranged is supported by a number of reports in the literature. Studies on the 
requirements for generation of Ab responses to repetitive determinants on 
polymers, polysaccharides and higher order structures such as viral capsid 
proteins indicated that high molecular weight arrays of Ag are efficient in 
eliciting an Ab response independent of T-cell help, whereas their less ordered 
counterparts are less immunogenic and require T-cell help (97,221,221,222). 
Certain bacteria, viruses, mammalian cells, some polymeric proteins like 
collagen, and hapten-protein complexes have repeating antigenic determinants. 
The multivalent presentation of antigenic determinants extensively cross-links 
BCRs and leads to B cell activation, proliferation, and Ig secretion that is 
characteristic of TI-2 responses. For example, multimerization of monomeric 
proteins by aggregation facilitates presentation of their Ag determinants in a 
highly arrayed structure fit for cross-linking BCRs and inducing Ab responses in 
the absence of T cell help (222).  
In addition, FDCs deliver secondary or co-stimulatory signals to B cells 
and the data presented here provide support for the involvement of FDC-C4BP 
that signals via B cell CD40, and FDC-BAFF that engages the B cell BAFF 
receptor. A role for other FDC molecules involved in signaling has not been 
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ruled out. For example, CD21L on FDCs engages CD21 in the B cell co-
receptor complex and CD21L-CD21 interactions not only promote Ag specific 
recall responses but also polyclonal responses induced by LPS (29,223). In 
addition, FDC-8D6 as well as BAFF inhibit B cell apoptosis (60,63,65,114,115); 
FDCs block IC mediated ITIM signaling in B cells via FcγRIIB and minimize 
this inhibitory pathway (30,57,58), and FDCs provide IL-6 for terminal B cell 
differentiation (68).  
Classic TI-2 Ags induce robust responses in splenic marginal zones 
(MZs) while lymph nodes are not heavily involved (224). In this respect, the 
reported FDC-dependent T-independent response appears to differ from classic 
TI-2 Ags. ICs are loaded on FDCs within minutes after Ag challenge (37) and 
follicular B cells appear to be heavily involved (Fig. 2). Lymph node responses 
are robust with GCs and plasmablasts apparent within 48 hrs. However, a role 
for other B cell subsets that can interact with the ICs in the FDC-ARR has not 
been ruled out. The anatomical proximity of the MZ to the splenic B cell 
follicles, where FDCs reside in the spleen, make it likely that a dynamic 
interaction between both compartments exists. An elegant commentary recently 
published on the follicular dimension of MZ B cells concluded with the a 
question whether MZ-B cells can be triggered to respond to Ags on FDCs when 
they visit the splenic follicles or not (225) and we plan to extend this work and 
test this possibility. 
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Responses to classical TI antigens appear to be more robust when T cells 
are present (97). The reported FDC-dependent TI response appears to be similar 
in that the 48 hr IgM responses in nu/+ mice were higher than in nu/nu mice 
(Fig. 1). Moreover, IgM production induced by FDC-ICs in vitro was also 
significantly enhanced at 48 hrs in the presence of normal T cells (Data not 
shown). The enhanced IgM response that occurs within 48 hrs is not likely 
attributable to MHC class II-restricted T-cell help as a period of ~48 hrs is 
needed before primed T cells are able to provide cognate T cell help.  However, 
cytokines and other T cell derived trophic factors may be present. For example, 
activated FDCs produce BAFF, IL-6, and IL-15 and these cytokines can rapidly 
induce cytokine production by conventional T cells (226-230). Moreover, NK T 
cells and γδT cells that mediate non-MHC class II-restricted non-cognate help 
may be a source of B cell activation factors within 48 hrs. We were impressed 
by the decline in IgM titers in nu/+ mice and we suspect that this will continue 
and this contrasts with the nu/nu mice that maintained their IgM for 7 weeks. 
The short time required to induce FDC-dependent TI IgM responses may 
have practical application. IgM is the first class of antibodies produced during a 
primary Ab response and it plays important roles in host protection [reviewed in 
(231)]. Moreover, its multimeric structure makes it a strong complement 
activator; a single bound IgM pentamer can trigger the classical pathway of 
complement activation and can lyse a red blood cell, while approximately a 
thousand IgG molecules are required to accomplish the same (232). In synergy 
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with complement, IgM offers immediate protection to systemic bacterial and 
viral infections (3) and patients with normal IgG levels but selective IgM 
deficiency suffer from morbid recurrent upper respiratory tract infections, 
asthma, celiac disease, and meningitis (233,234). Other potential applications 
include countering the negative effect of regulatory T cells and the non-
responder state as a consequence of a limited MHC-II repertoire that may be 
unable to load certain peptides. We reason that individuals who fail to respond 
to a vaccine, as a consequence of problems with Ag presenting cells or the effect 
of T regulatory cells, should mount rapid specific IgM responses when 
immunized with appropriate ICs. The ICs should load on FDCs and bypass 
limitations imposed by MHC and T cells. Similarly, specific IgM responses 
should be inducible in animals or people with congenital and/or acquired T cell 
insufficiencies (235,236) including HIV infected (237), aged (238), diabetic 
(239), uremic (240) and neonates (241,242). We look forward to experiments 
designed to test these postulates. 
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CHAPTER 6 
In vitro Induction of Human Primary Antibody Responses: A 
Novel Model for Rapid Vaccine Assessment 
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Introduction 
In vivo studies of human immune responses to therapies and vaccines are 
limited by technical and ethical considerations. Studies with closely related non-
human primates are confronted by problems such as the high cost, limited 
availability, paucity of genetic models for human diseases, and lack of 
genetically inbred strains suitable for stem cell or tissue transplantation. Studies 
in mice have been helpful in demonstrating the feasibility of stem cell 
transplantation and some other therapies; but, rodents are not humans, and 
human-related studies carried out solely in mice might not accurately predict the 
real outcome in humans. 
Inspite of progress that has been achieved since the inception of these 
models, major limitations prevent them from being fully representative of the 
human immune system. For example, the mouse thymus lacks the expression of 
HLA class I and II, which is required for the selection of T cells after human 
stem cell (HSC) engraftment. And inspite of the recent approach of transgenic 
expression of human HLA molecules in mice engrafted with HSCs, the limited 
diversity in the human major and minor histocompatibility alleles that can be 
expressed in a mouse, renders these optimized models inadequate to fully 
represent the human system (243).  
The initiation of an adaptive immune response in vivo is dependent not 
only on an efficient cross talk between the major players of the immune system, 
but also on a highly compatible and competent interaction between the immune 
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system cells and other molecules and non-immune cells, such as the stromal 
cells in primary and secondary lymphoid tissues. Despite the recent reports by 
the Garcia group, where humanized mice intrarectally infected with HIV 
showed depletion of T cells similar to humans, there was a significant difference 
in the phenotype of T cells in the humanized mice guts if compared to human 
gut CD4+T cells. T cells in the humanized mice guts showed low levels of 
CXCR4, compared to the co-expression of CCR5 and CXCR4 by human gut 
CD4+ T cells (244,245). 
Several attempts have been made to further manipulate the humanized 
mouse model to render it physiologically close enough to fully represent the 
human systems. One approach was the addition of human endothelium, growth 
factors, and chemokines, which might help promote the appropriate trafficking 
and expansion of human cells. Another approach was to engraft artificial lymph 
nodes consisting of biocompatible scaffolds containing human stromal cells in 
the humanized mouse models (243). 
However, even the optimized humanized mouse model does not solve 
the problem of the variation in the individual human immune responses to 
certain vaccines. Each person’s immune cells would be needed in a separate 
mouse model to faithfully predict specifically his/her response to a tested 
vaccine. The inpracticality of this approach and the increased desire for the 
reduction of the number of animals used to test vaccines, the animal suffering, 
and finding replacement methods for the biological quality control testing of the 
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human vaccines argues for the development of an efficient human in vitro 
immune system response-testing model. 
Unfortunately, induction of specific primary human antibody (Ab) 
responses in vitro has been challenging (246-252). This is attributable, at least in 
part, to the natural scarcity of antigen (Ag)-specific T and B cells in non-
immune individuals as well as the complexity of circuits controlling lymphocyte 
activation and proliferation (253)..  
The functional element of a human lymph node or spleen is the follicle, 
which develops a germinal center (GC) when stimulated by antigen 
(11,106,107,125,187,188,218,254-258). The GC is the "hot spot" in the lymph 
node or spleen where critical interactions take place in developing an effective 
humoral immune response. Upon antigen stimulation, follicles are replicated and 
an active human lymph node can have dozens of active follicles with 
functioning GCs. Interactions between B cells, T cells, and follicular dendritic 
cells (FDCs) take place in GCs.  These interactions result in stimulation of Ab 
specific B cells, Ig class switching, somatic hypermutation, and the selection of 
high affinity B cells responsible for affinity maturation and the production of 
high quality Ab (35,39).  
In this study, we sought to design in vitro GCs to examine humoral 
responses to vaccines.  Succinctly, while T cells are necessary for B cell 
responses to T dependent Ags, they are not sufficient for the development of 
fully functional and mature Ab responses that are required to assess most 
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vaccines. FDCs provide critical assistance needed for the B cells to achieve their 
full potential and accessory functions of FDCs and regulation of these functions 
is critical to an understanding of fully functional and mature Ab responses 
(35,38,40,44,45,159,259). 
Mature Ab responses involve dendritic cell (DC) maturation, Ag 
processing, MHC-restricted Ag presentation, CD4+ T cell priming, B cell 
activation, immune complex (IC) formation, IC trapping by FDCs, FDC-B cell 
interactions leading to clonal selection, somatic hypermutation and affinity 
maturation. When responding to T cell dependent Ags in vivo, these processes 
reach maturity in GCs. Accordingly, we sought to generate primary Ab 
responses in temporally-controlled GC reactions (GCRs) in vitro by sequential 
integration of the activated cellular components (260-264). 
Antibody responses are greatly influenced by the form of antigens and T 
cell help. Consequently, we started by characterizing the effect of these 
variables in well-defined test models prior to their integration in the in vitro 
model. Results showed that mature Ag-pulsed DCs are competent in priming 
CD4+ T cells in vitro, while antigens trapped in the form of ICs on the surface of 
FDCs efficiently stimulated B cells. Moreover, B cell help by cognate Ag-
specific T cells was an absolute necessity for class switching and affinity 
maturation.    
To develop our in vitro model, immature monocyte-derived DCs (mDCs) 
were pulsed with Ovalbumin (OVA) or recombinant protective antigen of 
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Bacillus anthracis (rPA) for processing. Bacterial lipopolysaccharide (LPS) was 
used as maturation signals for mDCs. Negatively selected CD4+ T cells were 
added for priming and ten days later, naïve B cells and FDCs bearing Ags in the 
form of ICs were added. Ag specific IgM and IgG were assessed by ELISA at 
different intervals, affinity maturation was assessed by salt dissociation, and 
cultures were microscopically examined for morphological alterations and 
cluster formation. Preliminary results show the clustering of CD4+ T cells with 
DCs through the 10 days of priming and fusion with FDC-B cell clusters when 
GCRs were induced. An initial response dominated by Ag-specific IgM was 
observed in the first week followed by class switching to a dominant IgG 
response in the second week. In addition, preliminary results suggest an increase 
in Ag specific IgG affinity in the second week and imply the increased 
efficiency of this in vitro model in predicting the human immune response to 
certain antigens like HIV-gp120 than experimental murine models. 
In summary, Ag specific affinity matured primary human Ab responses, 
with class switching from specific IgM to IgG was generated in GCRs entirely 
in vitro thus providing the means for individually and safely assessing emerging 
vaccines and therapeutics in a human immune system.  
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Materials and Methods 
Mice 
Normal 8–12 wk old BALB/c mice were purchased from the National 
Cancer Institute (Frederick, MD) or The Jackson Laboratory (Bar Harbor, ME). 
The mice were housed in standard plastic shoebox cages with filter tops and 
maintained under specific pathogen-free conditions in accordance with VCU 
Animal Care and Use guidelines. Food and water were supplied ad libitum.  
Germinal center reactions  in vitro  
To induce a human antigen-specific GCR in vitro, the different cellular 
components of the GC were prepared as follows:  
(1) Peripheral blood mononuclear cells (PBL) were obtained from 
heparinized blood by density centrifugation using Lymphocyte Separation 
Medium (ICN, Aurora, OH). Cells were centrifuged at 400 x g for 20 minutes, 
the cells were collected from the interface and washed three times in RPMI 1640 
media (Cellgro, VA).  After washing the cells were suspended in RPMI-1640 
supplemented with 10% of fetal calf serum (HyClone, Logan, Utah) and 
antibiotics for cell culture.  
(2) CD14+ human monocytes were isolated on MACS columns from the 
PBLs using CD14 MicroBeads, human, (Miltenyi Biotech, # 130-050-201).  
(3) Monocyte-derived dendritic cells (mDCs) were generated by treating 
107 CD14+ cells with a mixture of IL-4 (50 ng/ml) and GM-CSF (50 ng/ml). 
Two days later the cells were fed with another dose of the cytokines to enhance 
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their differentiation. On day 5, LPS was added at 1 μg/ml concentration together 
with 1 μg/ml OVA or rPA to provide Ag for processing and LPS for DC 
maturation.  
(4) After 8 hours, 20 x 106 CD4+ T cells isolated by Naïve CD4+ T Cell 
Isolation Kit II, human, (Miltenyi Biotech, #130-094-131) were added and left 
for 5 days for DCs to present OVA and prime the CD4+ T cells.  
(5) At the end of the 5 days the T cells and remaining DCs were spun 
down and 15 x 106 naïve B lymphocytes were isolated and added to them 
together with FDCs loaded with 5 μg OVA or rPA in ICs.  
(6) Murine FDCs were isolated from lymph nodes (axillary, lateral 
axillary, inguinal, popliteal, mesenteric, and paraaortic) of normal young adult 
mice as previously described (130).  In brief, One day before isolation, mice 
were irradiated with 1000 rad to eliminate most lymphocytes, and one day later 
mice were killed, and LNs were collected, opened, and treated with 1.5 ml of 
collagenase D (22 mg/ml, C-1088882; Roche), 0.5 ml of DNase I (5000 U/ml, 
D-4527;    Sigma-Aldrich), and 2 ml of DMEM with 20 mM HEPES buffer. 
After 45 min at 37°C in a CO2 incubator, released cells were washed in 5 ml of 
DMEM with 10% FCS. Cells were then sequentially incubated with FDC-
specific Ab (FDC-M1) for 45 min, 1 µg of biotinylated anti-rat kL chain for 45 
min, and 20 µl of anti-biotin microbeads (Miltenyi Biotec) for 15–20 min on ice. 
The cells were layered on a MACS LS column and washed with 10 ml of ice-
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cold MACS buffer. The column was removed from the VarioMACS, and the 
bound FDCs were released with 5 ml of MACS buffer.  
Cultures were assessed microscopically and differentiated cells were 
tracked with specific mAbs and examined with confocal microscopy. Culture 
supernatant fluids were collected one and two weeks later and OVA- and rPA-
specific IgG and IgM were assessed by ELISA.  
Affinity maturation in vitro 
Generation of high affinity antibodies is important for efficient immune 
responses. To test for affinity maturation in vitro we used a simple salt 
dissociation method for human cultures. In the salt dissociation method, we let 
OVA-specific IgG produced in 5 and 10 days old in vitro cultures to bind OVA 
coated plates. Two hours later, 1/16M-4M NaCl was used to dissociate the 
bound Abs for an hour on a shaker. Plates were washed and the remaining 
bound Abs (higher affinities) were detected using alkaline phosphatase labeled 
anti-human IgG and the optical densities (ODs) were obtained using an ELISA 
reader.  
In vitro GCRs versus animal models in predicting human immune responses  
Animal models and in vitro models may be equally valid in testing the 
human response to antigens that do not directly modify the response of the 
immune cells. However, antigens that have species-specific effects may be 
tested in animals but the results cannot be extrapolated from one species to the 
other. For example, gp120 is a glycoprotein exposed on the surface of the HIV 
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that binds human but not murine CD4 on CD4-expressing T cells (265-268). We 
reasoned that gp120 would block the T cell help if tested on human cells, 
whereas, a normal response would be generated if tested in BALB/c mice. To 
test our reasoning and consequently the efficiency of our in vitro human model, 
we immunized BALB/c mice with gp120 and tested their sera for mouse anti-
gp120, 7 and 14 days later using ELISA. In parallel, we generated human in 
vitro GCRs against gp120 and tested the culture supernatant fluids for human 
anti-gp120, 7 and 14 days later and both assessment techniques were compared.   
   
 199
Results   
Germinal center-like in vitro clusters  
Preliminary results showed the clustering of mature antigen-loaded 
monocyte-derived dendritic cells with CD4 T cells, and we reason this promted 
T cell priming. Preliminary confocal microscopy studies showed well-developed 
clusters of antigen-specific CD4 T cells associated with DCs. Additionally, B 
cells clustered with FDCs, and formed a B cell zone of FDCs and B cells 
segregated from the T cell zone in the GCR. Moreover, B cell proliferation 
resulted in the development of a high density and low density compartments 
similar to the dark and light zones of GCs in vivo (data not shown).  
Induction of primary human immune responses to OVA and rPA in vitro 
As shown in Fig. 1, GCRs in vitro were productive only in the presence 
of OVA-specific T cells and OVA-IC-loaded FDCs indicating the importance of 
specific T and FDC help to the antigen-specific B cells. Responses were typical 
of a T cell-dependent response in that, Ag-specific IgM dominated in the first 
week and that was followed by class-switching to Ag-specific IgG in the second 
week. Preliminary results with rPA showed a specific response similar to that of 
Ova (data not shown).    
Affinity maturation in vitro 
Preliminary studies using a simple salt dissociation method showed that 
the human in vitro immune responses exhibited higher affinity of Ag-specific 
Abs as they progress from the first week (5 days) to the second week (10 days). 
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(data not shown), at all molar concentrations of NaCl, bound Abs that resisted 
dissociation by the addition of salt (high affinity Abs) were higher at day 10 as 
compared to day 5 (data not shown).  
HIV-gp120 failed to induce Ag-specific IgG responses in human in vitro 
GRCs despite the generation of normal responses in BALB/c mice 
Our preliminary results showed that challenging BALB/c with gp120 
induced a normal T cell dependent response dominated by Ag-specific IgM in 
the first week that switched to gp120-specific IgG in the second week. In 
contrast, gp120 failed to induce class switching even after two weeks of setting 
up in vitro human GCRs (data not shown). The gp120 binds human CD4 T cells 
specifically, and inhibits T cell priming and we reason that this resulted in a lack 
of class switching in these cultures. The fact that FDCs bear ICs in a periodic 
arrangement capable of engaging multiple BCRs and induction of T-cell 
independent responses can explain production of gp120-specific IgM in the first 
week that persisted through the second week (34).     
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Figure 1: Induction of primary human immune responses to OVA.  Germinal centers 
developed in vitro where productive only in the presence of OVA-specific T cells and 
OVA IC-loaded FDCs indicating the importance of specific T and FDC help to the 
antigen-specific B cells. Responses were typical of a T cell-dependent nature. They were 
dominated by OVA-specific IgM (A) in the first week that class-switched to OVA-
specific IgG in the second week (B). 
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Discussion 
The data presented here support the novel concept that Ag specific 
primary human Ab responses, including Ig class switching can be generated in 
GCRs entirely in vitro. We report here that mature Ag-pulsed mDCs, primed 
MHC-matched human naïve CD4 T cells in vitro. Naïve B cells helped by IC-
bearing FDCs produced Ag-specific Abs dominated by IgM in the first week 
followed by class switching to a dominant IgG response in the second week and 
an increase in the affinity of Ag specific IgG. Preliminary data suggest the 
induction of affinity maturation and compartementalization in these GCRs in 
vitro.  
Traditionally, new vaccines and therapeutics are tested in animals like 
mice, rabbits or, in some cases in higher primates, like monkeys. Animal testing 
is time-consuming, expensive, controversial, and carries the risk of being 
untranslatable in humans. No matter how well an experimental vaccine works in 
animals, the application in humans is riddled with uncertainty and unforeseeable 
complications. Here, we report an in vitro model that may sidestep such 
devastating setbacks by allowing researchers to test vaccines and possibly 
therapeutics in human immune systems constructed in vitro.  
Speed and flexibility are two major advantages of the reported model. 
The need for speed has come about in response to emerging infectious diseases 
like SARS or avian flu. If a disease is spreading quickly and is highly virulent, 
time is of the essence and animal testing would take too long to be helpful.  
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Flexibility is a landmark of this model. Previous trials to induce human 
in vitro antibody responses were restricted to certain antigens for which primed 
cells can be isolated from immune human subjects like TT or HBV. In this 
model we bypassed this limitation by priming naïve human CD4 T cells in vitro 
using mature Ag-pulsed DCs. This allows screening of antigens from different 
sources including bacteria, fungi, parasites and viruses. In fact, the use of naïve 
cells gives the model flexibility as wide as the diversity of the B cell and T cell 
repertoires.  
The model can predict issues not apparent in studies conducted in animal 
models. For example, in contrast to the expected normal response of the murine 
model to HIV-gp120 exhibiting classic T-cell dependent class switching from 
Ag-specific IgM to IgG, the human cells in vitro may not switch to IgG, owing 
to the inhibitory effect of gp120 on the human but not the murine CD4 T-cell 
activity.  
The dose-dependent immuno-modulatory effects of certain drugs like 
chemotherapeutic agents can be simultaneously tested for toxicity without risk 
to human health using this model. Although, humanized SCID mice models 
have been traditionally developed for this purpose, their responses are low, they 
use a lot more human cells, they take more time (a month or more), they are 
expensive, and need special facilities for containment. More importantly, FDCs, 
the major B-cell co-stimulators in GCs, take 8 weeks or more to develop in 
SCID mice and humanized SCID mice would not be expected to work rapidly 
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by means of immune complexes being trapped on FDCs as we demonstrated in 
these chimeras.  
We are excited by the prospect of reconstructing GCRs in vitro where 
the important events for productive humoral immune responses take place and 
this is of utmost importance to critically assess vaccines. For example, it is not 
uncommon to find non-responders to particular vaccine and these people are put 
at risk when given a live vaccine. It may be possible to identify these people by 
setting up their immune system in vitro and determining their non-responsive or 
poor responsive state before they were challenged with a live vaccine capable of 
causing disease. In addition some therapeutic agents and industrial chemicals are 
toxic to the immune system and the in vitro immune system could be helpful in 
determining immunotoxicity in the context of the human immune system. The 
ability to get potent responses in vitro may even be useful in the production of 
human monoclonal Abs reactive against toxic agents and pathogens. In short, we 
report generation of primary human antibody responses entirely in vitro. The 
reported model can be used for the assessment of vaccines and therapeutics in a 
fast, flexible, and accurate way. 
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Summary and conclusion 
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FDC-FcγRIIB levels are up-regulated 1-3 days after challenge of actively 
immunized mice with Ag. This kinetics suggested that memory cells are not driving this 
response, prompting the hypothesis that IC-FDC interactions lead to FDC activation. To 
test this, mice passively immunized with anti-OVA Ab were OVA challenged to produce 
ICs. After 3 days, levels of ICs, FcγRIIB, ICAM-1, and VCAM-1 on FDC were analyzed. 
FDC were also stimulated with ICs in vitro, and mRNA for FcγRIIB, ICAM-1, and 
VCAM-1 was quantified by quantitative RT-PCR. IC labeling in passively immunized 
WT and FcγRIIB-/- mice revealed five to six FDC-reticula per LN midsagittal section. In 
WT mice, these IC-bearing FDC-reticula corresponded with FDC-reticula labeling for 
FcγRIIB, ICAM-1, and VCAM-1. Increases in these molecules on IC-stimulated FDC 
were confirmed by flow cytometry. FcγRIIB-/- mice showed normal trapping of ICs on 
FDC-reticula; mediated by CR, however, no increase in VCAM-1 or ICAM-1 was seen 
either on IC-bearing FDC-reticula or on purified FDCs. Addition of ICs in vitro resulted 
in a dramatic increase in mRNA for FcγRIIB, ICAM-1 and VCAM-1 in WT FDC, but 
not in FDC from FcγRIIB-/- mice, 2.4G2-pretreated WT FDC, B cells, or macrophages. 
Thus, although FDC-FcγRIIB was not essential for IC trapping, engagement of FDC-
FcγRIIB with ICs initiated an FDC activation pathway.  
Microbial molecular patterns engage TLRs and activate dendritic cells and other 
accessory cells. FDCs exist in resting and activated states, but are activated in GCs, where 
they provide accessory function. We reasoned that FDCs might express TLRs and that 
TLR-engagement might activate FDCs leading to the up-regulation of molecules 
important for accessory activity. To test this hypothesis, TLR4 expression on FDCs was 
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studied in situ with immunohistochemistry, followed by flow cytometry and RT-PCR 
analysis. TLR4 was expressed on FDC reticula in situ, and flow cytometry indicated that 
TLR4 was expressed on surface membranes and TLR4 message was readily apparent in 
FDCs by RT-PCR. Injecting mice or treating purified FDCs with LPS up-regulated 
molecules important for accessory activity, including FDC-FcγRIIB, FDC-ICAM-1, and 
FDC-VCAM-1. Treatment of purified FDCs with LPS also induced intracellular phospho-
IκB-α, indicating NF-κB activation, and that correlated with increased FcγRIIB, ICAM-1, 
and VCAM-1. FDCs in C3H/HeJ mice were not activated with LPS even when mice were 
reconstituted with C3H/HeN leukocytes, suggesting that engagement of FDC-TLR4 is 
necessary for activation. Moreover, activated FDCs exhibited increased accessory activity 
in anti-OVA recall responses in vitro, and the FDC number could be reduced 4-fold if 
they were activated. In short, we report expression of TLR4 on FDCs for the first time 
and that engagement of FDC-TLR4 activated NF-κB, up-regulated expression of 
molecules important in FDC accessory function, including FcγRIIB, ICAM-1, and 
VCAM-1, as well as FDC accessory activity in promoting recall IgG responses. 
 FDCs reside in GCs in which their dendrites interdigitate and form non-mobile 
networks. FDC purification requires the use of collagenase and selection columns and 
leaves FDCs without detectable dendrites; the cardinal morphological feature of FDCs, 
when examined by light microscopy. We have reasoned that isolated FDCs might 
reattach to a collagen matrix, extend their processes, and form immobile networks in 
vitro. As a test for this, cells were plated on collagen type I, laminin, biglycan, and 
hyaluronan. After 12 h, 80%–90% of FDCs adhered to all tested matrices but not to 
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plastic. Within 2 weeks, FDCs adhering to type I collagen had spread out and had begun 
to acquire processes with occasional interconnections. By day 30, most FDCs had fine 
processes that formed networks through interdigitation with neighboring cells. FDC 
identity was confirmed by FDC-M1 labeling, immune complex trapping, and retention by 
FDCs in the networks. Scanning electron microscopy confirmed that groups of FDCs 
were in networks composed of convolutions and branching dendrites emanating from 
FDC cell bodies. In vivo, collagen type I was co-localized with FDCs, 5 h after challenge 
of immune mice with antigen. However, 2 days later, the collagen type I fibers were 
largely found at the periphery of the active follicles. Flow cytometry established the 
expression of CD29 and CD44 on FDCs; this may have partly mediated FDC-collagen 
interactions. Thus, we report, for the first time, that FDCs attach to collagen type I in 
vitro and regenerate their processes and networks with features in common with networks 
present in vivo 
The contribution of IL-6 to terminal B cell differentiation has long been 
recognized and reports that FDCs produce IL-6 prompted the hypotheses that ICs induce 
FDCs to produce IL-6 and that FDC-IL-6 promotes GCRs, SHM and IgG production. 
FDCs were activated in vitro by addition of ICs and FDC-IL-6 production was 
determined. WT and IL-6 KO mice, as well as chimeras with WT and IL-6 KO cells, 
were immunized with NP-CGG and used to study anti-NIP responses, GC formation, and 
SHM in the VH186.2 gene segment in Ig-gamma. FDC-IL-6 increased when FDCs 
encountered ICs. At low immunogen dose, 1 µg NP-CGG/mouse, the IgG anti-NIP 
response in IL-6 KO mice was low and immunohistochemistry revealed a reduction in 
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both the number and size of GCs. The physiological relevance of FDC-IL-6 was apparent 
in the chimeric mice where total splenocytes from WT mice were unable to provide the 
IL-6 needed for normal IgG and GC responses in IL-6 KO animals with IL-6-defective 
FDCs. Moreover, the rate of mutation decreased from 18 to 8.9 mutations/1000 bases (P 
<0.001) in WT vs. IL-6 KO mice. Addition of anti-IL-6 to GCRs in vitro reduced Ab 
levels and SHM from 3.5 to 0.65 mutations/1000 bases (P<0.02). Thus, the absence of 
FDC-IL-6 correlated with a reduction in SHM that coincided with the reduction in GCs 
and specific anti-NIP. This is the first study to document that ICs induce FDC-IL-6 and 
that FDC-derived IL-6 is physiologically relevant in generating optimal GCRs, SHM, and 
IgG levels. 
FDCs periodically arrange membrane-bound ICs of T-dependent Ags 200–500Å 
apart, and in addition to Ag, they provide B cells with co-stimulatory signals. This 
prompted the hypothesis that Ag in FDC-ICs can simultaneously cross-link multiple 
BCRs and induce TI B cell activation. TI responses are characterized by rapid IgM 
production. OVA-IC-bearing FDCs induced OVA-specific IgM in anti-Thy-1-pretreated 
nude mice and by purified murine and human B cells in vitro within just 48 h. Moreover, 
nude mice immunized with OVA-ICs exhibited well-developed GL-7+ GCs with IC-
retaining FDC-reticula and Blimp-1+ plasmablasts within 48 h. In contrast, FDCs with 
unbound-OVA, which would have free access to BCRs, induced no GCs, plasmablasts, or 
IgM. Engagement of BCRs with rat-anti-mouse IgD (clone 11–26) does not activate B 
cells even when cross-linked. However, B cells were activated when anti-IgD-ICs, 
formed with Fc-specific rabbit anti-rat IgG, were loaded on FDCs. B cell activation was 
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indicated by high phosphotyrosine levels in caps and patches, expression of GL-7 and 
Blimp-1, and B cell proliferation within 48 h after stimulation with IC-bearing FDCs. 
Moreover, anti-IgD-IC-loaded FDCs induced strong polyclonal IgM responses within 48 
h. Blockade of FDC-FcγRIIB inhibited the ability of FDC-ICs to induce T-independent 
IgM responses. Similarly, neutralizing FDC-C4BP or -BAFF, to minimize these FDC-
costimulatory signals, also inhibited this FDC-dependent IgM response. This is the first 
report of FDC-dependent but TI responses to T cell-dependent Ags. 
Induction of potent primary human Ab responses entirely in vitro is challenging, 
although such in vitro responses could be helpful in assessing vaccines and therapeutics 
without jeopardizing human health. Given that DCs prime T cells and that FDCs promote 
B cell responses, and that the four players are indispensible for the induction of a primary 
Ab response, we hypothesized that a primary Ab response can be induced in temporally-
controlled GCRs in vitro. To test this, human monocyte derived-DCs were given OVA, 
anthrax rPA or HIV-gp120 for processing, matured with LPS, and CD4+ T cells were 
added for priming. Ten days later, naïve B cells and OVA, rPA or gp120 IC-bearing 
FDCs were added and Ab production was subsequently assayed by ELISA. The CD4+ T 
cells clustered with DCs through the 10 days of priming and fused with FDC-B cell 
clusters when GCRs were induced. IgM dominated the primary human immune response 
to OVA and rPA in the first week then declined as class switching to IgG was induced by 
the Ag-specific T cells. Moreover, high affinity Abs detectable in the second week 
replaced the low affinity Abs of the first week indicating affinity maturation. In contrast, 
antibodies against gp120 did not classswitch, which we attribute to the inhibitory activity 
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of gp120 on CD4+ T cells (265-268). Consequently, gp120 would be a problematic 
vaccine in humans inspite of its effective induction of an effective immune response in 
mice. In short, Ag specific primary human Ab responses, including Ig class switching 
from specific IgM to IgG and affinity maturation, can be generated in GCRs entirely in 
vitro. Thus, potential vaccines can be rapidly and safely assessed using the human 
immune system in an accurate and flexible way. 
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